Sleep Disorders and Kidney Transplant Outcomes: Findings From an 18-Year (1997-2015) Historical Cohort Study by Lubas, Margaret M.
Old Dominion University
ODU Digital Commons
Health Services Research Dissertations College of Health Sciences
Spring 2017
Sleep Disorders and Kidney Transplant Outcomes:




Follow this and additional works at: https://digitalcommons.odu.edu/healthservices_etds
Part of the Health Services Research Commons
This Dissertation is brought to you for free and open access by the College of Health Sciences at ODU Digital Commons. It has been accepted for
inclusion in Health Services Research Dissertations by an authorized administrator of ODU Digital Commons. For more information, please contact
digitalcommons@odu.edu.
Recommended Citation
Lubas, Margaret M.. "Sleep Disorders and Kidney Transplant Outcomes: Findings From an 18-Year (1997-2015) Historical Cohort







SLEEP DISORDERS AND KIDNEY TRANSPLANT OUTCOMES: 
FINDINGS FROM AN 18-YEAR (1997-2015) HISTORICAL COHORT STUDY 
by 
Margaret M. Lubas 
B.S. December 2006, York College of Pennsylvania 
MSW May 2009, The Catholic University of America 
 
 
A Dissertation Submitted to the Faculty of  
Old Dominion University in Partial Fulfillment of the 
Requirements for the Degree of 
 
DOCTOR OF PHILOSPHY 
 
HEALTH SERVICES RESEARCH 
 












        Approved by: 
 
        Mariana Szklo-Coxe (Director) 
 
        Daniel Russell (Member) 
 
J. Catesby Ware (Member) 
 






SLEEP DISORDERS AND KIDNEY TRANSPLANT OUTCOMES: 
FINDINGS FROM AN 18-YEAR (1997-2015) HISTORICAL COHORT STUDY 
 
Margaret M. Lubas 
Old Dominion University, 2017 
Director: Dr. Mariana Szklo-Coxe 
 
 
A historic cohort study of kidney transplant recipients with a failed graft was conducted 
to examine the associations between sleep disorders and kidney transplant outcomes.  Adult 
kidney transplant recipients who were transplanted and failed or died with a functioning graft 
during the designated study time period (January 1, 1997 to September 1, 2015, inclusive) were 
included (n=299).  The primary independent variables, any sleep disorder and any sleep-
disordered breathing disorders, were defined through a diagnosis in a subject’s medical record.  
Transplant outcomes included: death with a functioning graft, graft survival time, and patient 
survival time after graft failure. 
Chi-square statistics were used to compare the proportion of death with a functioning 
graft between subjects with versus without any sleep disorder and to help inform the censoring 
approach for graft survival time.  Kaplan Meier survival curves were used to examine the 
relationship of any sleep disorder to survival time.  Cox regression models, examined the 
adjusted relationship of any sleep disorder to the outcomes, graft survival time and patient 
survival time after graft failure.  Sub-analyses also examined associations between sleep-
disordered breathing disorders and these outcomes.   
The prevalence of any sleep disorder in this cohort was 20%, with the majority consisting 
of sleep apnea diagnoses, a sleep-disordered breathing disorder.  Given a statistically significant 
(p≤0.01, adjusted model) sleep disorder by transplant-year heterogeneity, Cox regression models 
  
 
were stratified by transplant-year for the graft survival outcome.  Having a sleep disorder, 
namely, sleep apnea, was associated with a statistically significantly increased risk of graft 
failure or cardiovascular related death with a functioning graft among patients transplanted in 
2009-2015 (adjusted HR=2.94, p<0.05).  Sleep disorders, namely, sleep apnea, were not, 
however, associated with an increased risk of death with a functioning graft or an increased risk 
of death after graft failure.   
In a single-center cohort of kidney transplant recipients with a failed graft, a sleep apnea 
diagnosis increased the risk of graft loss nearly three-fold among patients transplanted between 
2009-2015.  Further research is needed to better understand this relationship and whether 
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End-stage renal disease (ESRD) is a chronic health condition that describes total and 
permanent kidney failure and is also known as stage five of chronic kidney disease (CKD) 
(National Institute of Diabetes and Digestive and Kidney Diseases, 2016).  There are 
approximately 26 million Americans diagnosed with CKD, and, of those individuals, more than 
600,000 have progressed to stage five and are in renal failure (United States Renal Data System, 
2016).  ESRD is an irreversible condition, and once an individual progresses to this stage, 
medical intervention through dialysis or kidney transplantation is required for patient survival.  
Kidney transplantation is an intervention aimed at improving the health of ESRD patients as it 
allows patients to remain off of dialysis; thus, improving patient quality of life (Kovacs et al., 
2011; Smith et al., 2008), increasing survival (Wolfe et al., 1999), and reducing health care costs 
(United States Renal Data System, 2013).  Studies that attempt to identify modifiable risk factors 
related to improving health outcomes in kidney transplant recipients are needed at this time.  
  The purpose of this study was to examine the association between sleep disorders and 
kidney transplant outcomes of both graft survival and patient mortality, in a single-center study 
of patients with a failed kidney transplant.  A rationale for this study includes the high 
prevalence rates of sleep disturbances which are reported across the spectrum of chronic kidney 
disease (CKD) (Burkhalter et al., 2011; De Santo, Bartiromo, Cesare, & Cirillo, 2008; Pierratos 
& Hanly, 2011; Teixeria do Santos & Moraes de Almondes, 2015; Williams, McCrae, Rodrigue, 
& Patton, 2016; Zhang et al., 2014).  Additionally, the proposed study rationale is supported by 
the associations between adverse health outcomes and sleep disturbances throughout CKD and 
specifically, in kidney transplant patients (Benz, Pressman, Hovick, & Peterson, 2000; Jung, Lee, 
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Baek, Kim, & Lee, 2010; La Manna et al., 2011; Lee et al., 2015; Lindner et al., 2012; Molnar et 
al., 2010; Molnar et al., 2015; Szentkiralyi et al., 2011). 
Background 
Kidney transplantation is the preferred intervention for end-stage renal disease by both 
patients and providers (United States Renal Data System, 2016).  Graft survival time, the length 
of time the transplanted kidney remains functioning after surgery, is an important outcome 
measure of transplant success.  Transplant recipients are able to remain off of dialysis for the 
duration of time that their transplanted graft is functioning.  However, when the transplant fails, 
patients must return to dialysis for continued survival, and if medically appropriate, patients may 
subsequently be evaluated for another transplant (Marcen & Teruel, 2008).   National data have 
shown successful short-term outcomes of graft survival with averages of 1-year graft survival 
rates at 96% and 3-year graft survival rates at 88% (Matas et al., 2015). While data on long-term 
outcomes are reported less, as fewer studies have been conducted, the estimated national average 
for a kidney transplant graft half-life ranges from 8-12 years, meaning that 50% of transplant 
recipients maintain a functioning graft for approximately 8-12 years before the transplanted 
kidney fails (Hart et al., 2016; Lamb, Lodhi, & Meier-Kriesche, 2011).    
Nationally reported mortality rates for kidney transplant recipients within three years 
post-transplant remain very low, meaning that patients have a high likelihood of survival post-
transplant.  Patient survival 1-year post transplant is reported at 97%, and patient survival 3-year 
post transplant is reported at 93% (Matas et al., 2015).  Mortality in transplant recipients, while a 
separate outcome from graft survival, can also be closely related to graft survival.  In some 
instances, patient mortality can impact graft survival, such as in cases where a patient dies with a 
functioning graft, reducing the longevity of the transplant. While mortality rates are low in the 
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first three years after a transplant, such rates increase as graft survival time increases, and death 
with a functioning graft has been identified as one of the major causes of graft failure for patients 
who have maintained their transplant for 10 or more years (Matas et al., 2008).  In addition to 
death during the transplant course (death with a functioning graft), death after graft loss is 
another relevant outcome among kidney transplant recipients.  Although transplantation is 
intended to increase patient survival (Wolfe et al., 1999) and improve quality of life in end-stage 
renal disease (ESRD) patients (Kovacs et al., 2011; Smith et al., 2008), kidney transplant 
recipients have an elevated death rate after graft loss, compared to ESRD patients who have 
remained on dialysis (Kaplan & Meier-Kriesche, 2002; McCaughan et al., 2014; Perl et al., 
2012).   
The focus on graft survival and mortality outcomes from kidney transplant centers has 
centered on improving short-term outcomes, as presently (as of April, 2017), transplant 
reimbursement and quality oversight from the Centers for Medicare and Medicaid Services are 
based on 1-year outcomes (Conditions of Participation for Hospitals, 2007).  However, over the 
past twenty years, as improvements have been documented in graft survival and mortality 
outcomes at 1-year post-transplant (Matas et al., 2015) the focus on transplant research has 
begun to expand to other areas of need.  For instance, there have been few improvements in 
long-term graft survival outcomes, and the rate of patient death with a functioning graft has 
actually worsened for 10-year outcomes (Matas et al., 2015).  Moreover, there is limited research 
on the increased risk of patient mortality after graft loss.  Improving long-term graft survival and 
patient survival outcomes in the kidney transplant population is an important issue related to 
national health care costs, health care policy, and patient quality of life (Lodhi & Meier-
Kriesche, 2011; Mathis, 2015).  Research has been identified as an essential part of better 
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understanding long-term outcomes in kidney transplantation (American Society of 
Transplantation, 2015), and studies that attempt to identify patient-related variables associated 
with graft survival and mortality are needed at this time.   
Problem Statement 
Exploring patient-centered risk factors in transplant recipients may be an important next 
step for transplant research aimed at improving long-term outcomes.  Immunologic factors such 
as antigen matching and immunosuppressant medications have remained the focus of transplant 
research, as these variables are related to the risk of acute graft loss through cellular rejection 
(Mange, Cizman, Joffe, & Feldman, 2000; Pratschke, et al., 2016).  However, over the past 
decades, as the improvement of immunosuppressant medications has lessened the risk of acute 
cellular rejection, research has identified that non-immunologic variables are also important 
mediators of graft survival (Mange et al., 2000).  As patients now have a decreased risk of acute 
immunologic graft failure, a patient’s medical comorbidities or lifestyle factors may be strongly 
associated with graft survival and mortality outcomes; thus, the importance of how such factors 
can relate to transplant outcomes merits further consideration. Sleep disturbances may be related 
to transplant outcomes, as sleep influences physiological processes in the body and may impact 
kidney functioning through both indirect and direct mechanisms. 
Sleep and kidney functioning.  Sleep is an essential aspect of quality of life among 
patients with end-stage renal disease (ESRD) (Eryilmaz, Ozdemir, Yurtman, Cilli, & Karman, 
2005; Rodrigue et al., 2011).  Moreover, sleep has documented biological influences on health, 
as sleep disturbances have been associated with increased inflammation (Irwin et al., 1996), 
hypertension (Bansil et al., 2011; Lavie, Herer, & Hoffstein, 2000; Sasaki et al., 2013), and 
diabetes (Reutrakul & Van Cauter, 2014).  In turn, these problems can lead to endothelial 
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dysfunction and sympathetic activation, which have the potential to impact kidney functioning 
(Hanly & Ahmed, 2014; Nicholl et al., 2012; Ozok, Kanbay, Odabas, Covic, & Kanbay, 2014; 
Turek, Ricardo, & Lash, 2012).  A possible direct relationship between sleep disturbances and 
renal failure has been proposed through the effect of hypoxia on the kidney (Hanly & Ahmed, 
2014; Nicholl et al., 2012).  Hypoxia refers to tissues lacking adequate oxygen through the blood, 
and occurs in patients with sleep-disordered breathing disorders.  While the precise role that 
sleep disturbances play in kidney functioning remains unknown, the high prevalence of poor 
sleep quality (Burkhalter et al., 2011; Kachuee et al., 2007; Reilly-Spong, Park, & Gross, 2013; 
Silvas et al., 2012) and sleep disorders (Molnar et al., 2007a; Molnar et al., 2010; Szentkiralyi et 
al., 2011; Williams et al., 2016) among kidney transplant recipients calls for further exploration 
of the associations between sleep and kidney functioning, and a consideration of how sleep 
disturbances may impact transplant outcomes. 
Poor sleep quality and kidney transplant patients.  Poor sleep quality is common 
across the spectrum of chronic kidney disease (CKD) (Turek, Ricardo, & Lash, 2012), and 
remains prevalent among kidney transplant recipients.  Rates of clinically significant poor sleep 
quality range from 38 to 62% in kidney transplant recipients (Burkhalter et al., 2011; Kachuee et 
al., 2007; Reilly-Spong et al., 2013; Silvas et al., 2012).  While there is a noted high prevalence 
of sleep disorders across the stages of CKD (Hanley, 2014; Pierratos & Hanly, 2011), transplant 
patients, in particular, remain understudied among those with CKD (Merlino, Gigli, & Valente, 
2008; Molnar, Novak, & Musci, 2009).  High rates of poor sleep quality among transplant 
recipients (Burkhalter et al., 2011; Kachuee et al., 2007; Reilly-Spong et al., 2013; Silvas et al., 
2012) may be indicative of a high rate of undiagnosed sleep disorders in this population 
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(Burkhalter et al., 2013).  Therefore, the diagnosis and treatment of sleep disorders in kidney 
transplant recipients requires increased awareness (Merlino, Gigli, & Valente, 2008).   
Sleep disorders and kidney transplant patients.  The prevalence of sleep disorders in 
kidney transplant recipients is both an understudied and a complex topic.  While post-transplant 
improvement of sleep disorders has been documented (Auckley, Schmidt-Nowara, & Brown, 
1999; Beecroft, Zaltzman, Prasad, Meliton, & Hanly, 2008; Juardo-Gamez et al., 2008; Langevin 
et al., 1993; Winkelmann, Stautner, Samtleben, & Trankwalder, 2002), research shows that 
despite the potential for some improvement, that sleep disorders remain quite prevalent post-
transplant (Molnar et al., 2007a; Molnar et al., 2010; Szentkiralyi et al., 2011; Williams et al., 
2016).  The primary sleep disorders studied among kidney transplant recipients are sleep-related 
movement disorders, insomnia, and sleep-disordered breathing disorders.  Sleep-disordered 
breathing disorders, namely, obstructive sleep apnea, have the highest prevalence rate of sleep 
disorders in kidney transplant recipients, ranging from 25-45% of study samples, assessed 
through both self-report measures (Szentkiralyi et al., 2011) and polysomnography measures 
(Fornadi et al., 2012; Molnar et al., 2010). 
While clear consensus on the prevalence of sleep disorders among transplant patients 
remains limited (as few studies with large samples exist), associations between sleep disorders 
and various aspects of patient health for kidney transplant patients have been documented.  Both 
insomnia (Novaks et al., 2006) and sleep apnea (measured through self-report) (Molnar et al., 
2007a) have been found to be associated with reduced quality of life and declining renal function 
among kidney transplant recipients.  Restless leg syndrome is associated with an increased risk 
of mortality in kidney transplant patients (Molnar et al., 2007b).  Two studies have previously 
explored the relationship between sleep apnea and kidney transplant graft survival, finding 
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conflicting results.  Szentkiralyi and colleagues (2011) conducted a 66 month prospective cohort 
study and found that having a high risk of sleep apnea was an independent risk factor for graft 
failure in female kidney transplant patients.  However, a study by Fornadi and colleagues (2014) 
found no significant relationship between sleep apnea and graft failure risk in their 75 month 
prospective cohort study.  Sleep apnea was also not significantly associated with an increased 
all-cause mortality risk (Fornadi et al., 2014).  Both studies (Fornadi et al., 2014; Szentkiralyi et 
al., 2011) examined small samples of patients who had experienced graft failure and both 
examined mid-range graft survival and mortality outcomes at approximately 5-6 years post-
transplant.   
Presently, the relationship between sleep disorders and transplant outcomes remains 
understudied, as few studies have been published (Fornadi et al., 2014; Szentkiralyi et al., 2011).  
More research is needed to further explore the associations between sleep disorders and kidney 
transplant graft survival and patient mortality.  Moreover, studies that measure transplant 
outcomes beyond a 5-6 year post-transplant time period are needed.   
Due to limited research, the inclusion of a theoretical framework can be a helpful 
addition when further conceptualizing the relationship between sleep and transplant outcomes. 
Theoretical Framework: The Restoration Theory of Sleep 
The Restoration Theory of Sleep (Adams & Oswald, 1977; Oswald, 1980) constitutes the 
theoretical foundation for this study, and it is one of several proposed functional theories of 
sleep.  It proposes that sleep is essential for restoring physiological and brain functions within an 
individual, and further suggests that sleep disturbances play a vital role in adverse health 
outcomes through preventing the restorative functions that occur during sleep (Adams & 
Oswald, 1977; Oswald, 1980).  The foundation for this theory was developed through research 
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identifying physiological processes associated with sleep and wake cycles, such as protein 
synthesis (Adams & Oswald, 1977), nocturnal secretion of growth hormones (Adams & Oswald, 
1977; Oswald, 1980), and changes in metabolic rates (Oswald, 1980).  The Restoration Theory 
of Sleep (Adams & Oswald, 1977; Oswald, 1980) has provided the basis for the study’s 
development, and, in conjunction with the current literature, supports exploring the associations 
between sleep disturbances and kidney transplant outcomes of graft survival and mortality.  It is 
proposed that kidney transplant patients who experience sleep disturbances will lack the 
restorative benefits of sleep, which will thus reduce their graft survival time and increase their 
risk of mortality.  
Specific Aims 
The primary aim of this study was to determine the association between any sleep 
disorder and graft survival time. Graft survival time was defined as graft failure or 
cardiovascular related death with a functioning graft.  The proportion of patients who died with a 
functioning graft and the relationship of this to any sleep disorder was also evaluated.  In 
addition, the study also explored whether sleep-disordered breathing disorders, in particular, 
were associated with graft survival time and death with a functioning graft.  The secondary aim 
of the study was to examine whether having any sleep disorder was associated with a higher 
mortality hazard ratio after graft failure.  It was also examined specifically, if having a sleep-
disordered breathing disorder, versus not, was associated with a higher mortality hazard ratio 
after graft failure.   
Overview of Methods 
A historic cohort study of kidney transplant recipients with a failed graft was conducted 
to examine the association between sleep disorders and kidney transplant outcomes.  The study 
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sample came from a single-center, the Sentara Norfolk General Transplant Center (SNGH), a 
Medicare certified transplant center in Southeastern Virginia.  Inclusion criteria for the sample 
were as follows: adult SNGH kidney transplant recipients who were transplanted and 
experienced graft failure and/or died with a functioning graft during the timeframe of January 1, 
1997 to September 1, 2015, inclusive.  Criteria for exclusion were: SNGH kidney transplant 
recipients who received a previous kidney transplant or a multi-organ transplant, and recipients 
who experienced graft failure within the first 90 days of their transplant surgery.  The main 
independent variable of interest in this study was sleep disorders (any sleep disorder and 
specifically, sleep-disordered breathing disorders).  Sleep disorders were defined through a 
diagnosis in the patient’s medical record that was documented prior to graft failure.  Additional 
covariates were included in the study based on their relevance to the identified transplant 
outcomes and to the primary independent variables of interest, any sleep disorder and sleep-
disordered breathing disorders.  These covariates included: gender, race, age, body mass index, 
diabetes, hypertension, coronary artery disease, heart attack history, peripheral vascular disease, 
dyslipidemia, stroke history, end-stage renal disease etiology, education level, functional status, 
smoking history, tobacco pack-years, non-compliance with transplant medications, transplant 
type, human leukocyte antigen mismatch score, donor age, and year of transplant surgery. 
Analytic approach.  Descriptive statistics were used to describe the sample and to 
summarize prevalence rates of sleep disorders in the present sample.  Chi-square and 
independent t-test analyses compared the covariates among two groups within the sample, 
patients with any sleep disorder and those without a sleep disorder.  Chi-square statistics were 
also used to compare the proportion of death with a functioning graft in the any sleep disorder 
group to those without a sleep disorder.  Kaplan Meier survival curves (Kaplan & Meier, 1958) 
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were used to examine the relationship of any sleep disorder to survival time.  Further, the Cox 
regression (Cox, 1972) examined the adjusted relationship of any sleep disorder to the outcomes 
of graft survival time and patient survival time after graft failure.  Separate regression analyses 
were used to test the study hypotheses with covariate adjustment.  Sub-analyses involving sleep-
disordered breathing disorders, were also run for each study outcome (death with a functioning 
graft, graft survival time, and patient survival time after graft failure).  
Research Questions 
This study explored the associations between sleep disorders and transplant outcomes, 
namely, the relationship between having any diagnosed sleep disorders and transplant outcomes, 
and also, the associations between sleep-disordered breathing disorders (a category of sleep 
disorders) and transplant outcomes.  The study involved multivariate statistical analyses of 
historic cohort data from a single-transplant center to address the following research questions:   
1a) Of kidney transplant recipients with graft failure, do those with any diagnosed sleep 
disorder, versus those without, have a higher proportion of death with a functioning graft? 
1b) Of kidney transplant recipients with graft failure, do those with a diagnosed sleep-
disordered breathing disorder, versus those without, have a higher proportion of death 
with a functioning graft? 
 
2a) Of kidney transplant recipients with graft failure, do those with any diagnosed sleep 
disorder, versus those without, have a decreased graft survival time through graft failure or 
cardiovascular related death with a functioning graft? 
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2b) Of kidney transplant recipients with graft failure, do those with a diagnosed sleep-
disordered breathing disorder, versus those without, have a decreased graft survival time 
through graft failure or cardiovascular related death with a functioning graft? 
 
3a) Of kidney transplant recipients with graft failure, do those with any diagnosed sleep disorder, 
versus those without, have an increased mortality hazard ratio after graft failure? 
3b) Of kidney transplant recipients with graft failure, do those with a diagnosed sleep-
disordered breathing disorder, versus those without, have an increased mortality hazard ratio 






Chapter II is a critical review of the literature relevant to the identified aims of this study.  
The chapter is organized into two sections.  Section I reviews the literature on sleep disturbances 
across the spectrum of chronic kidney disease.  It begins with a brief overview of chronic kidney 
disease and the sleep literature, followed by a focus on end-stage renal disease, presenting the 
sleep literature as it relates to both dialysis and transplant patients.  Section I ends with the 
introduction of a theoretical framework that suggests a restorative benefit of sleep and presents 
an overview of the potential physiological mechanisms through which sleep disorders may relate 
to kidney functioning. Section II presents a brief summary of relevant literature pertaining to the 
dependent variables and study covariates.  
 Section I  
Chronic Kidney Disease  
Chronic kidney disease (CKD) is defined by structural or functional abnormalities of the 
kidney that result in a decreased level of kidney functioning for a period of at least three months 
(National Kidney Foundation, 2002).  CKD is a significant public health problem worldwide, 
and, in the United States, it is estimated that CKD is more common than diabetes.  National data 
based on NHANES reporting suggests that more than 14% of the United States adult population 
has CKD (United States Renal Data System, 2016).   
There are five stages of chronic kidney disease (CKD), with stage five end-stage renal 
disease (ESRD) being the most severe (National Kidney Foundation, 2002).  ESRD describes 
total and permanent kidney failure (National Institute of Diabetes and Digestive and Kidney 
Diseases, 2016) and is an irreversible condition.  Once an individual progresses to stage five, the 
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treatment objective is disease management.  Intervention outcomes are aimed at improving 
quality of life and increasing life expectancy, as patients who have progressed to ESRD have 
significantly higher rates of mortality than the general population (United States Renal Data 
System, 2016).  Although CKD is a chronic and progressive disease that ultimately ends in renal 
failure, there are significant health implications throughout the disease’s progression.  
Complications of CKD include cardiovascular events (Go, Chertow, Fan, McCulloch, & Hsu, 
2004; Meisinger, Doring, & Lowel, 2006; Weiner et al., 2006), anemia (McClellan et al., 2004; 
Thomas, Kanso, & Sedor, 2009), and metabolic bone disease (Martin & Gonzalez, 2007; 
Thomas et al., 2009).  Patients with CKD have higher infection risks (Naqvi & Collins, 2006), 
increased risk of strokes (Chen et al., 2012), and mortality (Astor, Hallan, Miller, Yeung, & 
Coresh, 2008; Go et al., 2004; Weiner, et al., 2006).  Overall, individuals diagnosed with CKD 
(at any stage) have increased health care costs and reduced quality of life (United States Renal 
Data System, 2016).   
Given the many complications associated with chronic kidney disease (CKD), research 
findings suggest that patients with CKD are more likely to die prior to progressing to stage five 
(Keith, Nichols, Gullion, Brown & Smith, 2004).  However, due to the high prevalence of CKD, 
a significant number of patients with kidney disease progresses to kidney failure, and 
subsequently requires significant medical intervention, either through dialysis or kidney 
transplantation, to continue to live.  In 2014, there were more than 600,000 Americans who had 
progressed to end-stage renal disease (ESRD) (United States Renal Data System, 2016).  It is 
estimated that by the year 2030, more than 2 million individuals will require dialysis or a kidney 
transplant (Szczech & Lazar, 2004). 
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The development of chronic kidney disease (CKD) and the rate at which CKD progresses 
varies, and it is likely related to numerous factors. Progression of CKD is related to physiological 
factors such as glomerular hemodynamic factors, proteinuria, and hypertension (Yu, 2003).  
However, there are many other risk factors, such as age, race, gender, as well as lifestyle 
variables, such as smoking, obesity, and diet; that may relate to this progression.  Progression of 
CKD can also be due to secondary factors that are unrelated to the initial disease (Metcalfe, 
2007; Yu, 2003). Recent literature from 2012 and on identifies poor sleep quality and the 
presence of sleep disorders as possible non-traditional risk factors for both development and 
progression of kidney disease (Lee et al., 2015; Molnar et al., 2015; Sabbatini et al., 2008; 
Sakaguchi et al., 2013; Turek, Ricardo, & Lash, 2012). In light of these recent studies, further 
consideration should be given to the prevalence and impact of sleep disturbances, poor sleep 
quality, and sleep disorders across the spectrum of CKD.   
Sleep Disturbances and Chronic Kidney Disease 
Sleep quality is a complex clinical construct that often represents self-reported 
complaints about sleep (Buysse, Reynolds, Monk, Berman, & Kupfer, 1989).  Poor sleep quality 
can be a symptom of a sleep disorder, or a related consequence of medical and psychological 
disorders; it can also be a combination of these factors.  Sleep quality is typically assessed via 
self-reported measures.  While many measures exist, a widely used and well-validated 
questionnaire is the Pittsburgh Sleep Quality Index (PSQI) (Buysse et al., 1989).  Although few 
studies have specifically examined sleep quality in early stages of chronic kidney disease (CKD) 
(often focusing on end-stage renal disease patients), two studies using the PSQI found a 
prevalence range of approximately 50-80% of poor sleep quality in pre-dialysis CKD patients 
(Illiescu, Yeates, & Holland, 2004; Zhang et al. 2014).  Kumar and colleagues (2010) also 
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measured self-reported sleep quality across a sample of 673 stage 3-5 CKD patients reporting the 
prevalence of poor sleep quality as 57%.  These studies document that a high occurrence of self-
reported sleep problems can occur even during early stages of CKD. 
In addition to the high rates of self-reported poor sleep quality across samples of chronic 
kidney disease (CKD) patients, there is also an increased prevalence of sleep disorders in CKD 
patients. Sleep disorders can be classified according to the International Classification of Sleep 
Disorders (ICSD) Third Edition (American Academy of Sleep Medicine, 2014), a classification 
system that groups sleep disorders among six primary categories.  There are three categories of 
sleep disorders based on the ICSD that are often explored across the spectrum of CKD, and they 
are, sleep-related breathing disorders, sleep-related movement disorders, and insomnia.  As with 
sleep quality, the majority of the research literature on sleep disorders has focused on end-stage 
renal disease patients.  However, some studies with pre-dialysis CKD patients have been 
reported.   
In 2006, De Santo and colleagues measured the prevalence of sleep disorders in a sample 
of newly diagnosed CKD patients using the Sleep Disorders Questionnaire (SDQ), a 26-item 
self-report measure.  The SDQ (Violani, Devoto, Lucidi, Lombardo, & Russo, 2004) was 
primarily created as a screening tool for insomnia and is based on the Diagnostic and Statistical 
Manual of Mental Disorders, 4th edition (DSM-IV-TR) criteria for insomnia (American 
Psychiatric Association, 2000).  However, this measure also includes general questions about 
other sleep behaviors (snoring, lapses in breathing during sleep, daytime sleepiness, 
sleepwalking).  Utilizing the SDQ, the prevalence rate of any sleep disturbance was reported in 
80% of their CKD sample of approximately 50 patients.  In 2008, De Santo and colleagues 
administered the SDQ to a larger sample of 124 newly diagnosed CKD patients, and they 
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included a chronically ill comparison group, matched on both age and gender.  Individuals in the 
comparison group included those with a non-renal related chronic illness, 50 with hepatitis C, 
and 64 with heart failure.  Prevalence rates of sleep disturbances as assessed by the SDQ in the 
comparison group were much lower, ranging from 25-30%, compared to 89% in the CKD group.  
This finding demonstrates a significantly higher prevalence of sleep complaints in patients with 
CKD.  A study by Ahmad, Gupta, Gupta, and Dhyani (2013) reported a prevalence of insomnia 
of 40% (assessed through a clinical interview), and a 51% prevalence of obstructive sleep apnea 
(assessed through the STOP-bang) in a sample of CKD patients including 104 both pre-dialysis 
and end-stage renal disease patients.   
Thus, overall, there is not a great deal of literature on the prevalence of sleep disorders in 
early stages of chronic kidney disease (CKD), and the use of objective measurement is lacking, 
yet, the studies that do exist highlight the pervasiveness of sleep complaints and sleep disorders 
in patients diagnosed with early stages of CKD.  More recent studies from 2008 and on have 
expanded beyond prevalence research and have begun to explore the potential associations of 
sleep disturbances and CKD.   
Sleep disturbances and progression of chronic kidney disease (CKD).  In addition to 
determining the prevalence of sleep disturbances among patients with CKD, some studies have 
attempted to further elucidate whether sleep disturbances may serve as a possible risk factor for 
CKD development and progression to kidney failure (Kumar et al., 2010; Lee et al., 2015; 
Molnar et al., 2015; Sabbatini et al., 2008).  Cross-sectional studies examining the relationship 
between sleep quality and kidney functioning have had conflicting results.  In 2014, a study by 
Zhang et al. found that poor sleep quality was associated with poorer kidney functioning.  After 
controlling for confounders, there was no direct relationship between poor sleep and decreased 
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kidney functioning.  Kumar et al. (2010) compared mean sleep quality scores across three stages 
of CKD and did not find any significant differences in sleep quality across the CKD stages.  
Kurella, Luan, Lash, and Chertow (2005) studied both end-stage renal disease (ESRD) and CKD 
patients to examine the relationship between sleep quality and kidney functioning. When 
analyses were restricted to CKD pre-dialysis patients only, an association between reduced 
kidney functioning and poor sleep quality was found.  However, this relationship was only 
present in non-African American patients, and it was weakened (yet remained significant) after 
adjustment for depression.  In a more robust examination of the relationship between sleep 
quality and kidney functioning, Sabbatini and colleagues (2008) conducted a three year 
prospective cohort study with 78 pre-dialysis CKD patients.  Researchers recorded the Pittsburgh 
Sleep Quality Index (PSQI) scores of the sample at baseline, and completed follow up measures 
two and three years after the initial baseline measurement.  While higher PSQI scores (poor sleep 
quality) were associated with poorer kidney functioning (as measured through creatinine 
clearance), an independent relationship was not found after controlling for age.   
Given the variability in the potential sources of the etiology of poor sleep quality, self-
reported sleep quality may not be the ideal construct to directly examine the relationship between 
the progression of chronic kidney disease (CKD) and sleep disturbances. Nonetheless, it is 
important to consider that, while some previous studies have not found direct relationships 
between sleep quality and kidney functioning, these studies have found other clinical 
associations of interest (Kumar et al., 2010; Zhang et al., 2014).  Zhang et al. (2014) reported 
that sleep quality was associated with cardiovascular damage in CKD patients, and Kumar et al. 
(2010) found that patients with poor sleep quality had a higher risk of mortality prior to reaching 
end-stage renal disease (ESRD).  Even without demonstrating a direct relationship between sleep 
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quality and kidney functioning, these studies indicated that there are clinically significant 
associations between sleep quality and adverse health outcomes in CKD patients.   
Other studies have gone beyond measures of sleep quality, and they have focused on 
sleep disorders, namely, sleep apnea, when evaluating the associations between sleep and 
chronic kidney disease (CKD) progression.  Nicholl et al. (2012) studied approximately 250 
patients diagnosed at various stages of CKD and compared the prevalence of sleep apnea across 
the sample. Patients were divided into three groups based on their kidney function, measured 
through their estimated glomerular filtration rate (eGFR) and were evaluated for sleep apnea by 
completing an overnight cardiopulmonary monitoring test.  Findings revealed that the prevalence 
of sleep apnea increased as kidney functioning decreased.  Of the patients in stages 1-2 (normal 
or mildly reduced kidney functioning), 27% were diagnosed with sleep apnea, of the patients in 
stages 3-4 (moderate to severely reduced kidney functioning), 41% were diagnosed with sleep 
apnea, and of those in stage 5 (kidney failure on dialysis), 57% were diagnosed with sleep apnea.  
Researchers also examined the prevalence of nocturnal hypoxia among these three groups and 
found that nocturnal hypoxia was higher in patients with late stage CKD (stages 3-4) and kidney 
failure (stage 5).  Although this was a cross-sectional study relying on a home monitored sleep 
evaluation, the differences between the three groups of CKD patients merits consideration.  
Based on their findings, researchers suggested that not only does sleep apnea prevalence increase 
as eGFR decreases, but that the prevalence of nocturnal hypoxia could be a contributing factor to 
kidney function decline (Nicholl et al., 2012).  In exploring another potential mechanism, 
Sakaguchi and colleagues (2013) found that moderate to severe nocturnal hypoxemia was 
associated with a three to fourfold faster decline in kidney functioning over the period of a year.  
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Although measurement of sleep disorders was not included in their study, nocturnal hypoxemia 
is often associated with sleep-disordered breathing in CKD patients (Hanly & Ahmed, 2014). 
Through a retrospective population-based cohort study, researchers in Taiwan sought to 
determine whether sleep apnea was both an independent risk factor for the development of 
chronic kidney disease (CKD) and progression to end-stage renal disease (ESRD) (Lee et al., 
2015).  Patients who were newly diagnosed with sleep apnea during an identified time frame and 
who did not have a diagnosis of CKD prior to that identified time frame were included in their 
sample (n=4,674).  A comparison group of patients matched on age and gender (n=23,370) 
without sleep apnea were also included.  During the identified 11-year study time frame, 
approximately 400 patients from the sample were diagnosed with CKD.  Patients with diagnosed 
sleep apnea had a 1.9-fold increase in CKD incidence, and 2.2-fold increase of ESRD diagnoses, 
compared to patients without sleep apnea.  These reported incidence rates reflect adjustment for 
covariates, which included known CKD risk factors, such as age, diabetes, hypertension and 
obesity.   
In a similarly designed retrospective cohort study of US veterans, the relationship 
between sleep apnea and chronic kidney disease (CKD) progression was explored (Molnar et al., 
2015).  However, in this study, early stage CKD patients were only included if they did not have 
a diagnosis of obstructive sleep apnea during the inclusion time period from 2004-2006. The 
observed study time frame was from 2004-2013 and, on average, patients were followed for 8 
years.  During the study time frame, patients who were newly diagnosed with obstructive sleep 
apnea (OSA) were compared to those in the sample who did not have a diagnosis of OSA.  
Molnar and colleagues (2015) found that veterans with untreated OSA had an increased risk of 
mortality (OR 1.86), even after adjustment for comorbid conditions, age, and sociodemographic 
20 
 
variables. Moreover, researchers found that patients with untreated OSA had a significantly 
higher risk of rapid CKD progression (OR, 1.24-1.35 in fully adjusted model).  In this large 
cohort of U.S. veterans, obstructive sleep apnea was associated with an increased all-cause 
mortality risk, and with a faster kidney function decline in a sample of CKD patients (Molnar et 
al., 2015).  These studies by Lee et al. (2015) and Molnar et al. (2015) suggest an association 
between sleep apnea and risk of CKD development (Lee et al., 2015) and an accelerated 
progression to ESRD in patients with sleep apnea (Lee et al., 2015; Molnar et al., 2015). 
There is strong support suggesting relationships between sleep disturbances (Sabbatini et 
al., 2008) and sleep apnea (Lee et al., 2015; Molnar et al., 2015; Nicholl et al., 2012) to kidney 
functioning. Even when associations of kidney functioning and sleep disturbances have been 
attenuated after controlling for covariates (Kurella et al., 2005; Zhang et al., 2014), it is 
important to consider that the weakening of this association could be representative of a 
multifactorial casual pathway between sleep and kidney functioning, rather than the portrayal of 
non-association.  If sleep disturbances, namely sleep apnea, are associated with kidney 
functioning and can hasten renal failure (Lee et al., 2015; Molnar et al., 2015), then consideration 
of sleep disturbances in patients who have progressed to renal failure are also important to 
examine. 
End-Stage Renal Disease (ESRD) and Sleep 
While research has identified that sleep disturbances are prevalent across all stages of 
chronic kidney disease (CKD) (Ahmad et al., 2013; De Santo et al., 2008; Pierratos & Hanly, 
2011), historically, the focus of sleep research in the CKD population has centered on end-stage 
renal disease (ESRD) patients who are treated with dialysis (Teixeria do Santos & Moraes de 
Almondes, 2015).  The diagnosis of ESRD or kidney failure, refers to both dialysis and 
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transplant patients.  However, there are many physiological differences among these two groups 
of patients according to the medical intervention aimed to treat their kidney failure.  Dialysis 
patients often have significant medical complications, due to both the kidney failure and dialysis 
treatment side effects; sleep disturbances can occur in relation to either kidney failure or dialysis 
side effects.  It is this dynamic that has likely pushed the focus of sleep literature towards ESRD 
dialysis patients, given the wide range of opportunity for sleep disturbances. 
Dialysis is a lifesaving medical intervention for end-stage renal disease (ESRD) patients 
that removes waste, fluid, and chemicals from an individual’s system.  Dialysis is utilized to 
prevent deaths from uremia, as there are many changes that physiologically take place when an 
individual’s kidneys are non-functioning; such as the build-up of uremic toxins and extracellular 
fluid.  Despite the necessity of dialysis for ESRD patients, the treatment can be associated with 
several complications such as: anxiety (Feroze et al., 2012), depression (Feroze et al., 2012), 
reduced quality of life (Elder et al., 2008), hypotension (Sulowicz & Radziszewski, 2006), and 
muscle cramping (Sulowicz & Radziszewski, 2006).  Moreover, a frequently reported but often 
under-addressed aspects of patient health and quality of life among ESRD patients are the high 
prevalence rates of poor sleep quality (Abdelwhab, Kamel, & Noshey, 2010; Elder, et al., 2008; 
Illiescue, et al., 2003) and sleep disorders (Musci et al., 2004; Nicholl et al., 2012; Winkelman, 
Chertow, & Laxarus, 1996).     
Sleep quality in dialysis patients.  Self-reported sleep quality problems are present in 
approximately 50-80% of dialysis patients (Abdelwhab et al., 2010; Elder, et al., 2008; Illiescue, 
et al., 2003).  In a literature review on end-stage renal disease (ESRD) and daytime sleepiness, 
Perl, Unruh, and Chan (2006) report an estimated prevalence of daytime sleepiness in 52-67% of 
dialysis patients.  Sleep disturbances among dialysis patients have been associated with poor 
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health outcomes.  Poor sleep quality has been associated with higher inflammatory markers 
(Abdelwhab et al., 2010; Chiu et al., 2009), poorer dialysis efficiency (Abdelwhab et al., 2010), 
higher body mass index (Elder et al., 2008), increased pain (Elder et al., 2008), and reduced 
quality of life (Abdelwhab et al., 2010; Elder et al., 2008; Illiescue, et al., 2003).  In addition to 
high rates of poor sleep quality, dialysis patients have higher rates of sleep disorders than the 
general population (Musci et al., 2004; Nicholl et al., 2012; Unruh et al., 2006; Winkelman et al., 
1996).  
Sleep disorders in dialysis patients.  Increased prevalence of sleep-disordered breathing 
disorders (Nicholl et al., 2012; Unruh et al., 2006), sleep-related movement disorders 
(Winkelman et al., 1996), and insomnia (Musci et al., 2004; Sabbatini et al., 2002) are commonly 
reported among end-stage renal disease (ESRD) dialysis patients.   Unruh et al. (2006) found 
four-fold higher odds of having severe sleep-disordered breathing among hemodialysis patients, 
when compared to controls matched on age, gender, race, and body mass index. Nicholl et al. 
(2012) found a 57% prevalence of sleep apnea in dialysis patients. Restless leg syndrome (RLS), 
a sleep-related movement disorder, is also identified as a common disorder in ESRD dialysis 
patients (Winkelman et al., 1996). The reported prevalence of RLS in dialysis samples often 
ranges from 15-20% (Araujo et al., 2010; Musci et al., 2004; Winkelman et al., 1996).  Insomnia 
symptoms have been self-reported in 45-50% of large samples of dialysis patients (Holley, 
Nespor, & Rault, 1992; Musci et al., 2004; Sabbatini et al., 2002).  In a multi-center study of 
over 800 dialysis patients in Italy, 80% of the sample was identified as having a sleep 
disturbance, as assessed by a self-administered questionnaire (Merlino et al., 2006). Insomnia, 
restless leg syndrome, and obstructive sleep apnea were among the most prevalently reported 
sleep disorders (Merlino et al., 2006).  High rates of sleep disorders have been reported in 
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dialysis samples through both self-report (Merlino et al., 2006; Musci et al., 2004; Sabbatini et 
al., 2002; Winkelman et al., 1996) and objective measurement (Nicholl et al., 2012; Unruh et al., 
2006).   
In addition to their increased prevalence in dialysis patients, sleep disorders have also 
been associated with adverse health outcomes in these patients.  In dialysis patients, restless leg 
syndrome has been associated with increased inflammation (Higuchi et al., 2015) and increased 
risk of cardiovascular disease (Lindner et al., 2012).  Both sleep-disordered breathing disorders 
and sleep-related movement disorders have been associated with mortality among end-stage 
renal disease (ESRD) dialysis patients.  Tang and colleagues (2010) found that a baseline apnea-
hypopnea index greater than 15 was an independent predictor of cardiovascular disease 
morbidity and all-cause mortality among their sample of 93 peritoneal dialysis patients.  
However, in a smaller study of 30 dialysis patients in Korea, periodic limb movement disorder 
(PLMD), rather than sleep-disordered breathing disorders, was an independent predictor of 
mortality (Jung et al., 2010).  Benz and colleagues (2000) also conducted a 20 month prospective 
cohort study following 29 dialysis patients, and they found PLMD to be an independent predictor 
of mortality among this sample.  La Manna and colleagues (2011) reported that dialysis patients 
with restless legs syndrome had increased rates of new cardiovascular events and mortality.   
The high prevalence of sleep disturbances (Musci et al., 2004; Nicholl et al., 2012; 
Sabbatini et al., 2002; Unruh et al., 2006; Winkelman et al., 1996) and the association of sleep 
with adverse health outcomes in end-stage renal disease (ESRD) dialysis patients (Higuchi et al., 
2015; La Manna et la., 2011; Lindner et al., 2012; Tang et al., 2010) suggests sleep as an 
important aspect of health among patients with kidney failure.  Understanding the prevalence and 
associations of sleep problems in ESRD patients who have undergone kidney transplantation 
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remains important in the chronic kidney disease and kidney failure literature.  Research 
examining sleep disturbances among kidney transplant patients may lead to an improvement in 
understanding the associations of sleep disturbances throughout the spectrum of chronic kidney 
disease.  Furthermore, sleep disturbance may be a modifiable risk factor that could improve the 
overall quality of life and health of kidney transplant recipients. 
Kidney Transplant Recipients and Sleep 
Kidney transplant recipients are defined as individuals with end-stage renal disease 
(ESRD) who do not require dialysis, due to undergoing a kidney transplant surgery.  While 
kidney transplantation is an intervention to treat ESRD, it is not a permanent curative 
intervention, and when the transplanted graft fails, patients require dialysis for continued 
survival.  Successful transplantation often results in increased survival (Wolfe et al., 1999), 
improved quality of life (Kovacs et al., 2011), and reduced health care costs (United States Renal 
Data System, 2013) for ESRD patients.  Kidney transplant management centers on two 
outcomes: 1) graft survival, the duration of time the transplanted kidney remains functioning, 
and 2) patient survival.  Mortality in kidney transplant recipients may be the cause of a 
premature graft failure or can occur at a higher rate after graft failure (Kaplan & Meier-Kriesche, 
2002; McCaughan et al., 2014; Perl et al., 2012).  While quality of life is not often viewed as a 
clinical outcome of transplant success, it is an intended goal of the transplant, and, ultimately, 
has been found to be associated with morbidity and mortality in transplant patients (Chang, 
Winsett, Gaber, & Hathaway, 2004; Griva, Davenport, & Newman, 2013; Molnar-Varga et al., 
2011).   
Although transplantation improves quality of life in comparison to patients on dialysis 
(Alvares, Cesar, Acurcio, Andrade, & Cherchiglia, 2012; Rodrigue et al., 2011), reduced quality 
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of life remains after transplantation even with improved kidney functioning (Alvares et al., 2012; 
Molnar, Novak, & Musci, 2009; Smith et al., 2008).  Sleep disturbances have been found to be 
associated with reduced quality of life in transplant patients (Molnar-Varga et al., 2011), as poor 
sleep has been associated with both the psychological (Kauchee et al., 2007) and physical 
(Kauchee et al., 2007; Rodrigue et al., 2011) components of quality of life measures. The 
relationship between reduced quality of life and poor health outcomes in kidney transplant 
patients may be due to the underlying presence of sleep disturbances (Molnar-Varga et al., 
2011), which are known to impact various physiological aspects of an individual.   
Sleep research may receive less attention in the transplant literature due to the restoration 
of kidney functioning, dialysis cessation, and the overall improvement in quality of life that can 
occur post-transplant (Kovacs et al., 2011; US Renal Data System, 2016).  However, such 
improvements have not resulted in the absence of sleep complaints in transplant patients.  More 
consideration must be given to how sleep disturbances can affect kidney transplant patients and 
transplant outcomes. 
Sleep quality and kidney transplant patients.  Poor sleep quality is self-reported 
among 38-62% of kidney transplant patients (Burkhalter et al., 2011; Kachuee et al., 2007; 
Reilly-Spong et al., 2013; Rodrigue et al., 2011; Silvas et al., 2012).  Although this prevalence 
range is less than the reported occurrence of poor sleep quality in dialysis patients (Abdelwhab et 
al., 2010; Elder, et al., 2008; Illiescue, et al., 2003), poor sleep quality remains an area of clinical 
concern for transplant patients.  Rodrigue et al. (2011) compared sleep quality in 100 pre-
transplant (dialysis) patients to 100 post-transplant patients.  Poor sleep quality assessed by the 
Pittsburgh Sleep Quality Index (PSQI), was indicated in 78% of the pre-transplant dialysis 
samples and 52% of the post-transplant sample.  Sabbatini and colleagues (2005) compared the 
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mean PSQI scores of a control group with no diagnosed kidney problems, to dialysis patients, 
and kidney transplant patients.  Researchers found that while dialysis patients had the worst sleep 
quality of the three groups (PSQI=8.52), that transplant patients’ sleep quality (PSQI=6.46) was 
statistically significantly worse than that of the control group (PSQI=3.54). Despite these 
findings of some improvement in sleep quality post-transplant, a study by Liaveri and colleagues 
(2017) found that kidney transplant patients reported worse sleep quality (as measured through 
the Athens Insomnia Scale) compared to a group of dialysis patients.  Additionally, a study by 
Silvas and colleagues (2012) found that rates of poor sleep quality 3-6 months post-transplant did 
not differ when measured again at 12-15 months post-transplant. Thus, while it seems that some 
improvements in sleep quality may occur post-transplant, sleep problems do not appear to 
completely resolve after transplant (Rodrigue et al., 2011; Sabbatini et al., 2005).  Moreover, 
sleep quality does not seem to continue to improve several months following the transplant 
surgery (Silvas et al. 2012), as patients further adjust and experience restored kidney functioning.   
The consequences of poor sleep quality are present in various aspects of patient health 
among kidney transplant patients.  Sleep quality has been found to be an independent predictor 
for post-transplant fatigue (Chan et al., 2013, Rodrigue et al., 2011) and reduced physical and 
social functioning in transplant patients (Liaveri et al., 2017; Silvas et al., 2012).  Poor sleep 
quality has also been correlated with increased pain (Liaveri et al., 2017; Reilly-Spong et al., 
2013; Kachuee et al., 2007), anxiety (Noohi, Tavallaii, Bazzaz, Khoddami-Vishte, & Saadat, 
2008; Kachuee et al., 2007), depression (Liaveri et al., 2017; Novaks et al. 2006), higher body 
mass index (Silva et al., 2012) and an increased number of medical comorbidities (Kachuee et 
al., 2007).  Moreover, sleep quality has been associated with both mental (Kauchee et al., 2007) 
and physical (Kauchee et al., 2007; Rodrigue et al., 2011) aspects of quality of life measures in 
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kidney transplant recipients.  Associations of sleep to quality of life measures are important, 
given that quality of life scores have been predictive of both graft failure (Griva et al., 2013) and 
mortality in kidney transplant patients (Griva et al., 2013, Molnar-Varga et al., 2011).  
Associations between sleep quality and various aspects of health in transplant patients merit the 
need for further exploration regarding how sleep quality and sleep disturbances could impact 
kidney transplant outcomes.  Studies on sleep disorders have begun to further address this topic. 
Sleep disorders and kidney transplant patients.  Only recently have sleep disorders 
received increased attention in kidney transplant patients.  In part, this diminished consideration 
may have been due to early case studies suggesting the improvement of sleep disorders post-
transplant (Auckley et al., 1999; Langevin et al., 1993).  While post-transplant improvement of 
sleep disorders has been documented (Auckley et al., 1999; Beecroft et al. 2008; Juardo-Gamez 
et al., 2008; Langevin et al., 1993; Winkelmann et al., 2002), sleep disorders remain quite 
prevalent in kidney transplant patients (Liaveri et al., 2017; Molnar et al., 2007a; Molnar et al., 
2010; Szentkiralyi et al., 2011; Williams et al., 2016).  The prevalence and impact of sleep 
disorders on kidney transplant recipients is presumably more complex than initially thought.  The 
primary sleep disorders studied among kidney transplant recipients are sleep-related movement 
disorders, insomnia, and sleep-disordered breathing disorders.   
Sleep-related movement disorders and kidney transplant patients.  Sleep-related 
movement disorders are defined by stereotyped movements that disrupt sleep (American 
Academy of Sleep Medicine, 2014).  Among transplant samples, restless leg syndrome (RLS) 
and periodic limb movement disorder (PLMD) remain the focus.  Sleep-related movement 
disorders, primarily, RLS, may improve post-transplant as this disorder can be related to uremic 
symptoms, such as anemia (Beecroft et al. 2008; Winkelmann et al., 2002).  Winkelmann and 
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colleagues (2002) followed 11 patients with RLS, assessing RLS symptoms through a 
questionnaire at baseline (prior to transplant) and two times post-transplant.  In all patients, RLS 
symptoms were no longer present less than one month post-transplant.  However, researchers 
found that symptoms of RLS began to reappear throughout the course of the transplant, and 
readily reappeared after patients began to experience graft failure.  Such findings of RLS 
improving post-transplant have been reinforced by other studies that report comparable 
prevalence rates for the general population and kidney transplant recipients (Molnar et al., 2005; 
Novaks et al., 2006).  However, reports of comparable rates of RLS in kidney transplant 
recipients to general population (Molnar et al., 2005; Molnar et al., 2007b; Novaks et al., 2006) 
and reported resolution of RLS symptoms post-transplant (Winkelmann et al., 2002), have relied 
on self-report questionnaires which have not been validated in transplant samples.   When 
objective measurements, such as polysomnography have been used, there remains a reported 
improvement of sleep-related movement disorders; however, such studies also report that some 
symptoms remain (Beecroft et al., 2008; Juardo-Gamez et al., 2008).  
In 2008, Beecroft et al. reported findings from a study, which, to their knowledge was the 
first prospective cohort study using polysomnography sleep measurement both pre-transplant and 
post-transplant to examine periodic limb movements.  In their sample, seven patients met criteria 
for periodic limb movement disorder prior to transplant.  After transplant, all seven patients had 
statistically significant reductions in their periodic limb movement index (PLMI).  Despite this 
improvement, PLMI remained elevated in three out of the seven patients, demonstrating that 
PLMI was reduced to the mild range in all patients, but PLMI remained at or above 15 for some 
patients, indicating a continued presence.  A study by Jurado-Gamez et al. (2008) also relied on 
polysomnography assessment of their nine patients, again comparing polysomnography 
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measures both pre to post-transplant.  In their small sample, PLMI statistically significantly 
decreased from 36 per hour, pre-transplant and to 24 per hour (post-transplant).  These findings 
demonstrate an improvement of PLMD (from moderate to mild), yet a persistence of periodic 
limb movement disorder symptoms.  William and colleagues (2015) compared a group (n=55) of 
pre-transplant patients on dialysis to a group of post-transplant patients using polysomnography 
measurement.  The pre-transplant sample had a diagnosed prevalence rate of 32% for RLS, while 
the transplant sample had a reduced prevalence of 13%.  Although the prevalence of RLS in the 
transplant sample was significantly lower in comparison to the dialysis sample, this remained 
higher than the prevalence of RLS in the general population.  Overall, studies have found that 
RLS and PLMD improve post-transplant (Beecroft et al., 2008; Juardo-Gamez et al., 2008; 
Winkelmann et al., 2002) but not fully (Beecroft et al., 2008; Juardo-Gamez et al., 2008; 
Williams et al., 2016). 
Insomnia and kidney transplant patients.  Insomnia is defined as difficulty with sleep 
initiation, duration, or quality that occurs repeatedly and despite adequate opportunities for sleep 
(American Academy of Sleep Medicine, 2014).  Insomnia is a prevalent problem in early stages 
of chronic kidney disease (CKD) (De Santo et al., 2008) and in dialysis patients (Holley, Nespor, 
& Rault, 1992; Musci et al., 2004; Sabbatini et al., 2012). However, there are few studies that 
evaluate its prevalence in kidney transplant patients.  The highest reported prevalence of 
insomnia came from a study by Fornadi et al. (2012) using the Athens Insomnia Scale (Soldatos, 
Dikeos, & Paparrigopoulos, 2000) in a sample of 100 kidney transplant patients.  In this 
transplant sample, 16% of patients met criteria for clinical insomnia (scoring 10 or higher). 
However, in a larger sample, Novaks et al. (2006) reported that the prevalence of insomnia in 
kidney transplant patients was similar to that of the general population.  Novaks and colleagues 
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administered the Athens Insomnia Scale (Soldatos et al., 2000) in a sample of over 800 kidney 
transplant patients.  They also compared these findings to a sample of dialysis patients, and to a 
gender-matched non-CKD group.  Clinical insomnia rates were reported to be 8% among the 
transplant and the non-CKD group, and 15% in the dialysis group.  However, researchers 
reported that rates of insomnia symptoms (insomnia complaints, but below clinical cut off 
scores) were higher among transplant patients than the general population.  In this study, 83% of 
the dialysis group reported at least one insomnia symptom, while 70% of the transplant group 
and only 50% of the non-CKD group reported at least one insomnia symptom.  Liaveri and 
colleagues (2017) also used the Athens Insomnia Scale (AIS) to measure insomnia symptoms 
among their sample of transplant patients, dialysis patients, and subjects with normal renal 
function.  They found that the highest mean AIS scores were observed in transplant patients; 
however, the mean AIS scores for each group were below the clinical cut-off for insomnia.  
Williams et al. (2016) compared insomnia symptoms in a sample of pre and post-transplant 
patients (n=55).  Using self-reported sleep diary calculations, 68% of insomnia symptoms were 
reported in pre-transplant dialysis patients, compared to 48% in post-transplant patients. Overall, 
few studies have explored the prevalence of insomnia in kidney transplant patients.  While the 
prevalence of clinical insomnia is decreased in kidney transplant samples in comparison to 
dialysis samples, insomnia symptoms remain elevated post-transplant (Fornadi et al., 2012; 
Liaveri et al., 2017; Novaks et al., 2006; Williams et al., 2016). 
Sleep-disordered breathing disorders and kidney transplant patients.  Sleep-disordered 
breathing disorders refer to a wide range of ventilation abnormalities that can occur during sleep.  
Typically these disorders are divided into four categories: obstructive sleep apnea, central sleep 
apnea syndrome, sleep-related hypoventilation disorders, and sleep-related hypoxemia disorder 
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(American Academy of Sleep Medicine, 2014).  Of these disorders, obstructive sleep apnea 
(OSA) and central sleep apnea (CSA) are commonly studied in kidney transplant samples, with 
obstructive sleep apnea being the most prevalently diagnosed (Molnar et al., 2010; Szentkiralyi 
et al., 2011).  
Although a few case reports in the 1990s documented an improvement in sleep apnea 
post-kidney transplant (Auckley et al., 1999; Langevin et al., 1993), this has not been a widely 
supported phenomenon.  Langevin et al. (1993) presented case reports on two patients; despite 
the reported improvement in the apnea-hypopnea index (AHI) from pre to post-transplant, both 
patients’ AHI remained at five and above, denoting some remaining disease presence.  Auckley 
et al. (1999) reported on a single patient whose severe sleep apnea improved post-transplant.  
However, this study relied on polysomnography diagnosis pre-transplant and on home oximetry 
monitoring post-transplant.  Both case reports offer limited generalizability on this topic.  In 
2008, Juardo-Gamez and colleagues (2008) published a prospective cohort study (n=9) 
evaluating patients by polysomnography prior to transplant and three months post-transplant.  In 
this sample, three patients were diagnosed with sleep apnea, and two out of the three patients 
improved post-transplant.  Despite an improvement in AHI, researchers found that the 
improvement in sleep efficiency changes were not statistically significant.  In a larger study, 18 
patients (11 patients with sleep apnea), were followed longitudinally pre and post-transplant and 
were evaluated through polysomnography.  After transplant, AHI and saturation of oxygen did 
not change significantly among the sample.  Of the 11 patients with sleep apnea, three patients 
were considered responders with their AHI reducing by 50% (or to below 10), but not all 
improved (Beecroft, Zaltzman, Prasad, Meliton, & Hanly, 2007).  Yet despite the possible post-
transplant improvement of sleep apnea that has been documented through small samples, there is 
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a reported high prevalence of sleep apnea among kidney transplant recipients.  Sleep apnea 
prevalence rates range from 25-45% in kidney transplant patients, assessed through both self-
report measures (Szentkiralyi et al., 2011) and polysomnography diagnosis (Fornadi et al., 2012; 
Molnar et al., 2010).  Such research indicates that despite some reported improvements, there 
remains an increased prevalence of sleep apnea in kidney transplant patients. 
It has been suggested (Mallamaci et al., 2009) that transplant patients do not have an 
increased prevalence of sleep-disordered breathing disorders, contending that the relationship is 
confounded by body mass index (BMI).  In a study of 163 transplant patients, sleep-disordered 
breathing was measured through a cardiorespiratory polygraph.  Mallamaci et al. (2009) found 
no difference in the prevalence of sleep-disordered breathing disorders when comparing 
transplant samples to an age, gender, and BMI matched comparison group.  While this finding is 
intriguing, it is important to note that several studies (Beecroft et al., 2007; Beecroft, Pierratos, & 
Hanly, 2009; Diaz de Atauri et al., 2003) have reported an atypical presentation of sleep-
disordered breathing among kidney transplant samples. Studies have found that obesity is not a 
significant marker or correlate of sleep-disordered breathing in transplant patients (Beecroft et 
al., 2007; Beecroft et al., 2009; Diaz de Atauri et al., 2003) as it is in the general population 
(Young et al., 2002).  To date, no other study has replicated the finding of Mallamaci et al. 
(2009), and, in general, the literature continues to suggest a high prevalence of sleep-disordered 
breathing disorders in kidney transplant patients irrespective of BMI. 
Associations of sleep disorders to health outcomes in kidney transplant patients.  
The literature on the presence of sleep disturbances in kidney transplant recipients and whether 
sleep improves post-transplant, remains intriguing yet understudied. Some research studies report 
that sleep disorders improve post-transplant (Auckley et al., 1999; Langevin et al., 1993; Novaks 
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et al., 2006; Winkelmann et al., 2002), while other studies reveal that sleep problems remain 
prevalent after transplant (Liaveri et al., 2017; Molnar et al., 2010; Szentkiralyi et al., 2011; 
Williams et al., 2016).  Studies have begun to document the association of sleep disorders with 
various aspects of kidney transplant patients’ health.  Kovacs et al. (2011) found that sleep 
disorders namely, restless leg syndrome, obstructive sleep apnea, and insomnia were associated 
with poorer quality of life post-transplant.  Additionally, both insomnia (Novaks et al., 2006) and 
an assessed risk of sleep apnea (Molnar et al., 2007a) have been found to be associated with 
reduced quality of life and declining renal function among transplant recipients.  The 
associations between sleep and quality of life are important to consider, given the strong 
predictive relationships between quality of life and clinical outcomes in kidney transplant 
recipients (Chang et al., 2004; Griva et al., 2013; Molnar-Varga et al., 2011).  
Sleep disorders have also been associated with clinical measures of poor health in kidney 
transplant patients.  Insomnia symptoms have been associated with higher inflammatory markers 
(increased IL-6) in transplant patients (Fornadi et al., 2012).  Molnar et al. (2010) found that 
transplant patients with obstructive sleep apnea were at an increased risk for stroke incidence and 
coronary heart disease.  In the study by Molnar et al. (2010), average overnight oxygen 
saturation was also inversely correlated with stroke and coronary heart disease risk.  A study by 
Daabis and El-Gohary (2012) reported a correlation between the apnea hypopnea index (AHI) 
and kidney function (as measured through estimated glomerular filtration rate) in a sample of 
kidney transplant patients with sleep apnea.  Molnar et al. (2007b) followed a cohort of over 800 
kidney transplant recipients for four years after transplant.  Although there were a small number 
of patients (n=38) within the cohort suspected to have restless leg syndrome (RLS) (based on the 
RLS questionnaire), patients with RLS, versus those without, had a two-fold increased risk of 
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mortality.  RLS remained an independent predictor for mortality even after controlling for 
covariates; however, this study found no association between RLS and risk of graft failure 
(Molnar et al., 2007b).  Although the relationship between sleep disorders and transplant 
outcomes remains understudied, two studies have applied a more in-depth approach to explore 
this (Fornadi et al., 2014; Szentkiralyi et al., 2011).  
 Szentkiralyi and colleagues (2011) conducted a 66 month longitudinal study to explore 
the relationship between obstructive sleep apnea (OSA) and graft failure in kidney transplant 
patients. In their sample of 823 kidney transplant patients, 28% (n=226) of patients were 
identified as being “high risk” for obstructive sleep apnea, as measured by the Berlin 
Questionnaire (Netzer, Stoohs, Netzer, Clark, & Strohl, 1999).  During the approximate five-year 
study time frame, 91 patients had a failed graft, and 138 patients died.  A high risk of obstructive 
sleep apnea was found to be an independent risk factor for graft failure in female kidney 
transplant patients.  A separate association between mortality and high risk for obstructive sleep 
apnea was found in males; however, this relationship was no longer significant after controlling 
for age.  In contrast to the study by Szentkiralyi et al. (2011), a study by Fornadi and colleagues 
(2014) found no relationship between sleep apnea and graft failure or mortality.  Fornadi and 
colleagues assessed 100 post-transplant patients for sleep apnea through polysomnography, and 
monitored graft functioning (eGFR) every six months over the time period of approximately six 
years.  Of the 100 patients included in the study sample, 25 were diagnosed with obstructive 
sleep apnea.  The rate of graft function decline was similar in both patients with obstructive sleep 
apnea and patients without sleep apnea.  Additionally, there were no significant differences in the 
mortality rates of the sample based on the diagnosed presence of obstructive sleep apnea.  While 
the prospective design of the study by Fornadi et al. (2014) is a significant strength, the lack of 
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association found in Fornadi et al. (2014) may have been due to the study being underpowered 
(as identified by Fornadi et al., 2014).  In addition, Szentkiralyi et al. (2011) and Fornadi et al. 
(2014) measured graft failure and graft functioning at short-term and mid-range time periods (six 
years post-transplant).  National averages for graft half-lives exceed eight years (Lamb et al., 
2011); therefore, longer study time frames may be needed to observe the association of 
obstructive sleep apnea with graft outcomes and mortality in transplant patients.  Despite this, 
both studies have addressed an interesting topic relevant to how sleep disorders may impact 
transplant patients, a topic often ignored in the chronic kidney disease literature. There are many 
proposed potential etiologies for sleep disturbance in kidney failure. 
Possible Etiologies of Sleep Disturbances in Kidney Failure 
Amidst the increased prevalence of sleep disturbances and their clinical consequences in 
end-stage renal disease (ESRD) patients both pre-transplant Higuchi et al., 2015; Kumar et al., 
2010; La Manna et la., 2011; Lindner et al., 2012; Tang et al., 2010;Zhang et al., 2014) and post-
transplant (Daabis & El-Gohary, 2012; Fornadi et al., 2012; Molnar et al., 2007b; Molnar et al., 
2010), understanding the possible etiologies of sleep disturbances in patients with kidney failure 
remains important.  Further consideration must be given to differing pathophysiologies of sleep 
disturbances that vary in healthy populations and then become increasingly complex among 
patients with kidney failure, consisting of both dialysis and transplant patients.   
It is essential to consider that, while sleep disorders may be directly related to kidney 
failure, the overall increased prevalence of sleep disturbances in the end-stage renal disease 
(ESRD) population may in part be associated with the increased presence of additional medical 
comorbidities that accompany kidney failure, or may even be a consequence of dialysis.  For 
instance, sleep apnea shares a common profile with other comorbidities common among ESRD 
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patients (obesity, hypertension, diabetes), and the increased prevalence of sleep apnea in this 
population could be due to these comorbidities.  Restless leg syndrome is associated with anemia 
(Winkelmann et al., 2002) and extra cellular fluid (Perl et al., 2006), and, therefore, may be 
related to some of the medical consequences of kidney failure.  The high prevalence of insomnia, 
in dialysis patients is also often associated with uremic symptoms, such as restless legs 
syndrome, and pruritus (Sabbatini et al., 2002), and it has been associated with psychological 
distress (Theofilou, 2013), which is common among dialysis patients (Feroze et al., 2012).  In 
addition to comorbidities and treatment side effects, dialysis as an intervention (in and of itself) 
has the potential to impact sleep in various ways.  For instance, the potential circadian impact of 
the time of treatment, increased body temperature, and the physiological impact of rapid fluid 
exchange are all mechanisms through which dialysis could impact sleep (Parker, Bliwise, Bailey, 
& Rye, 2005).  The complexity of kidney failure, coupled with several potential medical 
comorbidities, the presence of dialysis, and the range of physiological underpinnings of different 
sleep disorders, makes uncovering the directionality of the relationship between sleep and ESRD 
a difficult feat.   
While some variables that could impact sleep disorders in dialysis patients can change 
post-transplant, such as the cessation of dialysis and restoration of kidney functioning, new 
changes occur post-transplant that may also impact sleep.  For instance, the addition of new 
medications (immunosuppressants) and their potential side effects and physiological influences 
can impact sleep.  Furthermore, some medical conditions associated with end-stage renal disease 
(ESRD) (such as diabetes and hypertension) may not change post-transplant and could continue 
to influence sleep.  Moreover, disturbances in fatigue and mood often remain prevalent post-
transplant (Williams et al., 2016), which can in-turn continue to impact sleep in kidney transplant 
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recipients.  Thus, there is the potential for both shared and different mechanisms when exploring 
how sleep relates to ESRD patients both on dialysis and those who have received transplants. 
Presently, the relationship between sleep disturbances and transplant outcomes remains 
understudied, as few studies have been published (Fornadi et al., 2014; Szentkiralyi et al., 2011).  
However, given the increased prevalence of sleep disturbances across the spectrum of chronic 
kidney disease (CKD), and the identification of sleep disturbances as a risk factor for CKD 
development (Lee et al., 2015) and faster progression to end-stage renal disease (ESRD) (Lee et 
al., 2015; Molnar et al., 2015; Turek, Ricardo, & Lash, 2012), there is support for suggesting a 
relationship between sleep and kidney functioning (Abuyassin et al., 2015; Turek, Ricardo, & 
Lash, 2012).  If a relationship between sleep and kidney functioning exists, then ESRD patients 
with sleep disturbances who have undergone kidney transplantation may be at increased risk for 
renal dysfunction post-transplant.  Current literature supports the need for further exploring the 
role of sleep disturbances in the outcomes of kidney transplant recipients and, specifically, 
whether sleep disorders are associated with graft survival and mortality outcomes in transplant 
patients.  The application of theory can provide an important contribution to the framing of this 
topic.  Support for considering the role of sleep in kidney functioning comes from a theory that 
focuses on the restorative benefits of sleep. 
Theoretical Foundation  
The Restoration Theory of Sleep.  The Restoration Theory of Sleep (Adams & Oswald, 
1977; Oswald, 1980) represents the theoretical foundation for this study and is one of several 
proposed functional theories of sleep.  It proposes that sleep is essential for restoring the 
physiological and brain functions within an individual (Adams & Oswald, 1977; Oswald, 1980).  
The basis for this theory further suggests that sleep disturbances play a vital role in adverse 
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health outcomes through preventing the restorative functions that occur during sleep.  The theory 
began to take form in the 1970s and the 1980s and developed through studies identifying 
physiological processes associated with sleep and wake cycles from both animal and human 
models.  At its inception, the theory contended that sleep was associated with physiological 
functions through tissue restoration (Adams & Oswald, 1977; Oswald, 1980), protein synthesis 
(Adams & Oswald, 1977), nocturnal secretion of growth hormones (Adams & Oswald, 1977; 
Oswald, 1980), and changes in metabolic rates (Oswald, 1980).  The theory continues to evolve 
with the field of sleep medicine today, but it remains intact through the continued theorization 
that sleep plays a restorative role in brain and body functioning.  
Sleep is a cyclical process that occurs throughout various stages. There are five stages of 
sleep (Loomis, Harvey, & Hobart, 1937), and these stages are divided into two types of sleep; 
rapid eye movement (REM) sleep and non-REM sleep (Dement & Kleitman, 1957). REM sleep 
has been considered restorative for the brain, and non-REM sleep is restorative for the body.  
Throughout the different stages of sleep, various physiological processes and changes occur, 
which further demonstrates the important restorative processes that occur throughout sleep 
cycles.  Even in the early 1900s researchers uncovered the dipping of blood pressure that 
occurred within the first 1-2 hours of sleep (Kleitman, 1929).  If these vital physiological 
processes and changes that take place during sleep cycles are disrupted through sleep disorders, 
the theory contends that individuals then lack the restorative benefits that are intended to occur 
during sleep (Adams & Oswald, 1977; Oswald, 1980). 
The application of the Restoration Theory of Sleep (Adams & Oswald, 1977; Oswald, 
1980) has provided the basis for the present study’s development, and, in conjunction with the 
current literature, supports the exploration of assessing the associations of sleep disturbances and 
39 
 
kidney transplant outcomes.  Although the precise relationship between sleep and kidney 
functioning remains unknown, research in the field and the application of the Restoration Theory 
of Sleep (Adams & Oswald, 1977; Oswald, 1980) enables the identification of a functional and 
important relationship between sleep and kidney functioning that may be disrupted through sleep 
disturbances.  It is proposed that kidney transplant patients who experience sleep disturbances 
will lack the restorative benefits of sleep, which will shorten the longevity of their kidney 
transplant graft survival and increase the incidence of mortality.   
Potential Mechanisms of Sleep and Kidney Functioning 
Indirect mediators of sleep and kidney functioning.  There are several proposed 
mechanisms through which declining kidney function could be accelerated by the presence of 
sleep disturbances.  Turek and colleagues (2012) suggest that poor sleep quality and/or sleep 
disorders exacerbate the severity of three risk factors associated with renal failure: hypertension, 
diabetes, and obesity (through inflammation).  In turn, these risk factors influence increased 
sympathetic activation and endothelial dysfunction, two physiological mechanisms through 
which sleep can impact kidney functioning (Hanly, 2014; Nicholl et al., 2012; Ozok et al., 2014; 
Turek et al., 2012).  
 Hypertension.  Hypertension remains a leading cause of kidney failure in the United 
States (United States Renal Data System, 2016).  Hypertension can impact renal functioning 
through damaged blood vessels that occur in the kidney.  Although studies identifying a causal 
relationship between sleep and hypertension are unclear, several studies offer support for an 
association between hypertension and sleep disturbances.  A study using NHANES data from 
2005 to 2008 reported an association between an increased risk of hypertension among adults 
with a sleep disorder, who also reported short sleep (OR 2.3) (Bansil, Kuklina, Merritt, & Yoon, 
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2011).  A review (Palagini et al., 2013) of sleep deprivation studies summarized that both total 
and partial sleep deprivation has been associated with increased blood pressure.  Decreased slow 
wave sleep, has been associated with morning hypertension (Sasaki et al., 2013).  Moreover, 
there is a documented relationship between sleep apnea and blood pressure dipping, which 
typically occurs overnight, and is associated with difficult to treat hypertension.  Sleep-
disordered breathing severity has been associated with non-dipping systolic pressure (Hla et al., 
2008), and poor sleep quality has also been associated with non-dipping of both systolic and 
diastolic blood pressure (Huang et al., 2011).   
Diabetes. Diabetes is another leading cause of kidney failure in the United States (United 
States Renal Data System, 2016) and has been associated with sleep (Kendzerska, Gershon, 
Hawker, Tomlinson, & Leung, 2014; Nagayoshi et al., 2016; Reutrakul & Van Cauter, 2014).  
Diabetes is a pro-inflammatory state that can increase the risk of vascular diseases.  Sleep 
restriction and short sleep duration are both associated with increased abnormal glucose 
metabolism and literature reviews have documented the long-standing relationship between sleep 
disturbances and diabetes (Reutrakul & Van Cauter, 2014).  Studies have specifically found 
associations between sleep apnea and an increased risk of type II diabetes (Kendzerska et al., 
2014; Nagayoshi et al., 2016).  Both diabetes and hypertension commonly co-occur in patients.  
The conditions also share a physiological pathway with inflammation, all of which (individually 
and combined) can impact kidney functioning. 
Inflammation. Inflammation is associated with sleep, as research in other patient 
populations has linked sleep quality and sleep disorders to immune functioning (Bryant, Trinder 
& Curtis, 2004; Chiu et al., 2009; Irwin et al., 1996).  It has been suggested that several genes, 
which regulate the quantity of sleep an individual receives, are also involved in regulating the 
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immune system (Bryant et al., 2004).  Irwin and colleagues (1996) found that partial sleep 
deprivation reduced natural killer cells in individuals, and they also found that, with a recovery 
night of sleep, natural killer cell levels returned to base values.  End-stage renal disease patients 
with sleep disturbances have been found to have increased inflammation (Chiu et al., 2009).  The 
relationship of sleep to inflammation is difficult to measure among transplant patients due to 
immunosuppressant medications, but inflammation is common in chronic kidney disease and 
dialysis patients.  Moreover, inflammation has been associated with renal failure (Dahle et al., 
2011), as inflammatory cytokines associated with oxidative stress can promote tissue damage of 
the kidney, which can accelerate progression to kidney failure (Gupta et al., 2013; Xu et al., 
2015).  The occurrence of hypertension, diabetes, and inflammation are all distinct but shared 
pathways that can lead to more significant health damage when uncontrolled.   
Direct associations between sleep and kidney functioning.  Much of the literature on 
sleep and kidney functioning has focused on sleep-related breathing disorders which are 
considered the most prevalent sleep disorders in transplant patients.  Several theories have been 
proposed that sleep apnea can accelerate renal failure.  A possible direct relationship between 
sleep apnea and renal failure has been proposed through the effect of hypoxia on the kidney 
(Hanly, 2014; Nicholl et al., 2012).  Hypoxia refers to tissues lacking adequate oxygen through 
the blood.  In an animal model study, a mouse kidney was used to examine the renal response to 
hypoxia.  Hypoxia resulted in decreased renal function (measured through estimated glomerular 
filtration rate) (Galat, Robinson, & Rhodes, 1988).  A study by Ahmed and colleagues (2011) 
examined the effects of nocturnal hypoxia on kidney functioning.  In their sample of 858 
patients, 374 patients had nocturnal hypoxia.  It was found that patients with nocturnal hypoxia 
developed a three-fold risk of accelerated kidney loss, even after controlling for age, body mass 
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index, diabetes, and heart failure.  In a review of the molecular impact of the kidney, Haase 
(2013) identified that the kidney is particularly susceptible to hypoxic injury due to “its complex 
transport functions within a relatively narrow range of pO2” (Haase, 2013, pp. 537).   
Another potential direct mechanism through which sleep apnea may impact renal 
function is through proteinuria. Proteinuria is the presence of abnormal amounts of protein in 
urine, and can often reflect a kidney filtration problem which reduces renal function.  While 
there is research refuting the relationship between sleep apnea and proteinuria (Mello et al., 
2004), an association between proteinuria and sleep apnea in patients with chronic kidney 
disease has been reported (Chan et al., 2015). 
The implications of the associations between sleep and kidney functioning are vast, and 
involve several proposed mechanisms. The relationship between sleep and kidney functioning 
throughout all stages of chronic kidney disease further highlights the significance of this 
relationship.  If sleep relates to kidney functioning, then sleep disorders in kidney transplant 
recipients could very likely impact the clinical outcomes of the newly transplanted kidney, 
impacting both the longevity of the transplanted graft and patient survival. 
Section II 
Section I summarized the chronic kidney disease and transplant literature in relation to 
the main independent variable of the present study, sleep disorders.  Section II presents a brief 
review of the literature pertaining to the dependent variables, and to additional covariates 
included in this study.  The purpose of this section is to present the relevant literature providing 
an overview of the determined dependent variables, which include graft survival time and 
mortality (death with a functioning graft and patient survival time after graft failure).  
Subsequently, a summary of the relevant research literature pertaining to each covariate and its 
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association with transplant outcomes are presented, if known.  In addition, a brief summary of 
any known research on the relationship between each covariate and sleep disorders, the primary 
predictor, are also presented.   
Dependent Variables 
Graft survival.  Graft survival refers to the length of time the transplanted kidney 
remains functioning after surgery.  Graft survival time is the main transplant outcome of interest 
for both patients and providers because transplant recipients are able to remain off of dialysis for 
the duration of time that the transplanted graft remains functioning.  National graft survival data 
have shown successful short-term outcomes with averages of 1-year graft survival rates at 96% 
and 3-year graft survival rates at 88% (Matas et al., 2015). Data on long-term outcomes are less 
often reported, as fewer studies have been conducted.  However, the estimated national average 
for a kidney transplant graft half-life ranges from 8-12 years (Hart et al., 2017; Lamb et al., 
2011), meaning that 50% of transplant recipients maintain a functioning graft for approximately 
8-12 years before the transplanted kidney fails.   
Mortality.  Mortality in transplant recipients, while a separate outcome from graft 
survival, can be closely related to graft survival.  Patient mortality can impact graft survival 
outcomes registered in cases where a patient dies with a functioning graft, reducing the longevity 
of the transplant. Nationally reported mortality rates for kidney transplant recipients within the 
first three years post-transplant remain very low, with patient survival 1-year post-transplant 
reported at 97% and patient survival 3-year post-transplant reported at 93% (Matas et al., 2015).  
However, mortality rates increase as graft survival time increases, and death with a functioning 
graft has been identified as a primary cause of graft failure for patients who had maintained their 
transplant for 10 or more years (Matas et al., 2008).   
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Additionally, mortality rates for end stage renal disease patients (ESRD) increase after 
graft loss.  Although a long-term goal of transplant is to increase the survival of patients 
compared to those remaining on dialysis (Wolfe et al., 1999), kidney transplant recipients have 
an elevated death rate after graft loss, compared to patients who have remained on dialysis 
(Kaplan & Meier-Kriesche, 2002; McCaughan et al., 2014; Perl et al., 2012).  Mortality rates up 
to two years after graft failure are reported at approximately 25%, indicating an increased risk of 
death for patients who have experienced graft loss, compared to those ESRD patients who have 
remained on dialysis (Gill, Abichandani, Kausz, & Pereira, 2002; Rao et al., 2007). 
Study Covariates 
In addition to examining the primary predictor, sleep disorders, additional study 
covariates that might be related to the dependent variables (graft survival and mortality) and/or to 
sleep disorders were considered.  For each covariate its association with transplant outcomes are 
presented, if known.  In addition, a brief summary of any known research on the relationship 
between each covariate and sleep disorders, the primary predictor, are presented.   
Gender of the recipient.  Past studies have found that male kidney transplant recipients 
have shorter graft survival time compared to females (Chen et al., 2013; Meier-Kriesche et al., 
2001).  While the exact cause of this gender disparity is unknown, a literature review of gender 
and transplantation has suggested that longer graft survival times for females may be related to 
hormonal differences and the relation of this to the immune system (Sanfey, 2005).  Occurrence 
of death with a functioning graft does not differ by gender (Meier-Kriesche et al., 2001). 
In the general population, males have a higher prevalence of sleep apnea compared to 
females (Dancy et al., 2003).  However, in a gender comparison of sleep apnea among kidney 
transplant recipients, Musci and colleagues (2004) found no associations between gender and 
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sleep apnea.  Other sleep disorders, such as restless leg syndrome (Manconi et al., 2012) and 
insomnia (Lind, Aggen, Kirkpatrick, Kendler, & Amstadter, 2015; Zhang & Wing, 2006) are 
both found to be more prevalent among women in the general population.  
Race of the recipient.  African American transplant recipients have poorer graft survival 
outcomes compared to Caucasian, Hispanic, and Asian transplant recipients (Gordon, Ladner, 
Caicdeo, & Franklin, 2010; Keith, Cantarovich, Paraskevas, & Tchervenkov, 2006; Meier-
Kreische et al., 2001).  A cohort study of approximately 80,000 veterans found that, within a 
sample of patients with a universal access to health care, African Americans had a higher risk of 
graft failure (Chakkera et al., 2005), suggesting that differences in transplant outcomes related to 
race may not be a health disparity issue.  A systematic review summarizing racial disparities in 
kidney transplantation, identified a difference in immunologic risk factors in different ethnicities, 
proposing immunology risks as the reason for racial differences in graft survival (Gordon et al., 
2010).  Regarding mortality outcomes, such as death with a functioning graft, research has found 
that African Americans have a lower risk of death with a functioning graft compared to 
Caucasian transplant recipients (Ojo et al., 2000).   
A high prevalence of undiagnosed sleep apnea among minority populations has been 
identified (Chen et al., 2015).  Additionally, African Americans are more likely to report long or 
short sleep durations (Krueger & Friedman, 2009).  A systematic review on sleep and race 
suggested that racial disparities in sleep health may contribute to the higher proportion of 
cardiovascular disease among minority populations (Kingsbury, Buxton & Emmons, 2013). 
Age of the recipient.  Younger patients have a higher risk of graft failure (Keith et al., 
2006).  This may be related to an increased prevalence of non-adherence with 
immunosuppressant medications among younger patients (Brahm, Manfro, Mello, Cioato, & 
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Goncalves, 2012), which can greatly impact graft survival times.  Risk of death with a 
functioning graft is seven times higher in recipients over age 65 compared to adults ages 18-29 
(Ojo et al., 2000).  In addition, older patients have an increased risk of death after graft failure 
(McCaughan et al., 2014).   
Sleep architecture changes throughout the lifespan, and sleep disorders and sleep 
disturbances are more frequently reported among older adults (Vitiello, 1997).  Factors that 
influence the prevalence of sleep disorders within the context of age are likely vast and 
multifactorial; however, a review of the research suggests that in-part, increased sleep 
disturbances among older adults may be related to comorbid medical and psychiatric conditions 
and medications used to treat such conditions (Roepke & Ancoli-Israel, 2010). 
Body mass index.  A recent meta-analysis reported that patients with a higher body mass 
index (BMI) have been found to be at increased risk of graft failure and mortality post kidney 
transplant (Lafranca et al., 2015).  However, other studies have contradicted such findings, by 
reporting no difference in patient survival or graft survival time related to BMI in kidney 
transplant recipients (Khwaja & El-Nahas, 2012; Krishnan et al., 2015).  BMI listing criteria are 
common among transplant centers, meaning that centers may only medically clear patients for a 
transplant surgery if their BMI is within a certain range.  Such listing criteria are important to 
consider and may affect research findings.  Meier-Kriesche, Arndorfer, and Kaplan (2002) 
identified that extreme lows and extreme highs of BMI are the significant risk areas for 
transplant outcomes.  A BMI greater than 40 kg/m2 is considered to pose increased risks to 
transplant outcomes (Khwaja & El-Nahas, 2012); however, a BMI less than 40 kg/m2 is often 
required in order to be transplanted at many centers, and thus, it may be difficult to assess the 
true relationship between BMI and transplant outcomes. 
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Past studies have found that poor sleep quality is associated with higher BMI in 
transplant patients (Silvas et al. 2012).  BMI is also associated with a higher risk of sleep apnea 
in the general population (Young et al., 2002).  However, two past studies have proposed that 
BMI may not be associated with sleep apnea in kidney transplant patients (Beecroft et al., 2007; 
Diaz de Atauri et al., 2003), indicating a potentially different relationship between BMI and 
sleep apnea among kidney transplant recipients. 
Medical comorbidities.  The literature on medical comorbidities and transplant 
outcomes vary.  While research has found that patients with increased comorbidities do not have 
shorter graft survival time (Grosso et al., 2012), studies have also reported an increased risk of 
death with a functioning graft, and increased risk of mortality after graft loss in transplant 
patients with increased medical comorbidities (Grosso et al., 2012; Wu et al., 2005).  Research 
on comorbidity and transplant outcomes have included both measures of comorbidity scores and 
individual measurements of common comorbid conditions that may be relevant to transplant 
outcomes.  In the present study, the following comorbid conditions were measured individually: 
hypertension, diabetes, stroke history, heart attack history, peripheral vascular disease, coronary 
artery disease, and dyslipidemia.  The rationale for including these comorbid conditions can be 
found earlier in Section I (potential mechanisms of sleep and kidney functioning). 
The relationship between sleep disorders and medical comorbidities can vary and can be 
specific to each comorbidity being measured.  However, in a past study of kidney transplant 
recipients, it was found that patients with diagnosed sleep apnea did not have higher comorbidity 
scores, as measured through the Charlson Comorbidity Index, compared to those transplant 
patients without diagnosed sleep apnea (Molnar et al., 2010). 
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End-stage renal disease etiology.  There are many diagnoses that can cause end-stage 
renal disease (ESRD); however, in the United States, uncontrolled hypertension and diabetes are 
leading causes of ESRD (United States Renal Data System, 2016).  Other causes, such as genetic 
disorders, autoimmune diseases, and nephrotic syndrome can also lead to renal failure (United 
States Renal Data System, 2016).  Few studies have examined each specific cause of ESRD and 
compared transplant outcomes; however, recent national findings from the Scientific Registry of 
Transplant Recipients report that patients whose ESRD was caused by diabetes and hypertension 
have poorer graft survival outcomes, compared to patients with other etiologies (Hart et al., 
2016).  Additionally, a single-center study found that transplant patients diagnosed with an 
autoimmune disease, lupus, had poorer graft survival rates compared to non-lupus diagnosed 
ESRD patients (Lionaki et al., 2008).  This study reported similar patient survival rates among 
the lupus and non-lupus diagnosed group of ESRD patients (Lionaki et al., 2008). Despite 
limited research, ESRD etiology may be associated with comorbidities or disease presence that 
may influence the newly transplanted kidney. 
Only one study was found regarding end-stage renal disease (ESRD) etiology and its 
relation to sleep disorders.  Patients with a hypertensive ESRD etiology had worse sleep quality 
scores than patients whose ESRD was due to other causes (Ameli et al., 2007).  However, there 
does not to our knowledge appear to be further research on whether ESRD etiology may differ in 
the presence of a sleep disorder. 
Education level.   Few studies have examined education level as a predictor of kidney 
transplant graft survival.  In the literature, education level can sometimes serve as a proxy for 
socioeconomic status (SES), but it is important to consider that education level may also reflect 
access to care, or even health literacy in samples.  Of the studies that do exist, there is a reported 
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increased risk of graft failure in patients with less education (Gordon et al., 2010; Schaeffner, 
Mehta, & Wikelmayer, 2008).  There is no known relationship between mortality and education 
level in a sample of kidney transplant recipients (Schaeffener et al., 2008).   
Research suggests an association between low SES and an increased risk of sleep 
disturbances (Mezick et al., 2008; Patel, Grandner, Xie, Branas, & Gooneratne, 2010).  In a 
prospective cohort study, lower education levels were associated with an increased risk of self-
reported short sleep duration (Stamatakis, Kaplan, & Roberts, 2007). 
Functional status.  Functional status refers to an individual’s ability to manage activities 
of daily living and their degree of dependence on others.  Patients with no functional limitations 
report a better health-related quality of life post-transplant (Rebollo et al., 2000). Although few 
studies have explored functional status as a potential predictor of graft failure, Garonzik-Wang 
and colleagues (2012) reported that patients with limited functionality (as they defined frailty) 
were more likely to have delayed graft functioning, which has been associated with poorer 
transplant outcomes (Yarlagadda, Coca, Formica, Poggio, & Parikh, 2008).  In a large national 
sample of US kidney transplant recipients, pre-transplant functional status was found to be an 
independent predictor of patient survival post-transplant (Reese et al., 2015).   
Past research indicates a relationship between sleep disturbances and functional status.  
Both poor sleep quality (Chasens, Sereika, Burke, Strollo, & Korytkowski, 2014) and sleep-
disordered breathing disorders (Spira et al., 2014) have been found to be independent predictors 
of decreased functional status in patients with diabetes (Chasens et al., 2014) and older females 
(Spira et al., 2014). 
Non-compliance with transplant medications.   A meta-analysis of 36 studies reported 
that the odds of graft failure increased seven-fold when patients were non-adherent with 
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transplant immunosuppressant medications (Butler, Roderick, Mullee, Mason, & Peveler, 2004).  
Obtaining a clear hazard ratio of non-compliance and its relation to graft failure is difficult due to 
patient variation in the severity of non-compliance and variation in the time period that the non-
adherence to transplant medications occurred.  However, such findings demonstrates the widely 
supported significance of compliance with transplant medications post-transplant.  A recent 
study by Brahm and colleagues (2012) also reported that non-compliance with transplant 
medications was associated with poorer kidney function.  Research addressing transplant 
medication non-compliance and sleep disorders could not be found, to our knowledge. 
Smoking history and pack-years.  Smoking is a cardiovascular risk factor, and past 
research reports a relationship between smoking and transplant outcomes. Nourbala, Nemati, 
Rostami, and Einollahi, (2011) presented a systematic review on the impact of cigarette smoking 
of kidney transplant recipients on graft survival and patient survival.  Smoking history was 
associated with a higher risk of graft failure and patient mortality.   A study by Cosio and 
colleagues (1999) reported that smoking was associated with a higher risk of death with a 
functioning graft.   
Patients who smoke are more likely to report sleep disturbances (Phillips & Danner, 
1995); moreover, smoking is a risk factor for sleep-disordered breathing (Wetter, Young, 
Bidwell, Badr, & Palta, 1994).  The relationship between smoking and sleep disorders was also 
considered in the present study. 
Donor type.  Kidney transplantation includes the use of both living donor kidneys and 
deceased donor kidneys.  Living donor transplants typically result in longer graft survival time 
compared to deceased donor transplants (Cecka, 2001; Wang, Skeans, & Israni, 2016).  Living 
donor recipients tend to have fewer postoperative complications and readmissions, which may 
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also be related to long-term graft survival (Guimaraes, Araujo, Santos, Nunes, & Casal, 2015).  
Research addressing transplant donor type and sleep disorders could not be found, to our 
knowledge. 
Human Leukocyte Antigen (HLA) mismatch.  HLA mismatch is an immunology 
measure referring to the degree of antigen mismatch between the donor and recipient.  Such 
markers identify what cells belong to the recipient’s body and better HLA matching increases the 
chance of engraftment, which refers to when donated cells from the transplanted organ start to 
make new blood cells in the recipient (Nguyen, Williams, Wong, & Lim, 2013).  HLA antibodies 
play a role in the immune response in accepting a newly transplanted kidney.  Research supports 
that HLA matching can impact graft survival outcomes, as patients with a poorer antigen match 
have a higher risk of graft loss (Pirsch et al., 1996; Zhou & Cecka, 1993).  Research addressing 
HLA matching and sleep disorders could not be found, to our knowledge. 
Donor age.  The relationship between donor age and transplant outcomes vary.  Donor 
age was not found to be predictive of long-term graft survival in a study by Pirsch et al. (1992).  
However, a systematic review identified donor age as a powerful predictor in long-term graft 
survival (Schratzberger & Mayer 2003). Research addressing transplant donor age and sleep 
disorders could not be found, to our knowledge. 
Year of transplant surgery.  The year of transplant time frame in this study spans from 
1997 to 2015.  Consideration was given to documented changes or advances in the field of 
transplant that may be associated to transplant outcomes.  The most notable change over the past 
twenty years in the field of kidney transplant has been improvements in immunosuppressant 
medication which has led to improvements in graft survival.  In 1997, Prograf, an 
immunosuppressant medication gained FDA approval for kidney transplant (Bowman & 
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Brennan, 2008), and shortly after this approval, transplant centers throughout the United States 
started to use this medication.  Since the approval and use of Prograf, there have been decreases 
in acute rejection (Knoll, 2008).  National transplant data reports that the occurrence of rejection 
during the first year post-transplant has steadily improved since the use of Prograf (in the 1990s), 
but that these improvements have remained relatively stable since 2008 (Hart et al., 2016).  
Findings from the national database, the Scientific Registry of Transplant Recipients, also report 
a steady increase in graft half-lives and patient survival over the past twenty years (Matas et al., 
2014).  Such findings indicate that transplant graft survival outcomes and patient survival have 
improved throughout the study time period.   
Consideration in the present study was also given to the potential advances in the sleep 
field that may have taken place during the transplant time frame (1997-2015).  Thus, a variable, 
year of transplant was included.  Although sleep disorders, namely, sleep apnea have gained 
more widespread medical attention in the 1980s (Punjabi, 2008), increased awareness and 
diagnosis of sleep apnea and all sleep disorders have likely steadily increased over the past 20 
years, although this is difficult to quantify. 
Summary 
 The present study examined associations between sleep disorders and transplant 
outcomes, while considering key covariates that might be potential confounders and/or 
adjustment variables or might modify the relationship of sleep disorders to the identified 
dependent variables.  Section I of this review summarized the literature on sleep disturbances 
across the spectrum of chronic kidney disease, specifically, the sleep literature among kidney 
transplant patients.  Thus, it summarized the rationale and basis for the study development.  
Section II provided an overview of the relevant literature pertaining to the dependent variables, 
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main independent variable (sleep disorders), and other covariates.  The additional covariates 








The overall goal of the present study was to examine associations between sleep 
disorders and transplant outcomes; namely, death with a functioning graft, graft survival and 
patient survival after graft failure.  This chapter addresses following: the study setting, research 
design, data sources, protection of human subjects, data abstraction procedures, the 
operationalization of study variables, and hypotheses.  Following the presentation of study 
hypotheses, the statistical analysis plan and analytic approach for each hypothesis is further 
described.   
Study Setting  
 Data from this study came from a sample of patients who were transplanted at the Sentara 
Norfolk General Hospital (SNGH) Kidney Transplant Center, in Norfolk, Virginia.  SNGH is a 
Medicare certified kidney transplant center.  All patients transplanted at SNGH follow an 
immunosuppressant dosing protocol and a standardized post-transplant plan of care, with regards 
to the frequency of clinic visits and measures of laboratory monitoring of kidney functioning 
post-transplant.  Patients transplanted at SNGH are followed at least monthly for the first year 
after their transplant, then are evaluated annually for the duration of their functioning transplant.  
Once a transplanted kidney fails, patients are no longer followed at the SNGH transplant center. 
Study Design and Data Selection 
The study design is a historic cohort study that utilizes data from Sentara Norfolk General 
Hospital (SNGH) adult kidney transplant patients who have a failed kidney transplant graft 
and/or died with a functioning graft.  Data for the study involved merging two secondary 
sources, namely, a national transplant registry maintained by the United Network for Organ 
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Sharing (UNOS) and the medical records maintained by the transplant center (SNGH) from 
which the sample is selected.  The study time frame was determined by the availability of data 
from both sources.  Although the national registry of transplant outcomes (UNOS) has been in 
place since 1988, access to medical record data from the SNGH transplant center was only 
available back to 1997.  Therefore, the study time frame was determined to be January 1, 1997 to 
September 1, 2015, inclusive. 
Inclusion criteria for the sample were as follows: adult SNGH kidney transplant 
recipients who have been transplanted and experienced graft failure and/or death with a 
functioning graft during the time frame of January 1, 1997 to September 1, 2015, inclusive.  
Criteria for exclusion were: SNGH kidney transplant recipients who had received a previous 
kidney transplant or a multi-organ transplant, and patients who experienced graft failure within 
90 days of their transplant surgery.  Data were not obtained on those subjects who had a previous 
kidney transplant or a multi-organ transplant.  However, data were originally obtained regarding 
all others with graft failure, including subjects who experienced graft failure within 90 days of 
their transplant.  Graft failure within 90 days of a transplant occurs in less than 3% of US kidney 
transplants (Matas et al., 2015) and is considered a rare occurrence often related to surgical 
complications or complications from the donor kidney, and thus informed the exclusion of 40 
subjects.  There were 367 subjects that satisfied all inclusion criteria.  
Data Sources 
 The United Network for Organ Sharing (UNOS) is a private, non-profit organization, 
which manages the United States’ organ transplant system.  UNOS was formed in 1984 after the 
National Organ Transplant Act (NOTA; P.L. 98-507); however, it was not until 1988 that the 
organization began collecting regulated data on all organ transplants performed nationwide.  
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Since 1988, UNOS has maintained a database consisting of both donor and recipient information 
for each organ transplant performed in the United States at all Medicare certified transplant 
centers.  All study variables requested from UNOS are outlined in the UNOS data collection tool 
(Appendix A).   
 Medical records from the Sentara Norfolk General Transplant Center (SNGH) were the 
second data source for this study.  The SNGH data collection tool (Appendix B) outlines the 
variables and information that were abstracted from the SNGH medical record.  The SNGH 
medical record has two sources, EPICTM and VoyagerTM.  EPIC is an electronic health software 
that is utilized by the SNGH hospital system.  The SNGH transplant center began using EPIC 
software in 2009 as an electronic medical record.  Medical record data prior to 2009 was found 
in an additional abstraction source, the Voyager database.  Voyager is a Technicon Data System 
utilized by the SNGH hospital system that dates back to 1986.  Although the Voyager system 
dates back to 1986, the range of information that has been uploaded into this database varies and 
data on transplant patients was not recorded in Voyager until 1997.  Thus, the availability of the 
SNGH medical record data informed the designated study time frame.   
Protection of Human Subjects and Ethical Considerations 
This study received ethical approval from the Eastern Virginia Medical School 
Institutional Review Board (identifier 15-09-WC-0198).  Secondary approval was received from 
the Old Dominion University Institutional Review Board (identifier 826031).  Additionally, the 
Sentara Research Compliance Department approved this study.  A waiver of subject consent and 
a waiver of subject protected health information were approved through all previously mentioned 
ethical review parties.  The sample consisted only of data from patients with failed grafts or 
patients who died with a functioning graft, and this inclusion criteria was related to the protection 
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of human subjects.  Patients with failed grafts or those who died with a functioning graft were no 
longer being followed at the Sentara Norfolk General Hospital (SNGH) kidney transplant center 
during the time of data collection; therefore, any research on such patients, our study sample, 
would have no impact on the care received.   
Data Abstraction Procedures 
After receiving approval from the identified Institutional Review Boards, a data request 
was submitted to the United Network for Organ Sharing database (UNOS) for all variables 
outlined in the UNOS data collection tool (Appendix A).  Two subject identifiers listed in the 
UNOS data collection tool (name and date of birth) served as the linking mechanism between 
UNOS data and the Sentara Norfolk General Hospital (SNGH) medical record.  Upon receipt of 
UNOS data, variables from the SNGH data collection tool (Appendix B) were then abstracted 
from the SNGH medical record.  A systematic approach was followed when abstracting variables 
from the SNGH medical record.  First, the medical history section of the subject’s chart was 
reviewed for variable abstraction.  Then, all history and physical notes in the subject’s medical 
record were reviewed to verify medical history abstractions and date of diagnoses.  In addition, 
every pulmonary and anesthesia note in the subject’s medical record was specifically reviewed to 
further search for the documentation of any diagnosed sleep disorder that may not have been 
recorded in the subject’s medical history.  Whether any variable abstracted from the SNGH 
medical record occurred prior to transplant, during the transplant time, or after graft failure was 
recorded.  Abstraction from the SNGH medical record was completed by one member of the 
research team who followed a uniform process. 
 Only diagnosed sleep disorders, medical comorbidity diagnoses, and smoking history 
information reported prior to transplant and/or during the subject’s transplant time period were 
58 
 
considered in data analyses.  For example, if a patient had a sleep disorder that was noted in their 
medical record after their graft failed, this sleep disorder was not considered in the analysis.  The 
only exception to this was the documentation of the variable relating to smoking history as 
assessed by packs per year (tobacco pack-years); this was notated in the medical history section 
of the medical record and often did not include a diagnosis timeframe.  Therefore, the calculation 
of a subject’s smoking history pre-transplant or prior to graft failure could not be ascertained. 
Upon completion of abstraction, data collected from UNOS and the data abstracted from the 
SNGH medical record were aggregated into one database.  All potential identifying information 
was removed from the data set.  
Operational Definitions of Study Variables 
 Study variables outlined in the data collection tools (Appendices A and B) consist of 
independent variables and dependent variables.  Dependent variables, the identified transplant 
outcomes, were defined from the transplant literature and through consultation with transplant 
nephrologists.  The primary independent variables, any sleep disorder and sleep-disordered 
breathing disorders, were selected based on review of the literature and were operationally 
defined according to The International Classification of Sleep Disorders, Third Edition 
(American Academy of Sleep Medicine, 2014).  Additional study covariates were selected in 
consideration of the transplant literature and sleep literature, the operational definitions for these 
variables are summarized in Table 1.   
Dependent Variables.  Death with a functioning graft refers to graft failure due to the 
subject’s death, as opposed to graft failure resulting in return to dialysis.  Determination of graft 
failure due to death was reported by variables maintained in the United Network for Organ 
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Sharing (UNOS) database.  Any subject whose date of death was documented as the same date 
of graft failure was classified as “death with a functioning graft.” 
Graft survival time or duration of the transplant refers to the length of time the patient 
maintained a functioning kidney transplant.  The endpoint of graft survival time in this study was 
defined as graft failure or cardiovascular (CVD) related death with a functioning graft.  Data on 
graft survival time was reported by variables recorded in the UNOS database.  Graft survival 
time was calculated by subtracting the date of the subject’s graft failure from the date of their 
transplant.  Graft survival time was reported in days.  
Survival time after graft failure refers to survival time after a subject’s transplant graft 
failure.  Data on mortality after graft failure was reported by variables maintained in the UNOS 
database and through the most recent contact with subjects recorded in the Sentara Norfolk 
General (SNGH) medical record.  Subjects that died with a functioning graft had a survival time 
after graft failure of 0; therefore, these subjects were excluded from analyses.  Survival time after 
graft failure was reported in days. 
Primary Independent Variables.  Any sleep disorder is defined as any diagnosed sleep 
disorder documented in the subject’s medical record, as classified by The International 
Classification of Sleep Disorders, Third Edition (American Academy of Sleep Medicine, 2014).  
Sleep disorder classifications include six major categories: insomnia, sleep-related breathing 
disorders, sleep-related movement disorders, central disorders of hypersomnolence, circadian 
rhythm disorders, and parasomnias.  Documentation of diagnosed sleep disorders occurred 
through the assignment of medical terminology and ICD-10 codes located in the subject’s 
medical history section of their Sentara Norfolk General Hospital medical record, or through 
medical notations in their records.  When the date of any sleep disorder diagnosis could not be 
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ascertained, the date of the first medical record notation reporting the diagnosed sleep disorder 
was recorded. Only sleep disorders reported in the medical record pre-transplant and/or during 
the transplant time frame were included in analyses.  Diagnosed sleep disorders documented 
after graft failure were not included in the analyses. 
Sleep-disordered breathing disorders are a classification of sleep disorders which refer to 
a wide range of ventilation abnormalities that can occur during sleep.  Typically, these disorders 
are divided into four sub-categories: obstructive sleep apnea, central sleep apnea syndrome, 
sleep-related hypoventilation disorders, and sleep-related hypoxemia disorder (American 
Academy of Sleep Medicine, 2014).  Of these disorders, obstructive sleep apnea (OSA) and 
central sleep apnea (CSA) are commonly studied in kidney transplant samples; with obstructive 
sleep apnea being the most prevalently diagnosed (Molnar et al., 2009; Molnar et al., 2010; 
Szentkiralyi et al., 2011).  Documentation of diagnosed sleep-disordered breathing disorders 
occurred through the assignment of medical terminology and ICD-10 codes located in the 
subject’s medical history section of their Sentara Norfolk General Hospital medical record, or 
through medical notations in their records.  Only sleep-disordered breathing disorders reported in 
the medical record pre-transplant and/or during the transplant time frame were included in 
analyses.  Diagnosed sleep-disordered breathing disorders documented after graft failure were 
not included in the analyses. 
Additional Covariates.  Identified covariates can be organized into two categories: 
recipient-related variables and transplant-related variables.  Recipient variables refer to data 
about the transplant recipient and include: gender, race, age, body mass index (BMI), diabetes, 
hypertension, coronary artery disease, heart attack history, peripheral vascular disease, 
dyslipidemia, stroke history, end-stage renal disease etiology, education level, functional status, 
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smoking history, tobacco pack-years, and non-compliance with transplant medications.   
Transplant variables refer to data about the kidney donor or transplant surgery and include: 
transplant type, human leukocyte antigen (HLA) mismatch, donor age, and year of transplant 
surgery.  Table 1 provides a summary of covariates, including the variable measurement scale, 
the data source from which they were obtained, and operational definitions.  
 
Table 1. 










   
Gender 
 




















Categorical  SNGH Diagnosed diabetes documented prior to 
transplant or prior to graft failure (yes or no) 
Hypertension 
 
Categorical SNGH Diagnosed hypertension documented prior to 
transplant or prior to graft failure (yes or no) 
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Categorical  SNGH Diagnosed coronary artery disease documented 






Categorical  SNGH Diagnosed heart attack history documented 





Categorical  SNGH Diagnosed peripheral vascular disease 
documented prior to transplant or prior to graft 




Categorical  SNGH Diagnosed dyslipidemia documented prior to 




Categorical  SNGH Diagnosed stroke history documented prior to 




Categorical  UNOS Reported cause of end-stage renal disease 





Categorical  UNOS Highest level of education completed at the 
time of transplant (high school or below, 





Categorical  UNOS Karnofsky scale measure (nurse reported) of 
patient functional status at the time of 
transplant, full functionality (100%) or limited 







Categorical  SNGH Documented non-compliance with transplant 





Categorical SNGH Smoking history documented prior to transplant 






















   





Ordinal UNOS Scale of an immunology match between 
transplant recipient with donor kidney.  The 
degree of the match is measured on a 0-6 scale, 
with a 0 mismatch designating a perfect match 
and a 6 mismatch designating a poor match. Age of Donor 
 







Continuous  UNOS Calendar year when recipient was transplanted 
(1997-2015) 
 
Abbreviations: UNOS, United Network for Organ Sharing; SNGH, Sentara Norfolk General Hospital; HLA 
mismatch, human leukocyte antigen mismatch 
 
 
Missing Data  
Missing data were addressed after data abstraction had been completed. The variable, 
body mass index (BMI), had missing data due to lapsed time periods in which this variable was 
not maintained by the United Network for Organ Sharing (UNOS) database. A conditional 
means imputation was utilized to impute the 47 missing BMI values.  The imputation was 
informed by two variables, sleep apnea diagnosis and functional status (Karnofsky score measure 
of a patient’s functional status at the time of transplant), and it was performed by a statistical 
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consultant. There were 24 missing cases of the variable education level.  An imputation was not 
considered appropriate for education level; therefore, the decision was made to create a third 
category designated as “unknown”. The method of creating a category for missing or unknown 
data is recommended by Klein, Rizzo, Zhang, and Keiding (2001), and it is considered an 
appropriate method to address missing data in a survival analysis.  Tobacco pack-years, a 
variable abstracted from the SNGH medical record, had 48 cases of missing data.  After 
abstraction, pack-years was considered a limited variable due to the large amount of missing data 
and limited ability to verify pack-years prior to graft failure; therefore, the categorical variable, 
smoking history, was used instead of pack-years in multivariate models. 
The variable, recipient race, did not have any missing data; however, there were six 
subjects in the sample with a reported race other than African American and Caucasian.  Due to 
this small number, creating a third category for race was considered uninformative.  Therefore, 
these six subjects were collapsed into the category Caucasian.  According to the research 
literature, the largest racial disparity in transplant outcomes found has been between African 
Americans and other races (Caucasians, Asians, and Hispanics) (Gordon et al., 2010); thus, the 
above approach was considered appropriate. 
Hypotheses 
 Study hypotheses corresponded to three identified dependent variables: death with a 
functioning graft, graft survival time, and patient survival time after graft failure.  Six hypotheses 
were tested, including a main hypothesis and sub-hypothesis for each dependent variable.  
Hypothesis 1 examined the outcome death with a functioning graft, and it helped to inform the 
analytic approach for hypothesis 2, which examined graft survival time. 
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Hypothesis 1: Death with a functioning graft.  Hypothesis 1a: Of patients with graft 
failure, patients with any diagnosed sleep disorder have a statistically significantly higher 
proportion of graft failure due to death (compared to graft failure and return to dialysis) than 
patients without any diagnosed sleep disorder.  Sub-hypothesis 1b: Of patients with graft failure, 
patients with a diagnosed sleep-disordered breathing disorder have a statistically significantly 
higher proportion of graft failure due to death (compared to graft failure and return to dialysis) 
than patients without a diagnosed sleep-disordered breathing diagnosis. 
Hypothesis 2: Graft survival time.  Hypothesis 2a: Of patients with graft failure, 
patients with any diagnosed sleep disorder have statistically significantly shorter graft survival 
times than patients without any diagnosed sleep disorder, even after adjustment for potential 
confounders.  Sub-hypothesis 2b: Of patients with graft failure, patients with a diagnosed sleep-
disordered breathing disorder have statistically significantly shorter graft survival times than 
patients without a diagnosed sleep-disordered breathing disorder, even after adjustment for 
potential confounders. 
Hypothesis 3: Patient survival time after graft failure. Hypothesis 3a: Of patients with 
graft failure, patients with any diagnosed sleep disorder have a statistically significantly higher 
total death hazard after graft failure than patients without any diagnosed sleep disorder, even 
after adjustment for potential confounders.  Sub-hypothesis 3b: Of patients with graft failure, 
patients with a diagnosed sleep-disordered breathing disorder have a statistically significantly 
higher total death hazard after graft failure than patients without a diagnosed sleep-disordered 






Data was analyzed using SASTM  Enterprise Guide software, version 6.1.  Descriptive 
statistics were used to describe the sample and to summarize prevalence rates of sleep disorders 
in the sample.  Chi-square and independent t-test analyses compared the covariates among two 
groups within the sample, patients with any sleep disorder and those without any sleep disorder.  
Chi-square statistics were also used to test hypothesis 1, comparing the proportion of death with 
a functioning graft in those with any sleep disorder (or a sleep-disordered breathing disorder) to 
those without any sleep disorder.  Separate survival analyses including Kaplan Meier survival 
curves (Kaplan & Meier, 1958) and the Cox regression (Cox, 1972) were used to test hypothesis 
2 (graft survival time) and hypothesis 3 (patient survival after graft failure). The goal of survival 
analysis is to estimate and interpret survival and hazard functions from time-to-event data 
(Hosmer, Lemeshow, & May, 2008).  The utilization of survival curves allows for a comparison 
between two groups.  Further, the use of the Cox regression allows for the exploration of the 
relationship between a predictor variable and a survival outcome, while controlling for possible 
covariates.  Statistical significance was met for all analyses if the two-tailed p value was < .05.  
A general overview of the analysis plan is summarized below.  Subsequently, a more in-depth 
discussion of the each hypothesis and the analysis approach for each hypothesis is further 
outlined.  
Censoring. Survival analyses allow for the inclusion of censored data.  Censoring occurs 
when survival time becomes unknown for a subject.  Censoring may be the result of a patient 
being lost-to follow up, or a death from causes unrelated to a study hypothesis (competing risk), 
or the event not occurring during a designated study time frame (administrative censoring).  
Censoring resulting from any of these events is referred to as right censored data.  Censored data 
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may also be left censored, representing when true survival time is less than the observed survival 
time (Allison, 2010).  Censored survival times underestimate the true time to a designated event 
and the consideration of whether censoring in a study is informative is necessary to address 
(Allison, 2010).  Informative censoring occurs when censored observations are related to the 
research hypothesis (or a specific variable) and thus have the potential to lead to significant 
biases in findings (Allison, 2010).  Right censoring approaches are further defined in the analytic 
approach for hypotheses 2 and 3.  The censoring definitions and consideration of informative 
censoring are addressed further in the section outlining analysis plans for individual hypotheses.   
Survival curves. Survival curves plot the probability that an individual survives longer 
than a specified time, and can be graphed as a curve or step-function.  Survival curves are often 
useful for preliminary analyses of survival data (Allison, 2010).  The Kaplan Meier method was 
used to estimate survivor functions (Kaplan & Meier, 1958).  This method was used to examine 
the relationship of sleep disorders to survival time, by comparing the survival time of those with 
any sleep disorder to those without a sleep disorder.  In order to statistically compare the 
differences between two survival curves, the Log-Rank test was used. Alternatives to the Log-
Rank test exist; however, such methods involve weighted tests at different points in survival 
times (Wilcoxon, Tarone-West, and Flemington-Harrington) and did not offer additional benefits 
with regards to the hypotheses being tested in this study.  
Cox regression. The Cox regression (Cox, 1972) was used to examine univariate and 
multivariate relationships of predictors to the dependent variables in hypothesis 2 (graft survival 
time), and hypothesis 3 (patient survival after graft failure).  The Cox regression is a semi-
parametric regression technique that can be used to model time-to-event data.  The Cox 
Proportional Hazards Model (Cox PH) is the basic foundation for the Cox regression.  The Cox 
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PH is a survival analysis model that assumes a proportional hazard, meaning the assumption that 
hazard ratios of variables are constant over time. The basic mathematical foundation of the Cox 
PH model could be described as follows: 
h(t)= h0(t) exp {b1x1 + b2x2 + … +bgroupxgroup) 
h(t) represents the baseline hazard function, X represents the predictor variables, and b represents 
the regression coefficients. The regression coefficients present the relative effect of every 
predictor variable on the survivor function.  As the value of the predictor increases, the hazard of 
event occurrence increases.  Any violations of the proportional hazards assumption call for the 
consideration of utilizing extensions of the Cox PH Model, namely, the stratified Cox Model, or 
the extended Cox Model.  The decision to use an extension of the Cox PH Model comes from an 
iterative process of model building and testing model assumptions. 
 There are three primary assumptions for the Cox model: 1) proportional hazards 
assumption, 2) linearity assumption, and 3) additivity assumption.  The proportional hazards 
assumption refers to the assumption that the effect of a predictor variable is constant across all 
values of time, meaning that the hazard ratio of a variable does not vary with time.  The linearity 
assumption refers to continuous variables, when a single analytic unit is used, addressing that the 
shape of the relationship between continuous predictor variables and the log of the hazard should 
be a straight line.  The assumption of additivity addresses that joint effects of the predictors 
should equal the sum of their individual effects (multiplicative interaction).  When the latter 
assumption is not met, an interaction term can be added to the regression model.   
Power.  A power estimation was not computed in order to inform sample size as the 
sample size was limited by a designated retrospective study time frame.  In a survival analysis, 
power considerations are related to the number of events in a sample, rather than the number of 
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subjects (Bradburn, Clark, Love, & Altman, 2003; Hosmer et al., 2008).  Vittinghoff and 
McCulloch (2007) reported that, while 10 events per covariate have been considered the rule of 
thumb in regression models for adequate power and model stability, similar model stability and 
adequate power can be achieved with 5-9 events per covariate.  Consideration was given to the 
number of events per covariate, and the limitations of this approach are reported in the discussion 
section.  Moreover, confidence intervals were also reported for hazard ratios to garner 
information on power estimates and model stability (Hosmer et al., 2008)  
Preliminary Findings and Statistical Methods for Hypotheses 
Prior to the description of the analysis approach for each hypothesis, a brief summary of 
preliminary analyses are presented.  Preliminary analyses yielded findings that informed 
inclusion and exclusion changes prior to testing hypotheses.  After preliminary findings are 
reported, the analytic approach for each hypothesis is further described.  All results of hypothesis 
testing are provided in Chapter IV. 
Preliminary findings. Preliminary analyses identified an interaction between any sleep 
disorder and non-compliance with transplant medications (Figures 1 and 2).  Despite similar 
proportions of the number of non-compliant patients in those with any sleep disorder (13%) 
compared to those without any sleep disorder (14%), χ2=.062, df=1, p=.803; a difference was 
detected among the survival times between patients with any sleep disorder and those without, 
based on the level of non-compliance (yes or no).  A graphical analysis of Kaplan Meier curves 
revealed that, among the sample of compliant patients (Figure 1), graft survival times were 
similar for those with, versus without, any sleep disorder (n=299).  However, in the subset of 
non-compliant patients (Figure 2), those with any sleep disorder had better survival compared to 
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those without any sleep disorder (n=68).  Figures 1 and 2 indicate there was an interaction 













After consideration of this interaction, it was determined that there was not a large 
enough sample of non-compliant patients (n=68) to conduct stratified analyses and that non-
compliant patients should be excluded from analyses.  In addition, non-compliance is a known 
cause of early graft failure (Butler et al., 2004), and it had been included in the study as a control 
variable.  Thus, the decision to exclude non-compliant patients from all analyses was made prior 
to hypothesis testing.  Sixty-eight non-compliant subjects were removed from all analyses.  
Analyses for descriptive statistics and all hypothesis testing was thus carried out on the 
remaining 299 (of 367) subjects. 
Hypothesis 1 Approach: Chi-Square Test Comparing Proportions 
Hypothesis 1a: Of patients with graft failure, patients with any diagnosed sleep disorder 
have a statistically significantly higher proportion of graft failure due to death (compared to graft 
failure and return to dialysis) than patients without any diagnosed sleep disorder.  
Analytic approach.  The approach for hypothesis 1a involved using Chi-square statistics 
to compare the proportion of death with a functioning graft in subjects with any sleep disorder 
and those without a sleep disorder.  Two considerations were given to death with a functioning 
graft.  First a chi-square test was used to compare the proportion of all-cause death with a 
functioning graft among the group of subjects with any sleep disorder and those without a sleep 
disorder.  Then, using only subjects who died with a functioning graft, a comparison of the 
proportions for non-cardiovascular related death with a functioning graft, and cardiovascular 
(CVD) related death with a functioning graft among the any sleep disorder and non-sleep 
disorder group was made.  This determination was made because CVD related death with a 
functioning graft has been found to be the most common cause of death in kidney transplant 
patients and may be related to end-stage renal disease (Jardine, Gaston, Fellstrom, & Holdaas, 
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2011; Ojo et al., 2000).  In addition, sleep disturbances are often associated with a higher risk of 
CVD (Hoevenaar-Blom, Spijkerman, Kromhout, van den Berg, & Vershuren, 2011; Somers et 
al., 2008).  Thus, comparing the proportion of CVD related death among those with and without 
sleep disorders was considered relevant in a sample of kidney transplant recipients. 
Additionally, comparing the proportion of death with a functioning graft among subjects 
with any sleep disorder and those without any sleep disorder was also meant to inform the 
analytic approach for hypothesis 2, which involved examining the association between sleep 
disorders and graft survival time.  In kidney transplant recipients, a subject’s end of graft 
survival time can occur through one of two ways: 1) death with a functioning graft or 2) graft 
failure while the subject is still living (thereby resulting in the return to dialysis).  Determining 
whether to consider death with a functioning graft as an endpoint of graft survival time or as a 
censored observation (a competing risk) was necessary in order to test hypothesis 2.  In the 
transplant literature, there is no determined consensus on how to define the end of graft survival 
time. However, clearly defining events and censored observations is important in every survival 
analysis (Hosmer et al., 2008).  Additionally, when determining censoring approaches, an 
important assumption in a survival analysis is that censoring is independent or non-informative; 
if this assumption is violated, this can introduce bias into the results of the Kaplan Meier 
estimator and the Cox regression (Allison, 2010; Hosmer et al., 2008).  In our study, comparing 
the proportion of death with a functioning graft in subjects with any sleep disorder and those 
without a sleep disorder, was necessary to inform whether censoring death with a functioning 
graft could be considered informative censoring.  If subjects with any sleep disorder have a 
statistically significant higher proportion of death with a functioning graft compared to those 
without any sleep disorder, then censoring death with a functioning graft may bias survival 
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outcomes.  In that instance, death with a functioning graft should not be censored, and a 
competing risks model should be considered. 
Sub-hypothesis 1b. Of patients with graft failure, patients with a diagnosed sleep-
disordered breathing disorder have a statistically significantly higher proportion of graft failure 
due to death (compared to graft failure and return to dialysis) than patients without a diagnosed 
sleep-disordered breathing disorder.  
Analytic approach.  Sub-hypothesis 1b followed the same analysis plan outlined for 
hypothesis 1a.  However, the independent variable was patients with a sleep-disordered breathing 
disorder, instead of any sleep disorder. 
Hypothesis 2 Approach: Survival Analysis 
Hypothesis 2a: Of patients with graft failure, patients with any diagnosed sleep disorder 
have statistically significantly shorter graft survival times than patients without any diagnosed 
sleep disorder, even after adjustment for potential confounders.  
Analytic approach. Hypothesis 2a was evaluated through a process of calculating 
Kaplan Meier survival curves, which examined univariate analyses of covariates to graft survival 
time, followed by a multivariate stratified Cox regression model.  The Cox model, stratified by 
year of transplant surgery, examined the association between any sleep disorder and graft 
survival time while controlling for key covariates.  
Censoring. The subject selection criteria in this study involved only patients with a failed 
graft or those who died with a functioning graft.  Therefore, the only consideration for censoring 
involved subjects who died with a functioning graft, thereby resulting in the designation of graft 
failure.   
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As stated previously, hypothesis 1 was meant to help inform the censoring decision for 
the graft survival time outcome.  After comparing the proportion of death with a functioning 
graft (both all-cause death and a comparison of cardiovascular (CVD) related death and non-
CVD related death), neither all-cause death nor specifically CVD related death with a 
functioning graft was associated with any sleep disorder.  Thus, death with a functioning graft 
could be considered in the censoring determination. 
Consideration was then given as to whether excluding all-cause death with a functioning 
graft or if only excluding non-cardiovascular (CVD) related death with a functioning graft would 
be more appropriate.  Kidney transplant recipients are at increased risk for CVD related mortality 
compared to the general population, due to the overlap of disease etiologies in end-stage renal 
disease.  Moreover, CVD related death with a functioning graft may also be related to the 
decreased functioning of the transplanted kidney (Holme et al., 2013; Jardine et al., 2011; Meier-
Kriesche, Balgia, & Kaplan, 2003).  Therefore, in defining the censoring approach, rather than 
censoring all-cause death with a functioning graft, a decision was made to censor only non-CVD 
related deaths with a functioning graft.  The inclusion of CVD related death with a functioning 
graft as event (endpoint of graft survival time) acknowledges the potential for competing risks in 
graft failure, an important consideration in transplant graft survival studies (Holme et al., 2013).  
Graft survival time was operationally defined as graft loss and return to dialysis or CVD related 
death with a functioning graft. 
After defining the censoring approach (non-cardiovascular death with a functioning 
graft), consideration was also given to whether any of the identified study covariates may be 
associated with censoring.  Although this was previously addressed for the primary independent 
variable, any sleep disorder, in hypothesis 1, analyses were also conducted to assess covariate 
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associations regarding the chosen censoring approach.  This was examined by comparing the 
proportion censoring among the levels of categorical variables, and comparing the means of 
continuous variables for censored observations. This information is summarized in Appendix C.  
Four covariates were identified as being associated with the censoring approach: recipient age, 
diabetes, tobacco pack-years, and stroke history, and will be further addressed in the multivariate 
modeling process. 
Survival curves.  Kaplan Meier curves were computed to compare survival time between 
subjects with any sleep disorder versus those without any sleep disorder.  The Log-Rank test was 
used to summarize the difference in survival curves. Univariate analyses between the 
independent variable and all identified covariates to graft survival time were computed.  
Univariate analyses describe the association between one predictor variable to survival time 
without taking into account the impact of any other variables (Bradburn et al., 2003).   The 
following variables were included in the univariate analyses: any sleep disorder, age, education 
level, race, gender, body mass index, smoking history, tobacco pack-years, functionality, 
diabetes, dyslipidemia, coronary artery disease, heart attack, peripheral vascular disease, stroke 
history, heart attack history, donor age, donor type, human leukocyte antigen mismatch, end-
stage renal disease etiology, and year of transplant surgery.   
Stratification.  Prior to starting the covariate selection process in the multivariate model, 
two-way interactions were assessed for all study covariates at the p ≤ .05 level.  A statistically 
significant interaction was found between transplant year and any sleep disorder (p=.002).  The 
decision to run a Cox Model, stratified by year of transplant surgery, was determined based on 
the interaction between year of transplant surgery, and the variable, any sleep disorder.  In 
addition, the variable, year of transplant surgery, violated the proportional hazards assumption of 
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the Cox model (Appendix D).  Thus, in addition to recognizing the heterogeneity between two 
time periods, the stratification of this variable amends this proportional hazards violation.  Strata 
for this variable included two periods of transplant surgery, 1997-2008 and 2009-2015.   
Designation of year of transplant strata was determined through subject matter expertise.  
Consideration was given to any relevant changes in the transplant field or specifically at the 
Sentara Norfolk General Hospital (SNGH) transplant center that may have occurred throughout 
the study time frame (1997-2015).  Advances in surgical techniques, immunosuppressant 
medications, and changes in the allocation policy were considered.  No known national surgical 
advances or relevant changes in the organ allocation policy were noted during the study time 
period; however, two center specific considerations were given when determining strata.  First, a 
notable change in the quality of the transplant center’s medical records was noted.  In 2009, the 
SNGH transplant center began using an electronic medical record, and because some study 
variables were abstracted from the two sources of records, this was determined relevant to the 
study; and thus, informed the strata designation.  The second change that was given 
consideration in strata designation was the use of the medication, Prograf, which began in 2000 
at the SNGH center.  Prograf is considered to be a stronger immunosuppressant medication 
compared to those medications of the past, and since the approval of Prograf in the United States, 
there have been decreases in acute rejection (Knoll, 2008).  Given the improvement in graft 
survival associated with Prograf, initially this change was accounted for in the stratification 
through the creation of three strata: 1997-2000, 2001-2008, and 2009-2015.  However, there 
were no noted survival differences between the Pre-Prograf era (1997-2000) and Post-Prograf era 
(2001-2008), likely this was due to the short time frame involved in the study prior to the use of 
Prograf. Therefore, the decision was made to collapse the strata 1997-2000 and 2001-2008.  
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Thus, the final strata remained 1997-2008 and 2009-2015.  After making a decision to stratify 
analyses, Kaplan Meier curves were recomputed for each strata. 
Cox regression. In the multivariate modeling process, backward elimination was utilized 
as the covariate selection method to develop a final model.  Variables that were not significant (p 
≤ .05) and did not have a confounding effect on the main variable of interest, any sleep disorder, 
were removed individually until none of the remaining variables in the model met the specified 
significance level for removal (p ≤ .05).  Variables were removed from the model in the 
following order: body mass index, education level, coronary artery disease, heart attack history, 
peripheral vascular disease, smoking history, donor type, diabetes, end-stage renal disease 
etiology, dyslipidemia and donor age.   
Prior to selecting a final model, consideration was given to the potential for informative 
censoring and how this may bias the study findings (Appendix C).  The variable, stroke history, 
remained statistically significant in the final model predicting better graft survival.  However, 
due to a statistically significant higher proportion of censoring in subjects with a stroke history 
(χ2=7.7065, df=1, p < .01), the decision to remove the variable stroke history from the 
multivariate model was made.  There was no significant interaction between stroke and any sleep 
disorder with regard to the outcome.  Collinearity was also assessed prior to accepting a final 
model (Appendix E).  There was a high correlation between the variable race and human 
leukocyte antigen (HLA) mismatch.  The variable HLA mismatch was selected to remain in the 
final model based on the literature citing that racial differences in kidney transplant graft survival 
may be related to immunology differences among different ethnicities (Chakkera et al., 2005; 
Gordon et al., 2010).  In consideration of the literature, HLA mismatch is a more representative 
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measure of immunology.  Thus, the variable, HLA mismatch, remained in the final model and 
race was removed.  
After the completion of the covariate selection process, the final variables remaining in 
the model were: any sleep disorder, year of transplant surgery, recipient age at the time of 
transplant, functional status, human leukocyte antigen mismatch, and gender.  Due to the 
potential bias of any one covariate selection method (Burnham & Anderson, 2002), the best 
subset covariate selection method was also utilized to verify agreement between the selected 
covariates based on more than one covariate selection method.  Best subset selection in SAS, is 
an automated covariate selection method that is based on an algorithm developed by Furnival 
and Wilson (1974) that compares many combination of variables and selects the best subset of 
models according to goodness-of-fit criteria.  A best subset regression was computed in SAS and 
presented the ten best subsets.  The group of covariates that were determined through the 
backward elimination process were also presented in the list of potential models determined 
through the best subset covariate selection process. 
Prior to acceptance of the final model, model assumptions were assessed.  The 
proportional hazards assumption was first assessed graphically through transformed cumulative 
martingale residuals.  However, because graphical analyses can be somewhat subjective, an 
interaction with time was also computed for all variables in the final model.  The linearity 
assumption was assessed through graphs of functional form for continuous variables.  Additivity 
was previously assessed by evaluating interaction terms among predictors prior to development 
of a final model.   
Sub-hypothesis 2b. Of patients with graft failure, patients with a diagnosed sleep-
disordered breathing disorder have statistically significantly shorter graft survival times than 
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patients without a diagnosed sleep-disordered breathing disorder, even after adjustment for 
potential confounders.  
Analytic approach.  Sub-hypothesis 2b followed the same analysis plan outlined for 
hypothesis 2a.  However, the independent variable was patients with a sleep-disordered breathing 
disorder, instead of any sleep disorder. 
Hypothesis 3 Approach: Survival Analysis 
 
Hypothesis 3a: Of those with graft failure, patients with any diagnosed sleep disorder 
have a statistically significantly higher total death hazard after graft failure than patients without 
any diagnosed sleep disorder, even after adjustment for potential confounders.  
Analytic approach.  Hypothesis 3 was evaluated through the following: examination of 
a Kaplan Meier survival curve, univariate analyses of covariates to patient survival time after 
graft failure, and a multivariate Cox Regression model to test the association between any sleep 
disorder and patient survival time after graft failure.  Survival time after graft failure signified 
that only patients who experienced graft failure and continued to live were included in this 
model.  Thus, subjects who died with a functioning graft were not included in analyses.  
Censoring. Any subjects lost to follow-up or subjects who were still living at the end of 
the designated study time frame (September 1, 2015) were censored.  Consideration of 
informative censoring was given as to whether subjects lost to follow-up may be different than 
those not lost to follow-up.  Patients were likely to maintain follow-up records if they were re-
transplanted at the SNGH transplant center and receiving care for a subsequent transplant or if 
they received any type of medical care from the hospital system (Sentara) which relies on a 
shared medical record among all Sentara facilities.  Although re-transplanted patients may 
indicate a healthier sub-group of the population (compared to those patients who may not have 
80 
 
been medically cleared for a second transplant), due to the added ability to capture follow-up 
time through use of a Sentara facility, and, given the widespread presence of Sentara healthcare 
systems in the Virginia area, there was a high likelihood that patients may follow at a Sentara 
facility for their non-transplant care.  Thus, while the potential bias of the censoring approach 
could not entirely be ascertained, it was thought that the defined censoring mechanism was likely 
random (non-informative), indicating no concern for bias. 
Survival curves. Kaplan Meier curves were computed comparing patient survival time 
between those with any sleep disorder and those without a sleep disorder.  The Log-Rank test 
was used to compare differences between the two curves. Univariate measures of predictors to 
patient survival time were computed. Several study covariates outlined in Table 1 were not 
included in hypothesis 3 due to their lack of relevance to the outcome of patient survival after 
graft failure.  This was determined through subject matter expertise and previous research (Gill 
et al., 2002).  Transplant related variables including donor type, human leukocyte antigen 
mismatch, and age of donor, were removed because they are not related to patient survival after 
graft failure. Thus, the full subset of variables modeled included: any sleep disorder, age, 
education level, race, gender, body mass index, smoking history, pack-years, functionality, 
diabetes, coronary artery disease, peripheral vascular disease, stroke history, heart attack history, 
end-stage renal disease etiology, and year of transplant surgery.   
Cox regression. Prior to starting the covariate selection process in the multivariate model, 
assessment for statistically significant two way interactions were computed between all study 
covariates at the p ≤ .05 level.  A highly significant and clinically relevant interaction between 
recipient age and functional status (p=.003) was found, and the interaction term was included in 
the covariate selection process.  An interaction term between year of transplant surgery period 
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and any sleep disorder was not significant (p=.994), but it could not be assessed due to the small 
number of events in 2009-2015.  Thus, the Cox regression was not stratified by year of transplant 
surgery.  Year of transplant surgery was included in the model (at the start of the backward 
elimination process) in order to obtain its main effect.   
Backward elimination was utilized as the covariate selection method.  Variables that were 
not significant (p ≤ .05) and did not have a confounding effect on the main variable of interest, 
any sleep disorder, were removed individually until none of the remaining variables in the model 
met the specified significance level for removal.  Variables were removed from the model in the 
following order: education level, body mass index, smoking history, year of transplant surgery, 
heart attack history, diabetes, race, coronary artery disease, gender, stroke history, and peripheral 
vascular disease.  The variable, dyslipidemia, remained significant throughout the covariate 
selection process, but it was excluded in the final multivariate model after further insight from 
transplant nephrologists on the limitations of this variable in its abstraction as a dichotomous 
variable (yes or no) without treatment considerations.  After the completion of the covariate 
selection process, the final variables remaining in the model were: any sleep disorder, recipient 
age, functional status, and end stage renal disease etiology.  Due to the potential bias of any one 
covariate selection method (Burnham & Anderson, 2002), the best subset covariate selection 
method was also utilized to verify agreement between the selected covariates based on more than 
one covariate selection methods.  A best subset regression was computed in SAS and presented 
the ten best subsets of variables according to a goodness-of-fit criteria.  The group of covariates 
that were determined through the backward elimination process were also presented in the list of 
potential models determined through the best subset covariate selection process. 
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Prior to accepting a final model, model assumptions were assessed.  The proportional 
hazards assumption was assessed graphically through transformed cumulative martingale 
residuals and through computing an interaction with time for each variable in included in the 
final model.  The linearity assumption was assessed through graphs of functional form for 
continuous variables. Additivity was previously assessed by looking for interaction terms among 
predictors prior to development of a final model, which in included the age and functional status 
interaction.  Functional status refers to the subjects reported functional status at the time of 
transplant. 
Sub-hypothesis 3b. Of those with graft failure, patients with a diagnosed sleep-
disordered breathing disorder have a statistically significantly higher total death hazard after 
graft failure than patients without a diagnosed sleep-disordered breathing disorder, even after 
adjustment for potential confounders. 
Analytic approach.  Sub-hypothesis 3b followed the same analysis plan outlined for 
hypothesis 3a.  However, the independent variable was patients with a sleep-disordered breathing 






This chapter begins with a summary of descriptive statistics and group comparisons 
between patients with any sleep disorder and those without any sleep disorder.  Following 
descriptive summaries, the results of the evaluation of each main hypothesis (1a-3a) related to 
any sleep disorder are presented.  The results for sub-hypotheses (1b-3b) related to sleep-
disordered breathing disorders were very similar to findings for the main hypotheses (related to 
any sleep disorder), due to sleep-disordered breathing disorders accounting for 85% of the sleep 
disorders in the present cohort.  Thus, it is likely that sleep-disordered breathing disorders were 
driving the findings of the main hypotheses (any sleep disorder). 
The results of the main hypotheses (any sleep disorder) are presented and summarized.  
Following the presentation of results for all main hypotheses, the results for the sub-hypotheses 
(sleep-disordered breathing disorders) are presented. 
Descriptive Statistics 
At the outset of the study, 367 subjects satisfied inclusion criteria.  However, as 
previously addressed in Figures 1 and 2, after removing non-compliant patients from the cohort, 
the final cohort consisted of 299 subjects.  Tables 2 and 3 summarize the descriptive data of the 
study sample, consisting of patients compliant with their immunosuppressant medications, who 
were transplanted and experienced graft failure and/or died with a functioning graft during the 
designated study time frame (January 1, 1997 to September 1, 2015, inclusive).  The study 
sample consisted of a hypertensive (100%) and predominantly African American end-stage renal 
disease patient population (64%).  Subjects ranged in age from 18-76 years at the time of 
transplant, and the mean age reported at the time of transplant was approximately 50 years.  Of 




Descriptive Statistics for Categorical Variables in the Sample  
 
Variable Frequency n Percentage 
Sleep Disorders    
Any Sleep Disorder 61 299 20% 
No Sleep Disorder 238 299 80% 
    
Transplant Recipient Variables    
Female 132 299 44% 
Male 167 299 56% 
African American 190 299 64% 
Caucasian 104 299 36% 
Education Level (high school or below) 139 299 46.5% 
Education Level (beyond high school) 136 299 45.5% 
Education Level (unknown) 24 299 8% 
ESRD Etiology (hypertensive) 114 299 38% 
ESRD Etiology (other) 185 299 62% 
Smoking History (yes) 131 298 44% 
Functional Status (full) 153 299 51% 
Hypertension (yes) 299 299 100% 
Diabetes (yes) 183 299 61% 
Dyslipidemia (yes) 222 299 75% 
Coronary Artery Disease (yes) 69 299 23% 
Stroke History (yes) 57 299 19% 
Peripheral Vascular Disease (yes) 29 299 9.7% 
Heart Attack History (yes) 21 299 7% 
    
Transplant Variables    
Deceased Donor Transplant 173 299 58% 
Living Donor Transplant 126 299 42% 
Abbreviations: ESRD, end-stage renal disease 
 
Table 3. 
Descriptive Statistics for Continuous Variables in the Sample  
 
Variable n Mean (range) 
Age of Recipient (years) 299 49.78 (18-76) 
Age of Donor (years) 299 39.72 (2-73) 
Tobacco Pack-Years (years) 251 7.02 (0-96) 
BMI (kg/m2) 299 28.36 (16.27-54.01) 
HLA Mismatch Score (0-6)  299 3.54 (0-6) 
Abbreviations: BMI, body mass index; HLA, human leukocyte antigen 
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Table 4 summarizes the prevalence of all abstracted diagnosed sleep disorders, 
categorized by type of sleep disorder diagnosis.  Three classifications of sleep disorders were 
abstracted from the medical record: insomnia, periodic limb movement disorders, and sleep 
apnea (a classification of a sleep-disordered breathing disorder).  The total number of subjects 
with any sleep disorder in the sample (n=61) is less than the sum of the sleep disorders in Table 4 
due to some patients having co-occurring sleep disorders, often sleep apnea and insomnia.  Of 
those subjects with a diagnosed sleep disorder, 52 out of 61 subjects were diagnosed with sleep 
apnea (85%).  Given the high prevalence of sleep apnea among those with diagnosed sleep 
disorders, the sub-hypotheses related to sleep-disordered breathing disorders (sleep apnea) 
yielded similar findings to the hypotheses related to any sleep disorders.   
 
Table 4. 
Frequency of Diagnosed Sleep Disorders in the Sample (n=299) 
 
Sleep Disorder Frequency n Percentage 
Any Sleep Disorder  61 299 20% 
Sleep Apnea  52 299 17% 
Insomnia   8 299 3% 
Periodic Limb Movement Disorders 5 299 2% 
 
 
Summary Statistics for Group Differences 
 A chi-square test was used to compare categorical variables to determine whether 
differences existed between patients with any sleep disorder and patients without any sleep 
disorder.  An independent t-test was used to compare group differences among continuous 
variables.  Table 5 is a summary of group differences between categorical variables, and Table 6 
is a summary of group differences between continuous variables.  Tables 5 and 6 identify that 
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patients with any sleep disorder had a statistically significant higher prevalence of diabetes, a 
higher body mass index, and were more likely to have limited functionality (as reported on a 
Karnofsky scale) relative to those without any sleep disorder.  The variable, year of transplant 
surgery also differed among those with and without any sleep disorder, indicating that subjects 
with any sleep disorder, versus those without any sleep disorder were more likely to have had a 
more recent transplant. 
 
Table 5. 
Any Sleep Disorder versus No Sleep Disorder by Categorical Variables 
 








Gender   
Male  

























high school or below  
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Table 5. (continued) 















































Donor Type  
deceased donor  


















































Abbreviations: ESRD, end-stage renal disease 
* Significant at the p ≤ .05 level 
 
Table 6. 
Any Sleep Disorder versus No Sleep Disorder by Continuous Variables 
 






t DF P-Value 
 Mean Mean    
Body Mass Index (kg/m2) 31.39 27.59 5.08 297 .000* 
HLA Mismatch (0-6) 3.59 3.53 .22 297 .828 
Recipient Age (years) 50.74 49.54 .67 297 .501 
Donor Age (years) 38.87 39.93 .49 297 .625 
Pack-years (tobacco) 8.09 6.73 .06 249 .551 
Year of Transplant 2005 2003 3.51 297 .001* 
Abbreviations: HLA mismatch, human leukocyte antigen mismatch 
* Significant at the p ≤ .05 level 
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Results of Hypothesis 1a: Death with a Functioning Graft 
Hypothesis 1a: Of patients with graft failure, patients with any diagnosed sleep disorder have a 
statistically significantly higher proportion of graft failure due to death (compared to graft 
failure and return to dialysis) than patients without any diagnosed sleep disorder.  
Results of hypothesis 1a are summarized in Table 7.  The prevalence rates of subjects 
who experienced death with a functioning graft in the any sleep disorder group and the non-sleep 
disorder group were found to be virtually the same (44% vs 45%, respectively, p=.94).  Patients 
with any sleep disorder had a higher proportion of cardiovascular (CVD) related death with a 
functioning graft (37%) compared to those without any sleep disorder (25%), but this difference 
was not found to be statistically significant (p=.19).  
 
Table 7. 
Proportions of Death with a Functioning Graft in Patients with Any Sleep Disorder Compared to 
Patients without Any Sleep Disorder  
 
Death with a 
Functioning Graft 
Any Sleep Disorder 
(n=61) 


















 Any Sleep Disorder 
(n=27) 
No Sleep Disorder 
(n=106) 
   
 





























Results of Hypothesis 2a: Graft Survival Time 
Hypothesis 2a: Of patients with graft failure, patients with any diagnosed sleep disorder have 
statistically significantly shorter graft survival times than patients without any diagnosed sleep 
disorder, even after adjustment for potential confounders.  
 Hypothesis 2 tested the relationship between any sleep disorder and graft survival time, 
which was operationally defined as graft failure or cardiovascular (CVD) related death with a 
functioning graft.  Univariate analyses and bivariate Kaplan Meier curves are presented prior the 
multivariate stratified Cox regression.  Although 299 patients were included in the final sample, 
data on graft survival time was available for 297 patients.  Univariate and multivariate models 
consisted of 297 patients as the sample size to examine hypothesis 2.   As previously outlined, 
subjects were considered censored if they experienced non-CVD related death with a functioning 
graft.   
Table 8 is a summary of the univariate hazard ratio of each predictor variable to the 
dependent variable, graft survival time.  The univariate analyses are considered preliminary 
analyses for a multivariate Cox Regression; therefore, its results are not stratified.  The sample 
size, parameter estimate, hazard ratio, 95% confidence intervals for each hazard ratio, and 
statistical significance are reported.  Approximately 32% of the subjects were censored when 
evaluating hypothesis 2.  At the univariate level, statistically significant variables (p≤.05) 
associated with graft survival time were: age of recipient, race, gender, dyslipidemia, HLA, and 
year of transplant surgery.  A hazard ratio greater than 1 indicates a higher risk of the hazard of 
graft failure or cardiovascular (CVD) related death with a functioning graft, identifying shorter 
graft survival times.  A hazard ratio less than 1 identifies variables that are associated with longer 
graft survival times.  Moreover, it is important to consider that some variables with a hazard ratio 
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less than 1, predicting better survival, may be biased by informative censoring if such variable 
was also associated with non-CVD related death with a functioning graft (Appendix D).  For 
instance, the univariate hazard ratios presented for diabetes, increased number of pack-years, 
smoking history, stroke history, diagnosed coronary artery disease, diagnosed peripheral vascular 
disease, heart attack history, and recipients who are older all predict longer graft survival time.  
However, all of these variables were associated with higher rates of censoring (non-CVD related 
death with a functioning graft), as presented in Appendix D. 
 
Table 8. 
Univariate Analysis of Each Predictor Variable to Graft Failure or Cardiovascular Related 
Death with a Functioning Graft (All Non-Cardiovascular Related Deaths are Censored) 
 
Covariates N Parameter 
Estimate 
HR HR CI P-
value 
Any Sleep Disorder  















Sleep Apnea  
Yes (n=52) 



























High school or below (n=139)  






























































Table 8. (continued)      
Covariates N Parameter 
Estimate 
HR HR CI P-
value 













Smoking History  
Yes (n=131) 













































Yes (n=181)  






























Coronary Artery Disease  
Yes (n=68) 














Heart Attack History  
Yes (n=21) 














Peripheral Vascular Disease  
Yes (n=29) 





























Donor Type  
Living (n=125) 
















Table 8. (continued)      
Covariates N Parameter 
Estimate 
HR HR CI P-
value 











































Year of Transplant Surgery  































Abbreviations: ESRD, end-stage renal disease; HR, hazard ratio; HR CI, hazard ratio 95% confidence interval 
* Significant at the p ≤ .05 level 
 
Kaplan Meier curves. After univariate analyses were run, Kaplan Meier curves were 
computed.  For the entire follow-up period, the survival curves indicated no statistically 
significant difference in graft survival time between those with any sleep disorder versus those 
without (Log-Rank=.17, p=.679). Next, stratification according to two periods for the year of 
transplant was conducted as follows: Year of Transplant 1997-2008 and Year of Transplant 
2009-2015.   
Year of Transplant 1997-2008 contained 264 subjects (88.3% of the total sample).  The 
prevalence of any sleep disorder in 1997-2008 was 19%.  Table 9 summarizes the total number 
of censored data and events by sleep disorder category (presence or absence), for Year of 




Proportions of Censored Observations for Graft Survival Time According to the Presence and 
Absence of Any Sleep Disorder for Year of Transplant Surgery 1997-2008 
 









Presence 50 36 14 28% 
Absence 214 147 67 31% 




Figure 3 displays Kaplan Meier curves for Year of Transplant 1997-2008, comparing 
subjects with any sleep disorder to those without any sleep disorder with regard to graft survival 
time.  Median graft survival times for the group of subjects with any sleep disorder was longer 
than that for those without a sleep disorder (2,457 days and 2,313 days, respectively).  However, 




Figure 3. Kaplan Meier Survival Curves for Year of Transplant 1997-2008: Graft Survival Time 
by Presence and Absence of Any Sleep Disorder 
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Table 10 summarizes the total number of censored data and events by sleep disorder 
category (presence or absence), for year of transplant 2009-2015.  Data from 33 subjects were 
analyzed for this stratum.  The prevalence of any sleep disorder for those transplanted between 
2009-2015 was 33%.  The total rate of censoring was higher for those transplanted in 2009-2015 
(45%) compared to 1997-2008 (31%), indicating that subjects in 2009-2015 had a higher 
proportion of death with a functioning graft from non-CVD related causes compared to subjects 




Proportions of Censored Observations for Graft Survival Time According to the Presence and 
Absence of Any Sleep Disorder for Year of Transplant Surgery 2009-2015 
 
 









Presence 11 8 3 27% 
Absence 22 10 12 55% 
Total 33 18 15 45% 
 
 
Figure 4 displays Kaplan Meier curves for Year of Transplant 2009-2015, comparing 
subjects with any sleep disorder to those without a sleep disorder.  Median graft survival times 
for the group of subjects with any sleep disorder was 800 days and that for subjects without any 
sleep disorder was 1,834 days, indicating that patients with any sleep disorder had shorter graft 
survival times.  This difference in graft survival time between the two groups was statistically 





Figure 4. Kaplan Meier Survival Curves for Year of Transplant 2009-2015: Graft Survival Time 




Summary of Kaplan Meier curves. For patients transplanted in 1997-2008 (Figure 3), 
any sleep disorder was associated with longer graft survival versus no sleep disorder; however, 
this difference was not statistically significant (Log-Rank=1.19, p=.275).  For patients 
transplanted in 2009-2015 (Figure 4), any sleep disorder was statistically signficantly (Log-
Rank=3.82, p=.051) associated with shorter graft survival times relative to no sleep disorder. 
Stratified univariate results of any sleep disorder.  After computation of stratified 
Kaplan Meier curves, a stratified univariate analysis of any sleep disorder to graft survival time 
was computed to estimate the unadjusted hazard ratio of any sleep disorder with graft failure or 
cardiovascular related death with a functioning graft prior to multivariate testing.  Table 11 





Univariate (Unadjusted) Analysis: Association of Any Sleep Disorder with Graft Failure or 
Cardiovascular Related Death with a Functioning Graft (All Non-Cardiovascular Related 
Deaths Censored) According to Year of Transplant 
 







HR HR CI p-value 
Year of Transplant 1997-2008  
Any Sleep Disorder (n=50) 














Year of Transplant 2009-2015  
Any Sleep Disorder (n=11)  













Abbreviations: HR, hazard ratio; HR CI, hazard ratio 95% confidence interval 
N refers to the sample size for each strata  
The hazard ratio refers to the comparison of any sleep disorder versus no sleep disorder 
 
 
Multivariate results for hypothesis 2a. A multivariate Cox regression was used to 
estimate the adjusted hazard ratios for the association of any sleep disorder, versus no sleep 
disorder, with the risk of graft failure or cardiovascular (CVD) related death with a functioning 
graft, after adjustment of key covariates.  Backward elimination was used as the covariate 
selection process, resulting in the final model presented in Table 12a.  Parameter estimates, 
hazard ratios, 95% confidence intervals, and significance levels are presented for each variable 
that remained in the final model.  Table 12a presents the results of multivariate Cox regression 
with the statistically significant interaction term (p ≤ .01) between any sleep disorder and year of 
transplant strata.  The final model is presented below (Table 12a) and reflects an iterative process 






Results of the Multivariate Cox Regression Model: Interaction of Any Sleep Disorder and Year 





HR HR CI p-value 






















































Year of Transplant Surgerya 
1997- 2008 (n=264)  
2009-2015 (n=33) 
 
    
.667 
Any Sleep Disordera 




    
.0341 
 
Any Sleep Disorder*Year of 
Transplant Interaction Term 
 
1.370 
   
.010* 
Abbreviations: HR, hazard ratio; HR CI, hazard ratio 95% confidence interval, HLA, human leukocyte antigen 
mismatch 
Each variable is simultaneously and reciprocally adjusted for all the other variables in the model 
a: Main effects of hazard ratios are not reported in the multivariate model and cannot be interpreted in this table 
given the interaction term, see Table 12b 





The interaction between any sleep disorder and year of transplant surgery strata was 
statistically significant with full adjustments (p≤ .01).  The strata specific adjusted hazard ratios 
for graft failure or cardiovascular related death with a functioning graft are reported in Table 
12b, they are from the same model as presented in Table 12a. 
 
Table 12b. 
Adjusted Hazard Ratios for Graft Failure or Cardiovascular Related Death with a Functioning 
Graft with respect to Any Sleep Disorder Stratified by Year of Transplant 
 
Predictor N Parameter 
Estimate 
aHR HR CI p-value 
Year of Transplant 1997-2008  
Any Sleep Disorder(n=50)  















Year of Transplant 2009-2015 
Any Sleep Disorder (n=11)  














Abbreviations: aHR, adjusted hazard ratio; HR CI, hazard ratio 95% confidence interval 
N refers to the sample size for each strata  
For each stratum, the adjusted hazard ratio refers to the comparison of any sleep disorder versus no sleep disorder, 
adjusted for all other variables in the final model (recipient age, HLA mismatch, functional status, gender) 
*Significant at the p ≤ .05 level 
 
 
Summary of results for hypothesis 2a: graft failure or cardiovascular related death 
with a functioning graft.  The final model for graft survival time included recipient age, HLA 
mismatch, gender, functional status, and any sleep disorder.  Each hazard ratio presented in 
Table 12a represents the adjusted hazard ratio for each variable, while controlling for all other 
variables in the model.  Table 12b presents the adjusted hazard ratio for any sleep disorder, 
versus no sleep disorder, stratified by year of transplant, while adjusting for all variables 
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included in the final multivariate model presented in Table 12a (recipient age, human leukocyte 
antigen mismatch, gender, and functional status). 
For patients transplanted in 1997-2008, any sleep disorder, was associated with a 
decreased (albeit non-statistically significantly) risk of graft failure or cardiovascular related 
death with a functioning graft (adjusted Hazard Ratio (HR) = 0.73, 95% CI, 0.50-1.06) relative to 
no sleep disorder.  However, for patients transplanted in 2009-2015, any sleep disorder was 
strongly and statistically significantly (p=.03) associated with increased risk of graft failure or 
cardiovascular related death with a functioning graft (adjusted HR = 2.92, 95% CI, 1.11-7.69), 
relative to no sleep disorder.  Thus, the risk of graft failure or risk of cardiovascular related death 
with a functioning graft for patients with any sleep disorder transplanted in 2009-2015 was 
nearly three times the rate of patients without a sleep disorder transplanted in 2009-2015.  For 
the more recent time period of transplant (2009-2015), the null hypothesis was thus rejected for 
hypothesis 2a. 
Results of Hypothesis 3a: Patient Survival after Graft Failure 
Hypothesis 3a: Of patients with graft failure, patients with any diagnosed sleep disorder have a 
statistically significantly higher death hazard after graft failure than patients without any 
diagnosed sleep disorder, even after adjustment for potential confounders.  
Hypothesis 3 was tested regarding the relationship between any sleep disorder and patient 
survival time after graft failure.  Patients who died with a functioning graft (n=133) were not 
included in the analysis of hypothesis 3, as they did not have any survival time beyond their graft 
failure.  Thus, 164 patients were analyzed to examine patient survival time after graft failure.  
Patients lost to follow-up or those still living at the end of the study time frame were censored.  
Approximately two-thirds of the sample were censored in the examination of hypothesis 3 
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(n=104), indicating a high rate of censoring which can underestimate true survival times.  
Median patient survival time after graft failure was 3,249 days in the sample. 
Table 13 presents the univariate analyses of predictor variables to patient survival time 
after graft failure.  The sample size, parameter estimate, hazard ratio, 95% confidence intervals 
for hazard ratios, and the significance level are in reported in the table.  Several variables that 
were included in the model testing hypothesis 2 were not included in the model testing 
hypothesis 3 due to their lack of relevance.  Specifically, transplant-related variables such as: 
donor type, human leukocyte antigen mismatch, and age of donor were removed because they 
were not related to patient survival after graft failure, and, therefore, univariate analyses are not 
reported for these variables in Table 13.   
At the univariate level, statistically significant (p≤.05) variables associated with patient 
survival time after graft failure were: age of recipient, coronary artery disease, diabetes, and 
peripheral vascular disease.  A hazard ratio greater than 1 indicates a higher risk of patient death 
after graft failure, identifying shorter patient survival times.  A hazard ratio less than 1 identifies 
variables that are associated with increased patient survival times.   
 
Table 13. 
Univariate (Unadjusted) Analysis of the Association of Each Predictor Variable to Survival after 
Graft Failure with Censoring of Patients Lost to Follow-Up (N=164) 
 
Covariates N Parameter 
Estimate 
HR HR CI P-value 
Any Sleep Disorder  
Yes (n=34)  














Sleep Apnea  
Yes (n=38) 
















Table 13. (continued)      
Covariates N Parameter 
Estimate 
HR HR CI P-value 



























High school or below (n=75)  















































Smoking History  
Yes (n=65)  












































Yes (n=87)  















Yes (n=117)  

















Table 13. (continued)      
Covariates N Parameter 
Estimate 
HR HR CI P-value 
Coronary Artery Disease  
Yes (n=28)  














Heart Attack History  
Yes (n=6)  














Peripheral Vascular Disease  
Yes (n= 10)  














Stroke History  
Yes (n=16)  











































Year of Transplant Surgery Strata  














Abbreviations: ESRD, end-stage renal disease; HR, hazard ratio; HR CI, hazard ratio 95% confidence interval 




Kaplan Meier Curves.  After univariate analyses were run, Kaplan Meier curves were 
computed comparing patient survival time after graft failure according to the presence of any 
sleep disorder.  Table 14 summarizes the total number of events and censored observations by 
sleep disorder category (presence or absence).  Figure 5 presents Kaplan Meier curves.  Median 
patient survival time after graft failure for patients with any sleep disorder was much shorter 
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(2,421 days) than that for those without a sleep disorder (3,249 days).  Despite this large 
difference in median patient survival time, the survival curves were not statistically significantly 




Proportions of Censored Observations for Patient Survival Time after Graft Failure According 
to the Presence and Absence of Any Sleep Disorder (N=164) 
 
 









Presence 34 12 22 65% 
Absence 130 48 82 63% 






Figure 5. Kaplan Meier Survival Curves for Patient Survival Time after Graft Failure by 





Multivariate results for hypothesis 3a.  A multivariate Cox regression was used to 
estimate the hazard ratios for the associations of predictor variables with the risk of patient death 
after graft failure.  Of patients transplanted between 2009-2015, there were no events for any 
sleep disorder. Thus, this model could not be stratified by year of transplant as we did not find a 
statistically significant interaction between the variable, year of transplant surgery examined with 
2 strata and any sleep disorder (p=.994).  The period of transplant surgery (continuously) was 
included in the backward elimination selection process along with other variables.  The final 
model is presented below and reflects an iterative process of model building and verification of 































Results of the Multivariate Cox Regression Model: Association of Any Sleep Disorder with 




HR HR CI P-value 
Any Sleep Disorder  













ESRD Etiology  













Recipient Age at Time of Transplanta  
Years (n=164) 
 
    
.000* 




    
.013* 
 




   
.006* 
Abbreviations: ESRD, end-stage renal disease; HR, hazard ratio; HR CI, hazard ratio 95% confidence interval 
Each variable is simultaneously and reciprocally adjusted for all the other variables in the model. 
a: Main effects of hazard ratios are not reported in the multivariate model and cannot be interpreted in this table 
given the interaction term, but will be addressed in the summary section below. 
* Significant at the p ≤ .05 level 
 
 
Summary of multivariate results for hypothesis 3a.  The final model included an end-
stage renal disease (ESRD) etiology, any sleep disorder, and an interaction between recipient age 
and functional status.  Each hazard ratio presented in Table 15 represents the adjusted hazard 
ratio for each variable, while controlling for all other variables in the model.  Patients with any 
sleep disorder had an increase (3%) in the risk of death after graft failure compared to those 
without a sleep disorder, but this difference was not statistically significant (HR=1.03, 95% 
CI=.51-1.95, p=.925).     
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The statistically significant interaction between recipient age and functional status, 
signified that the risk of death increased as patients with limited functionality aged.  Of those 
with a limited functional status, as age increased the risk of death after graft failure increased by 
11% (HR=1.11, 95% CI=1.06-1.12).  Of those with no functional limitations (full functional 
status), as age increased the risk of death after graft failure also remained elevated (HR=1.03, 
95% CI=1.00-1.06), but this risk of death in those with a full functional status was lower 
compared to those with a limited functional status.  Figure 6 displays the interaction between 








Results of Sub-Hypotheses 1b-3b: Associations of Sleep-Disordered Breathing Disorders to 
Transplant Outcomes. 
 The study sub-hypotheses 1b-3b involved examining associations between sleep-
disordered breathing disorders (a subset of any sleep disorder) and transplant outcomes.  Each 
sub-hypothesis is stated below, followed by the results.  All of the diagnosed sleep-disordered 
breathing disorders abstracted were classified as sleep apnea (as previously summarized in Table 
4), and, thus, for the presentation of the sub-hypothesis results (Tables 16-22 and Figures 7-9), 
sleep-disordered breathing disorders are henceforth referred to as sleep apnea.  
Results of Sub-Hypothesis 1b: Death with a Functioning Graft 
Hypothesis 1b: Of patients with graft failure, patients with a diagnosed sleep-disordered 
breathing disorder have a statistically significantly higher proportion of graft failure due to 
death (compared to graft failure and return to dialysis) than patients without a diagnosed sleep-
disordered breathing diagnosis. 
Results of hypothesis 1b are summarized in Table 16.  The prevalence rates of subjects 
who experienced death with a functioning graft in those with sleep apnea and those without sleep 
apnea were found to be virtually the same (46% vs 44%, respectively, p=.81).  Patients with 
sleep apnea had a higher proportion of cardiovascular related death with a functioning graft 
(38%) compared to those without sleep apnea (25%), but this difference was not found to be 












Proportions of Death with a Functioning Graft in Patients with Sleep Apnea Compared to 
Patients without Sleep Apnea 
 
 Sleep Apnea 
(n=52) 

















 Sleep Apnea 
(n=24) 


























Abbreviations: CVD, cardiovascular disease 
 
 
Results of Sub- Hypothesis 2b: Graft Survival Time 
Hypothesis 2b: Of patients with graft failure, patients with a diagnosed sleep-disordered 
breathing disorder have statistically significantly shorter graft survival times than patients 
without a diagnosed sleep-disordered breathing disorder, even after adjustment for potential 
confounders.  
Kaplan Meier Curves.   For the entire follow-up period (1997-2015), the Kaplan Meier 
curves indicated no statistically significant difference in graft survival time between those with 
sleep apnea versus those without (p=.776). Next, stratification according to two periods for the 
year of transplant was conducted as follows: Year of Transplant 1997-2008 and Year of 
Transplant 2009-2015.  Table 17 summarizes the total number of censored data and events for 





Proportions of Censored Observations for Graft Survival Time According to the Presence and 












Presence 41 29 12 29% 
Absence 223 154 69 31% 
Total 264 183 81 31% 
 
 
Figure 7 displays Kaplan Meier curves for year of transplant 1997-2008, comparing 
subjects with sleep apnea to those without sleep apnea.  Median graft survival times for the 
group of subjects with sleep apnea was longer than that for those without sleep apnea (2,699 
days and 2,303 days, respectively). However, this difference (Figure 7) was not statistically 
significant (Log-Rank=.08, p=.277). 
 
Figure 7.  Kaplan Meier Survival Curves for Year of Transplant 1997-2008: Graft Survival Time 
by Presence and Absence of Sleep Apnea 
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Table 18 summarizes the total number of censored data and events for year of transplant 




Proportions of Censored Observations for Graft Survival Time According to the Presence and 












Presence 11 8 3 27% 
Absence 22 10 12 55% 
Total 33 18 15 45% 
 
 
Figure 8 displays Kaplan Meier curves for year of transplant 2009-2015, comparing 
subjects with sleep apnea to those without sleep apnea.  Median graft survival times for the 
group of subjects with sleep apnea was shorter than that for those without sleep apnea (800 days 
and 1,834 days, respectively).  This difference in graft survival time between the two groups 






Figure 8. Kaplan Meier Survival Curves for Year of Transplant 2009-2015: Graft Survival Time 




Stratified univariate results of sleep apnea.  After computation of stratified Kaplan 
Meier curves, a stratified univariate analysis of sleep apnea to graft survival time was computed 
to estimate the unadjusted hazard ratio of sleep apnea with graft failure or cardiovascular related 
death with a functioning graft, prior to multivariate testing.  Table 19 presents that stratified 









Univariate (Unadjusted) Analysis: Association of Sleep Apnea with Graft Failure or 
Cardiovascular Related Death with a Functioning Graft (All Non-Cardiovascular Deaths 
Censored) According to Year of Transplant 
 







HR HR CI p-value 
Year of Transplant 1997-2008  
Sleep Apnea (n=41) 














Year of Transplant 2009-2015  
Sleep Apnea (n=11)  













Abbreviations: HR, hazard ratio; HR CI, hazard ratio 95% confidence interval 
N refers to the sample size for each strata  
The hazard ratio refers to the comparison of any sleep disorder versus no sleep disorder 
 
 
Multivariate results for hypothesis 2b. A multivariate Cox regression was used to 
estimate the adjusted hazard ratios for the association of sleep apnea with the risk of graft failure 
or cardiovascular (CVD) related death with a functioning graft, after adjustment of key 
covariates.  Backward elimination was used as the covariate selection process, resulting in the 
final model presented in Table 20a.  Parameter estimates, hazard ratios, 95% confidence intervals 
and significance levels are presented for each variable that remained in the final model.  Table 
20a presents the results of multivariate Cox regression with the statistically significant 












Results of the Multivariate Cox Regression Model: Interaction of Sleep Apnea and Year of 





HR HR CI p-value 
















































Year of Transplant Surgerya 
1997-2008 (n=264) 
2009-2015 (n=33) 





    
.052 
Sleep Apnea*Year of Transplant 
Interaction Term 
 
 1.476   .006* 
Abbreviations: HR, hazard ratio; HR CI, hazard ratio 95% confidence interval, HLA, human leukocyte antigen 
mismatch 
Each Variable is simultaneously and reciprocally adjusted for all the other variables in the model 
a: Main effects of hazard ratios are not reported in the multivariate model and cannot be interpreted in this table 
given the interaction term, see Table 20b. 





The interaction between sleep apnea and year of transplant surgery strata was statistically 
significant with adjustments (p≤ .01).  The strata specific adjusted hazard ratios for graft failure 
or cardiovascular related death with a functioning graft are reported in Table 20b.  These are 




Adjusted Hazard Ratios for Graft Failure or Cardiovascular Related Death with a Functioning 
Graft with respect to Sleep Apnea Stratified by Year of Transplant 
 
Predictor N Parameter 
Estimate 
aHR HR CI p-value 
Year of Transplant 
1997-2008 
Sleep Apnea (n=41) 



















Year of Transplant 
2009-2015 
Sleep Apnea (n=11) 



















Abbreviations: aHR, adjusted hazard ratio; HR CI, hazard ratio 95% confidence interval 
N refers to the sample size for each strata  
For each stratum, the adjusted hazard ratio refers to the comparison of sleep apnea versus no sleep apnea, adjusted 
for all other variables in the final model (recipient age, HLA mismatch, functional status, gender) 
*Significant at the p ≤ .05 level 
 
 
Summary of results for hypothesis 2b: graft failure or cardiovascular related death 
with a functioning graft.  The final model for graft survival time included recipient age, human 
leukocyte antigen (HLA) mismatch, gender, functional status, and sleep apnea.  Each hazard 
ratio presented in Table 20a represents the adjusted hazard ratio for each variable, while 
controlling for all other variables in the model.  Table 20b presents the adjusted hazard ratio for 
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sleep apnea, versus no sleep apnea, stratified by year of transplant, while adjusting for all 
variables included in final multivariate model presented in Table 20a (recipient age, HLA 
mismatch, gender, and functional status). 
For patients transplanted in 1997-2008, sleep apnea was associated with a decreased 
(albeit non-statistically significantly) risk of graft failure or cardiovascular related death with a 
functioning graft (adjusted Hazard Ratio (HR) = 0.67, 95% CI, 0.45-1.01) relative to no sleep 
apnea.  However, for patients transplanted in 2009-2015, sleep apnea was strongly and 
statistically significantly (p=.03) associated with increased risk of graft failure or cardiovascular 
related death with a functioning graft (adjusted HR = 2.94, 95% CI, 1.12-7.76), relative to no 
sleep apnea.  For the more recent time period of transplant (2009-2015), the null hypothesis was 
thus rejected for hypothesis 2b. 
Results of Sub-Hypothesis 3b: Patient Survival after Graft Failure 
Hypothesis 3b: Of those with graft failure, patients with a diagnosed sleep-disordered breathing 
disorder have a statistically significantly higher death hazard after graft failure than patients 
without a diagnosed sleep-disordered breathing disorder, even after adjustment for potential 
confounders. 
Kaplan Meier Curves.  Kaplan Meier curves were computed comparing patient survival 
time after graft failure according to the presence of sleep apnea.  Table 21 summarizes the total 
number of events and censored observations by sleep apnea category (presence or absence).  
Figure 9 presents Kaplan Meier curves.  Median patient survival time after graft failure for 
patients with sleep apnea was much shorter (2,421 days) than that for those without a sleep apnea 
(3,249 days).  Despite this large difference in median patient survival time, the survival curves 




Proportions of Censored Observations for Patient Survival Time after Graft Failure According 












Presence 28 10 18 64% 
Absence 136 50 86 63% 




Fig 9: Kaplan Meier Survival Curves for Patient Survival Time after Graft Failure by Presence 




Multivariate results for hypothesis 3b.  A multivariate Cox regression was used to 
estimate the hazard ratios for the associations of predictor variables with the risk of patient death 
after graft failure. Of patients transplanted between 2009-2015, there were no events for subjects 
with sleep apnea diagnoses. Thus, this model could not be stratified by year of transplant.  As we 
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did not find a statistically significant interaction between year of transplant surgery (2009-2015 
and 1998-2008) and sleep apnea (p=.986), the period of transplant surgery (continuous variable) 
was included in the backward elimination selection process along with other variables.  The final 
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Summary of multivariate results for hypothesis 3b.  The final model included a 
recipient age and functional status interaction, end-stage renal disease (ESRD) etiology, and 
sleep apnea.  Each hazard ratio presented in Table 22 represents the adjusted hazard ratio for 
each variable, while controlling for all other variables in the model.  Patients with sleep apnea 
had an increase (5%) in the risk of death after graft failure compared to those without sleep 





DISCUSSION AND CONCLUSIONS 
The primary purpose of this historic cohort study was to investigate the associations 
between sleep disorders and clinical transplant outcomes in a sample of kidney transplant 
recipients with a failed graft.  This chapter presents a discussion of the results organized by each 
hypothesis.  Results of hypothesis testing are summarized and interpreted in relation to the 
primary independent variables, any sleep disorder (main predictor for the main hypotheses) and 
sleep-disordered breathing disorders (main predictor for the sub-hypotheses).  While both the 
main hypotheses and sub-hypotheses are presented, the focus of this discussion centers on the 
associations between sleep-disordered breathing disorders, namely, sleep apnea, to transplant 
outcomes.  Sleep apnea will be discussed as 85% of the sleep disorders in our sample consisted 
of sleep apnea diagnoses, a type of a sleep-disordered breathing disorder, and of those with 
sleep-disordered breathing disorders, 100% had sleep apnea. 
  Following the discussion of the results pertaining to sleep apnea, for the hypotheses that 
involve multivariate modeling, a brief discussion of additional study covariates and their 
relationship to the transplant outcomes are presented.  Then, study limitations and health policy 
implications of the study are addressed.  The chapter concludes with the presentation of future 
research topics and with concluding remarks. 
Discussion of Hypothesis 1: Death with a Functioning Graft 
Death with a functioning graft is the leading cause of graft loss in patients who have 
maintained a transplant for 10 or more years (Matas et al., 2008).  Identifying modifiable risk 
factors associated with death with a functioning graft is a relevant topic in the transplant field 
and may help improve long-term patient outcomes.  It was hypothesized that patients with any 
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sleep disorder would have a statistically significantly higher proportion of death with a 
functioning graft compared to those without a sleep disorder.  The sub-hypothesis posited that 
patients with a sleep-disordered breathing disorder (sleep apnea) would have a higher proportion 
of death with a functioning graft compared to those without a sleep-disordered breathing 
disorder.  For both any sleep disorder and sleep apnea, there were no statistically significant 
differences found for the proportion of death with a functioning graft based on the diagnosis of 
any sleep disorder or, specifically, sleep apnea.  Of patients with any sleep disorder, 44% died 
with a functioning graft, which was similar to those without a sleep disorder (45%).  The 
proportion of death with a functioning graft in patients with sleep apnea was 46%, and 44% in 
those patients without sleep apnea.   
Sleep apnea and death with a functioning graft.  A relationship between sleep apnea 
and death with a functioning graft was proposed due to research identifying an increased risk of 
mortality among patients with sleep apnea, in non-transplant samples (Lavie, 2007; Marshall, 
Wong, Cullen, Knuiman, & Grunstein, 2014; Young et al., 2008).  In the present study, there are 
two considerations that may explain the lack of association between sleep apnea and death with a 
functioning graft.  First, the lack of association may be explained by the inability to assess the 
severity of sleep apnea and to account for this in analyses.  Past research reporting the 
associations between sleep apnea and mortality identifies such relationships in patients with 
severe (Young et al., 2008), and moderate to severe sleep apnea (Marshall et al., 2014).  
Specifically, in a sample of end-stage renal disease patients on dialysis, Tang and colleagues 
(2010) found that moderate to severe sleep apnea was an independent predictor of mortality.  
These findings offer some support for the importance of considering severity when examining 
the relationship between sleep apnea and mortality.  In the present study, we were unable to 
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examine the relationship between moderate to severe sleep apnea and death with a functioning 
graft due to the unavailability of data on sleep apnea severity. 
Second, the lack of association between sleep apnea and death with a functioning graft 
may be due to an absence of a relationship between sleep apnea and increased risk of mortality in 
kidney transplant recipients.  Although research has identified a relationship between sleep apnea 
and increased risk of mortality in patients with end-stage renal disease (ESRD) (Tang et al., 
2010), past studies among transplant recipients have found no relationship between sleep apnea 
and death with a functioning graft (Fornadi et al., 2014; Szentkiralyi et al., 2011), even when 
assessing this relationship in patients with moderate to severe sleep apnea (Fornadi et al., 2014).  
It is important to consider that sleep apnea may not increase the risk of mortality in ESRD 
patients, who are already at increased risk for cardiovascular disease. A systematic review of the 
sleep apnea and mortality research cited conflicting evidence as to whether the presence of sleep 
apnea in patients with existing cardiovascular disease increased mortality risk, beyond the risk of 
the cardiovascular disease itself (Lavie, 2007).  Kidney transplant recipients have an increased 
occurrence of cardiovascular disease, which may be related to their renal failure, and further, 
cardiovascular disease is common in (ESRD) patients with sleep apnea and those without sleep 
apnea (Weiner et al., 2006).  Thus, the presence of sleep apnea may not pose an additive risk of 
mortality in kidney transplant recipients given the existing high prevalence of cardiovascular 
disease among ESRD patients. 
 Relationship of death with a functioning graft to hypothesis 2 (graft survival time).  
Comparing the proportion of death with a functioning graft in subjects with sleep apnea and 
those without sleep apnea was also intended to help inform the analytic approach for examining 
the relationship between sleep apnea and graft survival time (hypothesis 2b).  In the transplant 
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literature, death with a functioning graft can be considered the end of graft survival time for a 
subject, or it can be considered a competing risk of graft loss.  Understanding the association 
between death with a functioning graft and sleep apnea was important to determine whether 
deaths could be censored or whether a competing risks model should be used when examining 
the association between sleep apnea and graft survival time.  In finding that sleep apnea was not 
associated with death with a functioning graft, we determined that death with a functioning graft 
could be treated as a censored observation for the graft survival time outcome (hypothesis 2b) 
without significant concern for bias.  Had we found a statistically significant higher proportion of 
subjects with sleep apnea who experienced death with a functioning graft, then censoring this 
outcome (death with a functioning graft) could have led to considerable bias in the analysis.   
Although there was no statistically significant association between sleep apnea and death 
with a functioning graft (either all-cause or cardiovascular related death), it was determined that 
only non-cardiovascular (CVD) related deaths would be treated as censored observations.  CVD 
related deaths were retained in the analysis as “events” (end of graft survival time), because 
CVD related deaths may be related to the decreased function of the transplanted kidney (Jardine 
et al., 2011; Meier-Kriesche et al., 2003).  In doing so, we attempted to account for a competing 
risk in our analysis, but one that could be related to the graft failure of the transplanted kidney. 
Discussion of Hypothesis 2: Graft Survival Time 
Graft survival time is a measure of transplant longevity, and it is the primary measure of 
transplant success for both patients and providers. In our study, graft survival time was 
operationally defined as graft failure or cardiovascular (CVD) related death with a functioning 
graft.  It was hypothesized that patients with, versus without, any sleep disorder would have a 
higher hazard of graft failure or CVD related death with a functioning graft.  The sub-hypothesis 
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posited that patients with a sleep-disordered breathing disorder, versus without, would have a 
higher hazard of graft failure or CVD related death with a functioning graft.  The null hypothesis 
was rejected for both the main and sub-hypotheses related to the findings that patients with any 
sleep disorder transplanted in 2009-2015 (adjusted HR=2.92, p=.030) had nearly a three-fold 
increased risk of graft failure or CVD related death with a functioning graft, compared to those 
without a sleep disorder, in a model adjusted for recipient age, HLA mismatch, functional status, 
and gender.  Findings yielded similar results for the sub-hypothesis, as patients with sleep apnea 
transplanted in 2009-2015 had a similar hazard of graft loss (adjusted HR= 2.94, p=.029), 
demonstrating a statistically significant increased risk of graft failure or CVD related death with 
a functioning graft.  Prior to the discussion of the results, stratification is addressed. 
Stratification.  When interpreting results, consideration was given to the statistically 
significant interaction between sleep apnea and year of transplant time period and how the 
relationship of sleep apnea and graft survival time varied by the two year of transplant strata.  
Patients transplanted in 1997-2008 with sleep apnea, versus without, had a decreased risk of graft 
failure or cardiovascular (CVD) related death with a functioning graft, although this was not 
statistically significant.  Patients transplanted during 2009-2015 with sleep apnea, versus 
without, had a statistically significant increased risk of graft failure or CVD related death with a 
functioning graft in adjusted models.      
Designation of year of transplant strata was determined through subject matter expertise.  
Consideration was given to center-specific changes, transplant advances, and allocation policy 
changes that could have occurred throughout the study time period (1997-2015).  After 
consideration of several factors that could inform the strata designation for the variable, year of 
transplant surgery, a change in the quality of the transplant center’s medical records relevant to 
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the study was determined to inform how the year of transplant time periods would be designated.  
In 2009, the transplant center implemented an electronic medical record (EMR) which served as 
a more robust source for data abstraction compared to the previous source (Voyager) and 
resulted in an increased abstraction of diagnosed sleep disorders in the 2009-2015 strata.  This 
data source change also had the potential to impact the patients transplanted in 1997-2008, as 
patients who were transplanted earlier eventually had a more robust medical record source from 
which to abstract a diagnosed sleep disorder if they survived until 2009.  That may in part be 
why patients with sleep apnea had increased graft survival times in 1997-2008, as we were more 
likely to find sleep apnea diagnoses through the electronic medical record, which became 
available in 2009. 
The prevalence of sleep apnea and how this differed among the two year of transplant 
time periods (1997-2008 and 2009-2015) merits consideration. In 1997-2008, the prevalence of 
sleep apnea was 16%.  In 2009-2015, the prevalence of sleep apnea was 33%.  The higher 
prevalence of sleep disorders abstracted in 2009-2015 with the presence of the electronic medical 
record (EMR) may be representative of the EMR as a better abstraction source, or it may reflect 
an increased awareness and diagnosis of sleep apnea in the recent years.  Additionally, the lower 
prevalence of sleep apnea in 1997-2008 may reflect a higher prevalence of undiagnosed (or 
unrecorded) sleep apnea in the sample, which could have impacted study outcomes for that time 
period.   
  Lastly, it is important to consider that the two strata (1997-2008 and 2009-2015) 
represent two different time periods with the regards to graft survival time, both due to the study 
design and overall advances in transplantation.  First, these two time periods reflect different 
durations with regards to graft survival time (opportunity to fail) because the study cohort only 
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included those subjects with graft failure or those who died with a functioning graft during the 
time period of 1997-2015.  Thus, patients transplanted in 1997-2008 had a longer opportunity to 
fail during the study time period, which resulted in this time period having longer median 
survival times due to being able to capture longer survival times.  The time period of 2009-2015 
only captured patients with early or mid-range graft loss, but it represents a more modern era of 
transplant.  National transplant data reports that the occurrence of rejection during the first year 
post-transplant has steadily decreased since the 1990s but that these improvements have 
remained relatively stable since 2008 (Hart et al., 2016). Thus, the 2009-2015 time period is 
more reflective of the current rates of acute rejection (which have stabilized), while the acute 
rejection rates during the time period of 1997-2008 were likely higher and varied throughout that 
time period. 
In summary, although the findings from the year of transplant time period 2009-2015 
involve a much smaller sample, this time period reflects a more reliable medical record source 
(which is relevant to this study’s design), and the time period also reflects a more stable time 
period with regards to transplant outcomes.  Specifically, improvement in the decreased risk of 
acute rejection has been the most notable outcome change (nationally) that has taken place in the 
past twenty years of transplant (Hart et al., 2016).  Furthermore, as this improvement has 
remained relatively stable since 2008 (Hart et al., 2016), this further supports the significance of 
the associations found between sleep apnea and graft survival time in the 2009-2015 year of 
transplant time period. 
Sleep apnea and graft survival time.  Patients with sleep apnea who were transplanted 
in 2009-2015 had a higher hazard of graft failure or cardiovascular (CVD) related death with a 
functioning graft compared to those without sleep apnea.  Two studies have explored the 
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association of sleep apnea to graft survival time and found conflicting results.  Szentkiralyi and 
colleagues (2011) found that having a high risk of sleep apnea (measured through the Berlin 
Questionnaire) was an independent risk factor for graft failure in female kidney transplant 
patients.  However, a study by Fornadi and colleagues (2014) using polysomnography 
measurement found no relationship between sleep apnea and graft failure risk.  Both studies 
relied on small samples of patients who had experienced graft failure, each consisting of less 
than 100 patients with graft failure and involved a predominantly Caucasian sample of transplant 
patients from Budapest, Hungary (Fornadi et al., 2014; Szentkiralyi et al., 2011).  The present 
study attempts to expand upon this past literature, and it is the first study, to our knowledge, that 
examines the association between sleep apnea and graft survival time in a US transplant sample.  
Our study time frame involved an 18-year period; however, we only found an increased risk for 
graft loss, with respect to sleep apnea, for the 2009-2015 time period which reflects early to mid-
range graft loss.  Additionally, the sample of patients in our study differed from other samples 
(Fornadi et al., 2014; Szentkiralyi et al., 2011) involving a hypertensive sample of kidney 
transplant recipients with a failed graft, consisting of predominately African American patients 
in Southeastern Virginia.  
Potential Mechanisms.  There are several potential mechanisms that may underlie the 
relationship between sleep apnea and kidney functioning post-transplant.  A possible direct 
relationship between sleep apnea and renal failure has been proposed through the effect of 
hypoxia on the kidney (Hanly & Ahmed, 2014; Nicholl et al., 2012).  In a sample of over 300 
patients, nocturnal hypoxia was associated with accelerated loss of renal function, even after 
adjustment for relevant covariates that may impact renal loss, such as age, body mass index, 
diabetes, and heart failure (Ahmed et al., 2011).  Another potential mechanism through which 
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sleep apnea may impact kidney functioning is through proteinuria.  Proteinuria is the presence of 
abnormal amounts of protein in urine, and it can often reflect a kidney filtration problem.  The 
presence of proteinuria after a kidney transplant is associated with reduced graft survival time 
(Amer & Cosio, 2009; Amer et al., 2007; Halimi et al., 2005), and an association has been found 
between proteinuria and sleep apnea in patients with chronic kidney disease (Chan et al., 2015).   
Indirect mechanisms linking sleep apnea to kidney functioning may also occur through 
hypertension, diabetes, and obesity (inflammation) (Hanly & Ahmed, 2014; Ozok et al., 2014; 
Nicholl et al., 2012; Turek, Ricardo, & Lash, 2012).  There is a relationship between sleep apnea 
and difficult to control hypertension (Hla et al., 2008; Huang et al., 2011), increased risk of type 
II diabetes (Kendzerska et al., 2014; Nagayoshi et al., 2016), and obesity (Young et al., 2002).  
Our findings also suggest such associations.  As our entire sample was hypertensive, an 
association between sleep apnea and hypertension could not be evaluated in our study.  However, 
patients with sleep apnea in our sample were found to have a statistically significantly higher 
prevalence of diabetes and a higher body mass index than patients without sleep apnea.  
Hypertension, diabetes, and inflammation are all known risk factors for renal failure (Turek, 
Ricardo, & Lash, 2012), and they can impact the graft survival of a newly transplanted kidney.  
Given the many potential direct or indirect and interrelated mechanisms through which 
sleep apnea may relate to kidney functioning, it is probably more realistic to consider this 
relationship in the context of a multifactorial causal pathway.  For instance, not only can hypoxia 
directly impact the organ function of the kidneys (Abuyassin et al., 2015), but also, hypoxia can 
be associated with hyperactivity of the sympathetic nervous system (Narkiewicz &Somers, 
1997).  Increased sympathetic activation results in a physiological state that can damage kidney 
function through various pathways, such as increased sensitivity to norepinephrine and resistant 
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hypertension (Adeseun & Ross, 2010; Schalich et al., 2009).  Thus, there is support that 
increased sympathetic activation may be a primary pathway through which hypoxia from sleep-
disordered breathing can lead to kidney failure (Schalich et al., 2009). 
Additional covariates and graft survival time.  In the final multivariate model, four 
additional covariates remained statistically significantly associated with graft survival time, and 
included: recipient age, human leukocyte antigen (HLA) mismatch, gender, and functional 
status.  These variables were identified as key covariates and remained in the multivariate model 
for adjustment.  However, the significance and direction of these covariates in the present study 
are similar to the findings of other US kidney transplant studies, including multi-center studies 
and larger population based cohort studies.  These findings are briefly summarized below. 
 In the present study, younger patients had a slightly higher risk of graft failure or 
cardiovascular (CVD) related death with a functioning graft.  Although age was associated with 
censoring, which may have led to an overestimation of survival times for older patients, previous 
research has also reported a higher risk of graft loss in younger patients (Keith et al., 2006).  This 
may be due to the increased prevalence of immunosuppressant non-compliance in younger 
patients (Brahm et al., 2012), which remains a significant cause of early graft loss.  HLA 
mismatch was also associated with graft survival, indicating a higher risk of graft loss with 
poorer antigen matches between the donor and recipient, a finding that is also supported in the 
transplant literature (Pirsch et al., 1996; Zhou & Cecka, 1993).  Additionally, we found that 
males had approximately a 50% higher risk of graft failure or CVD related death with a 
functioning graft, compared to females, a finding that has been reflected in larger transplant 
studies (Chen et al., 2013; Meier-Kriesche et al., 2001; Nyberg, Blohme, & Norden, 1997).  
Lastly, patients with limited functional status at the time of transplant (<100% Karnofsky score), 
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compared to those identified as having full functionality, had a statistically significantly  
increased risk of graft failure or CVD related death with a functioning graft.  In previous 
research, reduced functionality has been associated with delayed graft function (Garonzik-Wang, 
2012), a risk factor in graft loss (Yarlagadda et al., 2008). 
Although race was not included in the final model due to collinearity between race and 
HLA mismatch, race remained statistically significantly associated with graft failure or 
cardiovascular (CVD) related death with a functioning graft at the univariate (HR=1.62, p=.002) 
and multivariate levels (adjusted HR=1.53, p=.013).  Such findings suggest that African 
Americans had a 53% higher risk of graft failure or CVD related death with a functioning graft 
than Caucasians even after adjustments.  This finding is consistent with past literature (Chakkera 
et al., 2005; Meier-Kreische et al., 2001), including data from a large nationally representative 
sample of US transplant recipients (n=73,477) (Meier-Kreische et al., 2001). 
Discussion of Hypothesis 3: Patient Survival Time after Graft Failure 
Patient survival time after graft failure is a relevant, yet understudied, phenomenon in the 
transplant literature.  Compared to end-stage renal disease (ESRD) patients who have remained 
on dialysis, ESRD transplant patients have an increased risk of death after graft failure during the 
three years following their graft loss (Kaplan & Meier-Kriesche, 2002; McCaughan et al., 2014; 
Perl et al., 2012).  Although transplantation is intended to increase ESRD patient survival (Wolfe 
et al., 1999) and improve quality of life (Kovacs et al., 2011; Smith et al., 2008), the long-term 
impact of immunosuppression and the health implications of a second progressive period of 
chronic kidney disease may be factors that increase mortality risk after graft loss (McCaughan et 
al., 2014).  It was hypothesized that patients with any sleep disorder would have a higher hazard 
of mortality after graft failure compared to those without a sleep disorder.  The sub-hypothesis 
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proposed patients with a sleep-disordered breathing disorder would have a higher hazard of 
mortality after graft failure compared to those without a sleep-disordered breathing disorder.   No 
statistically significant differences in patient survival time after graft failure based on the 
presence of any sleep disorder, or, specifically, sleep apnea, were found.   Sleep apnea was not 
statistically significantly associated with an increased risk of death after graft loss in our sample 
(HR=1.05, p=.887).  Median patient survival time after graft failure for patients with sleep apnea 
was much shorter (2,421 days) than the median survival time for those without sleep apnea 
(3,249 days).  However, the lack of statistical significance of the relationship between sleep 
apnea and patient survival time after graft loss may have been impacted by the high rate of 
censoring (64%) for this outcome.  Additionally, despite a known interaction between sleep 
apnea and year of transplant, we were unable to stratify sleep apnea in the Cox regression 
analysis by year of transplant due to there being too few events in the 2009-2015 strata. This may 
have also impacted our findings. 
Sleep apnea and patient survival time after graft failure.  To our knowledge, this was 
the first study to examine the relationship between sleep disorders, particularly, sleep apnea, and 
patient survival time after graft failure.  It was hypothesized that patients with sleep apnea would 
have an increased risk of death post graft failure.  Possible mechanisms (while beyond the scope 
of this study) might include the associations between sleep apnea and increased inflammation 
(Calvin, Albuquerque, Lopez-Jimenez, & Somers, 2009), and the associations between moderate 
to severe sleep apnea and an increased risk of mortality in non-transplant samples (Lavie, 2007; 
Marshall et al., 2014; Young et al., 2008).   
In addition to the sample limitations that may have impacted our findings (high rate of 
censoring and inability to stratify analyses), as addressed previously, the inability to measure 
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severity of sleep apnea may have impacted our findings and could be a potential limitation of the 
present study.  Furthermore, it remains important to consider that sleep apnea may not increase 
the risk of mortality in an end-stage renal disease (ESRD) sample with a high prevalence of 
cardiovascular disease (Lavie, 2007).  Fornadi and colleagues (2014) examined the relationship 
of patient death after graft loss (although this outcome was grouped with death with a 
functioning graft), and they found no relationship between moderate to severe sleep apnea and 
mortality risk after graft loss (Fornadi et al., 2014). 
Additional covariates and patient survival time after graft failure.  In the final 
multivariate model, three additional covariates remained statistically significantly associated 
with patient survival time after graft failure, and included end-stage renal disease (ESRD) 
etiology, recipient age, and functional status.  Patients whose ESRD etiology was hypertensive 
nephersclerorsis had a decreased risk of death after graft loss compared to other ESRD 
etiologies.  Patients whose ESRD is caused by hypertension may have less comorbidities or 
serious health conditions than other diseases that can contribute to ESRD, such as lupus, an 
autoimmune disease, or diabetes, a disease that can often cause many additional health 
complications.  Increased recipient age and decreased functional status were independently 
associated with a higher risk of mortality after graft failure.  Furthermore, there was a 
statistically significant interaction between these two variables, which signified that the risk of 
death after graft failure increased as patients with limited functionality aged.   
Generally, there has been limited research identifying variables that are associated with 
patient survival time after graft failure, and findings from this study can hopefully contribute to 
the transplant literature.  Other research has identified recipient age, diabetes, and cardiovascular 
disease as variables associated with an increased risk of death post graft failure (McCaughan et 
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al., 2014).  A study by McCaughan et al. (2014) also found that re-transplantation is a primary 
factor in increased likelihood of survival after graft failure.  Re-transplantation was not analyzed 
in the present study, thus, due to the lack of assessment of this variable, the inability to control 
for re-transplantation may have impacted our findings. 
Summary for the Discussion of Results (Hypotheses 1-3) 
 Results of hypothesis testing suggested that sleep disorders, namely, sleep apnea, were 
not associated with mortality outcomes in our sample of kidney transplant recipients with a failed 
graft.  The lack of an association between sleep apnea and death with a functioning graft and risk 
of patient mortality after graft failure might be explained through one of two primary 
considerations.  First, there may be a relationship between sleep apnea and mortality outcomes in 
kidney transplant recipients, but the relationship may only exist between patients with moderate 
to severe sleep apnea, and we were unable to test these associations in this study as we lacked 
severity data.  Second, there may not be a relationship between sleep disorders and mortality in a 
kidney transplant sample that has an existing increased prevalence of cardiovascular disease 
which may be related to end-stage renal disease.  Thus, the presence of sleep apnea may not pose 
an additive risk of mortality in a sample of patients with existing cardiovascular disease.   
Although no relationship was found between sleep apnea and increased proportion of 
death with a functioning graft (hypothesis 1b), the results of hypothesis 1b can also provide 
further insight into the interpretation of the results for the graft survival time outcome 
(hypothesis 2b).  In our study, the end of graft survival time was defined as graft failure and 
return to dialysis or cardiovascular (CVD) related death with a functioning graft (which could 
also be related to renal dysfunction) (Jardine et al., 2011; Meier-Kriesche et al., 2003).  In other 
words, we examined graft survival time without the end of survival time being driven by all-
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cause mortality (specifically, non-CVD related mortality).  This is an important distinction when 
interpreting the graft survival findings because the relationship between sleep apnea and graft 
survival time could involve different mechanisms through which sleep apnea relates to graft loss 
due to all-cause mortality or graft loss due to renal dysfunction (the failure of the transplanted 
kidney). 
 A relationship was found between sleep apnea, and an increased risk of graft failure or 
cardiovascular related death with a functioning graft among patients transplanted in 2009-2015.  
Within the context of this finding, the lack of association between sleep apnea and death with a 
functioning graft may indicate that sleep apnea may be a factor in reducing graft survival time 
through impacting the renal function of the transplanted kidney, rather than due an increased risk 
of death with a functioning graft in kidney transplant recipients.  Previous research has identified 
sleep apnea as a risk factor for renal dysfunction through chronic kidney disease development 
(Lee et al., 2015) and faster progression to kidney failure (Lee et al., 2015; Molnar et al., 2015); 
therefore, it is not unfounded to consider that sleep apnea may also accelerate kidney failure 
post-transplant.  Thus, a better understanding of sleep apnea and how it can relate to kidney 
functioning is important.  While there are several potential mechanisms through which sleep 
apnea could impact kidney functioning, there is strong support for a multifactorial casual 
pathway that may begin through the impact of hypoxia both directly on the kidney and then 
indirectly through the pathway of increased sympathetic activation (Abuyassin et al., 2015; 
Adeseun & Ross, 2010; Schalich et al., 2009).  Further understanding of these mechanisms and 
whether treatment of sleep apnea can improve renal function (or slow the rate of progression to 
kidney failure) may help to improve transplant outcomes.  Our findings regarding the association 
between sleep apnea and increased risk of graft loss are relevant to the chronic kidney disease 
134 
 
literature, but also, specifically, to the kidney transplant literature.  Such findings merit further 
consideration of sleep disorders, and specifically sleep apnea, among transplant nephrologists.  
In addition to the relevance of the present study to the transplant literature, our findings also 
contribute to the literature characterizing the growing public health concern regarding sleep 
apnea in the United States.   
The estimated prevalence of sleep apnea in the US varies based on age and gender but 
ranges approximately from 3-10% in those aged 30-49 years old, and 9-17% in those aged 50-70 
years old.  These prevalence rates reflect a substantial increase of sleep apnea over the last two 
decades (Peppard et al., 2013).  Among the general population, sleep apnea is associated with a 
reported increase in health service utilization (Kao, Lee, Lin, Tsai & Chung, 2015; Kapur et al., 
2002), an increased risk of cardiovascular disease (Shahar et al., 2001) and an increased risk of 
mortality (Lavie, 2007; Marshall et al., 2014; Young et al., 2008).  As the incidence of sleep 
apnea continues to increase, more research is needed to examine the potential associations 
between sleep apnea and adverse health outcomes.  In our sample of kidney transplant recipients, 
a statistically significant association between sleep apnea diagnosis and shorter graft survival 
time was found in patients transplanted in 2009-2015.  This finding further highlights the 
pervasive and negative health risks of sleep apnea. 
Limitations  
It is important to consider the findings of this study within the context of its limitations, 
and causal associations cannot be ascertained from a single observational study.  First, the data 
for the primary independent variable (sleep disorders) were limited to sleep disorders that were 
documented in the subjects’ medical records.  Therefore, results may be impacted by 
undiagnosed sleep disorders or sleep disorders that were diagnosed but not reported in the 
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medical record.  While the prevalence of sleep apnea in the general population is estimated to 
range from 3-17% based on age and gender considerations (Peppard et al., 2013), there is 
literature to support a higher prevalence of sleep apnea among patients with end-stage renal 
disease (ESRD) (Hanly, 2004; Unruh et al., 2006).  Furthermore, the estimated prevalence of 
sleep apnea among transplant samples has been reported to range from 25-45% (Fornadi et al., 
2012; Molnar et al., 2010; Szentkiralyi et al., 2011).  The prevalence of sleep apnea in our cohort 
was 17%, which is lower than the estimated prevalence in other kidney transplant samples and 
may indicate that some subjects who were classified as not having sleep apnea in our study may 
have had sleep apnea that was undiagnosed or that this diagnosis was not reported in their 
medical record. 
In addition to the potential for undiagnosed sleep disorders to affect study results, there 
was insufficient information provided in the medical records on the severity or treatment of the 
diagnosed sleep disorders that were included in analyses.  Often, the literature summarizing 
associations between sleep apnea and adverse health outcomes are centered on moderate to 
severe apnea (Marshall et al., 2014; Young et al., 2008), and such severity information may have 
been relevant to transplant outcomes.  Additionally, the inability to assess whether patients with 
diagnosed sleep disorders, specifically sleep apnea, were receiving treatment was a limitation. 
Patients examined in this study may have been treated for sleep apnea, and this may have 
impacted the relationship of sleep apnea to graft survival time.  It could be informative to 
compare transplant outcomes among patients treated with continuous positive airway pressure 
(CPAP) therapy versus those who were not.  Patients treated with CPAP may have had better 
graft survival outcomes.  Other unknown variables, such as patient compliance with comorbid 
conditions that are known to relate to kidney function and/or patient survival (ie diabetes 
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management), and a subject’s overall access to care, are examples of variables that are relevant 
to the study outcomes but that could not be assessed in our study as they were not available in 
the data.  Additionally, re-transplantation is a known variable related to patient survival time 
after graft loss (McCaughan et al., 2014), and this variable was not examined in our study.  
The Sentara Norfolk General Hospital (SNGH) medical record consisted of two different 
sources throughout the 1997-2015 study time frame.  Thus, another limitation of the study is 
related to the change of the data abstraction source that occurred for medical records after 2009.  
Data was available from 1997-2008 through Voyager, a digital storage system for past history 
and physicals and physicians’ records.  In 2009, Epic, an electronic medical record came into use 
at the SNGH transplant center.  The data stored in Epic involves a more robust source than the 
data found in Voyager, and this primarily impacted the abstraction of diagnosed sleep disorders, 
as the abstraction of sleep disorders involved a multi-pronged approach.  Sleep disorders were 
not only abstracted from a subject’s medical history, but they also were abstracted from 
pulmonary and anesthesia notes.  Moreover, it was not uncommon to find sleep disorders 
diagnoses reported in pulmonary notes when that same sleep disorder was not listed in a 
subject’s medical history, thus supporting the consideration that a more robust abstraction source 
influenced the abstraction of sleep disorders. 
Limitations of the sampling approach are also important to consider.  This study was 
limited to a sample of patients with graft failure or those who died with a functioning graft.  
Patients who were transplanted and still surviving were excluded.  Such exclusion resulted in a 
sample that is not fully representative of kidney transplant recipients at the Sentara Norfolk 
General Transplant Center who were transplanted during the study time frame (January 1, 1997 
to September 1, 2015, inclusive).  The exclusion of censored subjects can introduce bias into a 
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study.  However, given the 18-year study time frame, the exclusion of patients who were still 
surviving did not systematically exclude all long-term survival times, and that is a strength of the 
study time frame, despite only having a sample of subjects with a failed graft or those who died 
with a functioning graft. 
Additionally, this study utilizes data from one transplant center during an approximate 
18-year time frame; therefore, findings can only be carefully generalized to graft failure 
populations admitted to similar hospitals and with the same characteristics as this study sample.  
However, despite limitations of a single-center sample, utilizing data from one transplant center 
did offer some uniformity in the patients’ characteristics, thus increasing internal validity.  
Patients transplanted at the Sentara Norfolk General Hospital transplant center follow the same 
pre-transplant evaluations and follow a standardized post-transplant plan of care, including a 
standard immunosuppressant dosing protocol, thus highlighting a benefit of single-center 
sampling.   
Lastly, power and analysis limitations should be considered when interpreting results.  
For analyses related to graft survival time (hypothesis 2), the findings from 2009-2015 were 
based on an analysis of 18 events.  Relying on a stratum with a small number of events can result 
in model instability for multivariate models, which can overestimate hazard ratios and 
confidence intervals (Hosmer et al., 2008).  Less conservative views of model stability 
recommend at least 5-9 events per covariate (Vittinghoff & McCulloch, 2007).  When examining 
graft survival time (hypothesis 2), we had 4 events per covariate in the 2009-2015 strata, which 
is less than the number of recommended events.  However, a univariate analysis stratified by 
year of transplant surgery that examined the association of any sleep disorder and of sleep apnea 
with graft survival time was computed and yielded similar hazard ratios and significance values 
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compared to the multivariate model.  The similar hazard ratios and significance values at the 
univariate level prior to the addition of other predictor variables may offer some support in 
considering that the significant relationship between sleep disorder and graft survival time was 
not over inflated by model instability in the 2009-2015 strata.   
In the analysis of hypothesis 3, related to examining patient survival time after graft 
failure, due to the lack of events in 2009-2015, the method of stratification by year of transplant 
could not be utilized, and this may have impacted findings.  Additionally, the high prevalence of 
censoring (64%) that was present in patient survival time after graft failure may have also led to 
biased findings in underestimating the variance in survival times (Hosmer et al., 2008).   
Health Policy Implications 
Despite the identified limitations, valuable information can be garnered from this study, 
and findings can hopefully contribute to the transplant literature.  Health policy implications 
related to this study merit consideration at the transplant center-specific level.  Given the 
association found between sleep apnea diagnosis and an increased risk of graft failure or 
cardiovascular related death with a functioning graft in patients transplanted in 2009-2015, an 
increased awareness of sleep disorders is important.  Recommendations were made to the 
Sentara Norfolk General Hospital (SNGH) Transplant Center to consider screening patients for 
sleep apnea as part of the pre-transplant medical evaluation.  Screening for sleep apnea involves 
a low cost and limited time investment and can easily be incorporated into the SNGH pre-
transplant medical evaluation.  The STOP-Bang (Chung et al., 2008) and the Berlin 
questionnaire (Netzer et al., 1999) are examples of self-report measures that assess the risk of 
obstructive sleep apnea.  Each measure can be completed in less than five minutes, and patients 
who are identified as high risk for obstructive sleep apnea can then be referred for a sleep study 
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for further evaluation.  This process could be incorporated into the SNGH pre-transplant 
evaluation policy, which would standardize it across the center. 
Consideration of national policy recommendations based on the findings of this study 
would require further research, due to the single-center nature of this study.  However, our study 
follows the recommendation of the American Society of Transplantation which has called for 
research on modifiable patient risk factors that may relate to long-term graft survival (American 
Society of Transplantation, 2015).  Our findings suggest further consideration and evaluation of 
a novel patient risk factor, sleep disorders.  Additional transplant research on sleep disorders, 
namely, sleep apnea, and how treatment of such may impact transplant outcomes are needed. 
Future Research  
The findings from this study highlight several questions that remain unanswered and 
present opportunities for future research.  Three main considerations for future research are 
addressed.  First, additional studies exploring the association between sleep disorders with graft 
survival and patient survival are needed.  The estimated prevalence of sleep apnea in kidney 
transplant samples ranges from 25-45% (Fornadi et al., 2012; Molnar et al., 2010; Szentkiralyi et 
al., 2011), highlighting the potential significance of this disorder in kidney transplant recipients.  
A better understanding of sleep apnea and its associations to transplant outcomes is important.  
Multi-center studies are encouraged to further examine whether sleep disorders are associated 
with transplant outcomes amongst robust patient characteristics.  Future research could include 
polysomnographic measurement of sleep disorders, as a limitation of this study involved reliance 
on medical record diagnoses. Additionally, polysomnographic measurement would provide the 
ability to classify the severity of sleep apnea through the apnea–hypopnea index.   
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In addition to better understanding relationships between sleep apnea and transplant 
outcomes, studies that examine the impact of continuous positive airway pressure (CPAP) 
treatment in transplant outcomes also merit consideration. Given the association between sleep 
apnea and risk of graft failure in this study and previous research (Szentkiralyi et al., 2011), 
further studies are needed to determine whether treatment of sleep apnea improves graft survival 
outcomes.  An indirect relationship between CPAP use and improvement of kidney functioning 
may be supported through past studies identifying improvements in hypertension control (Chin et 
al., 2006; Gottlieb et al., 2014; Lozano et al., 2010) and blood glucose control (Babu, Herdegen, 
Fogelfeld, Shott, & Mazzone, 2005) after CPAP use.  Hypertension and diabetes control are both 
important factors in post-transplant management.  A potential direct relationship supporting 
CPAP therapy in transplant patients may be seen through the association between CPAP use and 
decreased proteinuria (Chaudhary, Sklar, Chaudhary, Kolbeck, & Speir, 1988).  Moreover, two 
studies have explored the potential implications of CPAP use on kidney functioning.  Short-term 
CPAP use in patients with obstructive sleep apnea has been shown to increase renal plasma flow, 
and reduce the filtration fraction, suggesting that CPAP use may be able to prevent renal 
dysfunction (Kinebuchi et al., 2014).  A study by Nicholl and colleagues (2014) reported 
improvement in kidney function after four weeks of CPAP use.  If sleep apnea remains a factor 
associated with increased risk of graft failure, then research comparing the renal function of 
treated and untreated patients with sleep apnea will be needed.   
Lastly, as this study follows the recommendations of the American Society of 
Transplantation identifying the need for more research on modifiable patient predictors of long-
term graft loss (American Society of Transplantation, 2015), transplant centers may consider 
using the design of this study as a potential model for future transplant research.  Combining data 
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from a national transplant registry with the transplant center’s medical record data can be an 
important method in studying novel risk factors that may be related to transplant outcomes 
beyond the variables that are collected by the United Network for Organ Sharing (UNOS) 
database. 
Conclusions 
The present study examined the associations between sleep disorders and three relevant 
transplant outcomes: death with a functioning graft, graft survival time, and patient survival time 
after graft failure.  Sleep apnea,  which comprised 85% of all diagnosed sleep disorders in this 
sample, was statistically significantly associated with an increased risk of graft failure or 
cardiovascular related death with a functioning graft among patients transplanted in 2009-2015, 
while being associated with a decreased, albeit not statistically significant, risk for those 
transplanted in 1997-2008.  Sleep apnea statistically significantly increased the risk of graft loss 
nearly three-fold among patients transplanted in 2009-2015.  
This study supports previous research which found an association between sleep apnea 
and increased risk of graft failure in female kidney transplant recipients (Szentkiralyi et al., 
2011).  Study findings also identify the need for new research on sleep apnea and transplant 
outcomes and suggest the importance of investigating whether treatment of sleep apnea can 
improve transplant outcomes. While research is needed on the impact of continuous positive 
airway pressure (CPAP) therapy on transplant outcomes, awareness and management of sleep 
apnea among the medically complex transplant patient is important and requires keen awareness 
among all treating providers.  Screening for sleep apnea in transplant evaluations, where patients 




This study, to our knowledge, is the first to examine sleep disorders and transplant 
outcomes in a sample of US transplant patients with a failed graft over an 18-year time period. 
The study’s methodology, analytic approach, and identified limitations may help to inform future 
studies of this nature.  Further consideration of sleep disorders and of their associations to patient 
outcomes and quality of life remains a significant area with several future research opportunities.  
Sleep disorders, specifically, sleep apnea, are prevalent throughout the spectrum of chronic 
kidney disease, and remain prevalent post-transplant.  Understanding the role of sleep 
disturbances in adverse health outcomes extends beyond the sleep medicine professional.  
Awareness of the significance of sleep disorders and how they can impact transplant outcomes is 
needed among all types of medical providers, patients, and public health professionals to help 
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1. Name  ____________ 
2. Date of Birth ______ (month/day/year) 
3. Date of Transplant ______ (month/day/year) 
4. Race/ethnicity 
 African American 
 Asian 
 Caucasian 
 Hispanic or Latino 
 Other: _____________ 




7.  Date of Graft Failure ______ (month/day/year) 
8. Graft Failure Outcome 
 Graft Failure 
 Patient Death 
9. Donor Type 
 Deceased Donor 
 Living Donor 
 
10. HLA Mismatch  0-6  
11. ESRD Etiology 
 Hypertension 
 Hypertension & 
Diabetes 




12. Cause of Patient Death  _____________________ 
13. Date of Recipient Death (if applicable) ______ (month/day/year) 
14. Age of Donor at Time of Transplant  ___ years 
15. Age of Recipient at Time of Transplant ___ years 
16. Year of Transplant Surgery ______  
17. Graft Survival Time ______ days 
18. Education Level (at the time of 
transplant) 
______ (highest grade level completed) 
19. Karnofsky Score (at the time of 
transplant) 
______ (0-100) 
20. Non-compliance with 
immunosuppressant medications 
       






21. Diagnosed sleep disorder 
 yes1 
 no2 
22. Sleep disorder ___ (name, ICD-9/10 code, and treatment comments) 
23. Date of sleep disorder diagnosis (if 




 documented pre-transplant  
 documented post-transplant  
25. Diabetes 
 
 documented pre-transplant  
 documented post-transplant  
26. Hyperlipidemia/Dyslipidemia 
 
 documented pre-transplant  
 documented post-transplant  
27. Stroke 
 documented pre-transplant  
 documented post-transplant 
28. Myocardial Infarction 
 
 documented pre-transplant  
 documented post-transplant  
29. Coronary Artery Disease 
 
 documented pre-transplant  
 documented post-transplant 
30. Peripheral Vascular Disease 
 
 documented pre-transplant  
 documented post-transplant 
31. Immunosuppressant Medications (check 






 Sandimmune  
 Rappamune  
 Neoral  
 Gengraf  
 
32. Smoking history ___ (pack-years) 










Table 23 presents the Chi-square statistic and significance values comparing the 
proportion of censoring in all categorical study variables.  Diabetes and stroke history were 
found to have a statistically significant difference (p ≤0.05) in censoring among the categories. It 
was found that patients with diabetes and patients with a history of a stroke were more likely to 
be censored (non-cardiovascular related death with a functioning graft). 
 
Table 23. 









Sleep Disorder  1   
YES (61) 28% (17/61)  .7656 .3816 
NO (237) 34% (80/237)  
     
Gender  1   
Male (167)  32% (53/167)  .1146 .7350 
Female (131)  34% (44/131)  
     
Race  1   
Caucasian (108) 37% (40/108)  1.5531 .2127 
African American (109) 30% (57/190)  
     
Smoking History  1   
Yes (131) 37% (48/131)  1.6892 .1937 
No (166) 30% (49/166)  
     
Diabetes  1   
Yes (182) 37% (68/182)  4.9317 .0264* 
No (116) 25% (29/116)  
     
Dyslipidemia  1   
Yes (221) 34% (74/221)  .3397 .5600 
No (77) 30% (23/77)  
     
Coronary Artery 
Disease 
 1   
Yes (69)  39% (27/69)  1.7708 .1833 
No (229) 31% (70/229)  
     
176 
 








Stroke History  1   
Yes (56) 48% (27/56)  7.7065 .0055* 
No (242) 29% (70/242)  
     
Heart Attack History  1   
Yes (21) 38% (8/21)  .3164 .5738 
No (277) 32% (89/277)  
     
Donor Type  1   
Living Donor (125) 34% (42/125)  .1081 .7424 
Deceased Donor (173) 32% (55/173)  
     
Functional Status  1   
Full (152) 31% (47/152)  .3751 .5402 
Limited (146) 34% (50/146)  
     
ESRD Etiology  1   
Hypertension (113) 30% (34/113)  .5025 .4784 
Other (185) 34% (63/185)  
     
Education Level  2   
Unknown (24) 33% (8/24)  4.1060 .1283 
High School or Below 
(139) 
 38% (53/139)  
Beyond High School 
(135) 
27% (36/135)  
     
Peripheral Vascular 
Disease 
 1   
Yes (29) 41% (12/29)  1.1406 .2855 
No (269) 32% (85/269)  
     
 
Table 24 presents the t-score statistic and significance value (both one and two tailed) 
comparing the proportion of censoring in all continuous study variables.  The variables tobacco 
pack-years and recipient age were associated with censoring.  Older patients were more likely to 
be censored (one-tailed significance, p<.001).  Patients with increased tobacco pack-years were 
more likely to be censored (one-tailed significance, p<.04).  One-tailed significance was 


















Pack Years 9.7 5.8 1.76 124 .0810 .0405* 
Recipient Age 55 47 5.82 229 <.0001* <.0001* 
Body Mass Index 28.21 28.44 .34 296 .7320 .366 
HLA Mismatch 3.33 3.64 1.53 296 .1263 .0634 
Donor Age 41 39 .97 296 .3308 .1654 
Year of Transplant 
Surgery 





















The outputs below present the violation of the proportional hazards assumption for the 
variable year of transplant surgery.  Both the graphical analysis (p=.0220) and the calculation of 








Prior to multivariate modeling, a test for collinearity was conducted using a variable 
reduction method in SAS, PROC VARCLUS (SAS Institute Inc, 2011).  PROC VAR CLUS 
divides a set of study variables into hierarchical clusters.  The program begins with a single 
cluster, then runs several iterations splitting clusters into correlated variables.  Below is the SAS 
output of the final iteration, identifying three clusters of correlated variables.  Cluster 1 identifies 
a correlation between the variable year of transplant surgery and functionality status.  A decision 
regarding this correlation was not needed due to the stratification of year of transplant surgery.  
Cluster 2 indicated a high correlation between diabetes and recipient age.  However, diabetes 
was not a significant predictor of graft survival time at the univariate or multivariate level, 
therefore, no determination was needed.  Cluster 3 indicated a high correlation between the 
variables, race and HLA.  Both race and HLA were significant predictors in the univariate and 
multivariate analyses; therefore a determination was needed regarding what variable to retain in 
the final model.  The variable HLA mismatch was selected based on the literature indicating that 
African Americans have poorer graft survival outcomes than other races, but that this may be 
more reflective of immunology variables (Gordon et al., 2010).  Because the variable HLA 
mismatch is a measure of donor and recipient antigen match, and is representative of an 
immunology measure, the determination was made to retain the variable HLA mismatch (and 








 Appendix F presents the verification of model assumptions for hypothesis 2 (graft 
survival time).  The figures below are a graphical measure of proportional hazard assumptions.  
For each covariate included in the final model the graphical assessment of the proportional 
hazards assumption reported a p ≥.05, thus indicating no violation of the proportional hazards 
assumption for gender, functionality, recipient age, HLA, and the interaction between any 
diagnosed sleep disorder and year of transplant surgery. 
   




 Regarding the variable any diagnosed sleep disrder the graphical measurement of the 
proportional hazards assumption indicted a potential violation (p=.0040).  However, as graphical 
measurements can sometimes be biased an interaction between the variable any diagnosed sleep 
disorder and time (graft survival time) was computed. 
 
 
 This table below is a SAS output of the assessment of the proportional hazards 
assumption by computing an interaction with time for the variable any diagnosed sleep disorder 






The linearity assumption was assessed through a measure of functional form for all continuous 
variables in final Cox model.  The functional form of recipient age, and HLA both indicate no 









Appendix G presents the verification of model assumptions for hypothesis 3 (patient 
survival after graft failure.  The figures below are a graphical measure of proportional hazard 
assumptions.  For each variable included in the final model the graphical assessment of the 
proportional hazards assumption reported  p ≥ .05, thus indicating no violation of the 
proportional hazards assumption for any diagnosed sleep disorder, functionality, recipient age, 
ESRD etiology, and the age by functionality interaction 
 
   
 






The linearity assumption was assessed through a measure of functional form for all 
continuous variables in final Cox model.  The functional form of recipient age indicated no 
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